

530 017

10/530017

Rec'd PCT/PTO 01 APR 2005

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
15 April 2004 (15.04.2004)

PCT

(10) International Publication Number
WO 2004/030521 A2

(51) International Patent Classification⁷:

A61B

(74) Agents: CORLESS, Peter, F. et al.; Edwards & Angell,
LLP, P.O. Box 9169, Boston, MA 02209 (US).

(21) International Application Number:

PCT/US2003/031089

(22) International Filing Date: 1 October 2003 (01.10.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/414,647

1 October 2002 (01.10.2002) US

(71) Applicant (for all designated States except US): THE
JOHNS HOPKINS UNIVERSITY [US/US]; 3400 N.
Charles Street, Baltimore, MD 21218 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): CLARKE, William,
A. [US/US]; 10200 Hickory Ridge Road #103, Columbia,
MD 21044 (US). SILVERMAN, Benjamin, Charles
[US/US]; 1105 Runnymede Court, Bel Air, MD 21014
(US). MOLMENTI, Ernesto, Pompeo [AR/US]; 2515
Boston Street #402, Baltimore, MD 21224 (US). ZHANG,
Zhen [CN/US]; 5461 Columbia Road, Apt. 736, Colum-
bia, MD 21044 (US). CHAN, Daniel, Wanyui [US/US];
12925 Wexford Park, Clarksville, MD 21029-1401 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,
MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT,
RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: USE OF BIOMARKERS FOR DETECTING ACUTE RENAL TRANSPLANT REJECTION

(57) Abstract: The present invention relates to a method of qualifying kidney transplant rejection status in a subject comprising: (a) measuring at least one of the disclosed Biomarkers in a sample from the subject and (b) correlating the measurement with kidney transplant rejection status. The invention further relates to kits for qualifying kidney transplant rejection status in a subject.

WO 2004/030521 A2

USE OF BIOMARKERS FOR DETECTING ACUTE RENAL TRANSPLANT REJECTION

This application claims the benefit of U.S. provisional application no. 60/414,647, filed October 1, 2002; which application is incorporated by reference herein in its entirety.

FIELD OF THE INVENTION

The invention provides for Biomarkers important in the detection of acute renal transplant rejection. The Biomarkers were identified by distinguishing the urine protein profile of renal transplant patients with no rejection and those with acute rejection using SELDI analysis. The present invention relates the Biomarkers to a system and method in which the Biomarkers are used for the qualification of kidney transplant rejection status.

BACKGROUND OF THE INVENTION

Despite overall improvements associated with advances in immunosuppression regimens, rejection still occurs and has a deleterious effect on graft survival. The projected half-life of grafts transplanted in recent years was found to be almost double among those with no episodes of clinical acute rejection. (Hariharan S, Johnson CP, Bresnahan BA, et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med. 2000; 342: 605-612; and Burke JF Jr, Pirsch JD, Ramos EL, et al. Long-term efficacy and safety of cyclosporine in renal-transplant recipients. N Engl J Med. 1994; 331: 358-363.) Acute rejection has been reported to cause a 20% reduction in the 1-year survival rate and a 4-year diminution in the projected half-life of cadaver allografts. (Li B, Hartono C, Ding R, et al. Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine. N Engl J Med. 2001; 344: 947-954. ; and Cecka JM. The UNOS Scientific Renal Transplant Registry. In: Cecka JM, Terasaki PI, eds. Clinical Transplantation 1999. Los Angeles: UCLA Immunogenetics

Center; 2000: 1-21.) During the first year after transplantation, approximately 35% of recipients will experience an episode of acute rejection. Reports also suggest that rejection is detected in 30% of biopsies done in patients thought to be having stable renal function or to have been successfully treated for rejection.(Rush DN, Henry SF, Jeffery JR, et al. Histological findings in early routine biopsies of stable renal allograft recipients. Transplantation. 1994; 57: 208-211.; and Gaber LW, Moore LW, Gaber AO, et al. Correlation of histology to clinical rejection reversal: a thymoglobulin multicenter trial report. Kidney Int. 1999; 55: 2415-2422.) The projected half-life of cadaveric renal transplants for recipients with and without an episode of clinical rejection was 7.0 versus 8.8 years and 8.8 versus 17.9 years in 1988 and 1995, respectively. When data corresponding to patients who died with a functioning graft were censored, there was a 31% increase in projected graft half-life during this period for recipients with an episode of rejection. The corresponding increase among patients with no rejection was 110%.(Hariharan S, Johnson CP, Bresnahan BA, et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med. 2000; 342: 605-612.). The reduction in the relative hazard of graft failure during the first year after transplantation was 7.1% per year from 1988 to 1996.

Rejection can be defined as the immunologic interaction between host and allograft in which reactivity by the former leads to a sudden deterioration in physiologic function of the latter.(Almond PS, Matas A, Gillingham KJ, et al. Risk factors for chronic rejection in renal allograft recipients. Transplantation. 1993; 55: 752-756; Gulanikar AC, MacDonald AS, Sungurtekin U, et al. The incidence and impact of early rejection episodes on graft outcome in recipients of first cadaver kidney transplants. Transplantation. 1992; 53: 323-328; Lindholm A, Ohlman S, Albrechtsen D, et al. The impact of acute rejection episodes on long-term graft function and outcome in 1347 primary renal transplants treated by 3 cyclosporine regimens. Transplantation. 1993; 56: 307-315; and Cecka JM. The UNOS Scientific Renal Transplant Registry. In: Cecka JM, Terasaki PI, eds. Clinical Transplantation 1999. Los Angeles: UCLA Immunogenetics Center; 2000: 1-21.). Successful management requires early detection along with adequate treatment. Available diagnostic methods include clinical presentation, biochemical parameters, and tissue biopsies. The first two are not infallible. Serum creatinine, usually the first available

indication of allograft dysfunction, is not particularly sensitive or specific.

Furthermore, it may not reflect early changes, since renal function may not always correlate with histologic improvement.(Roberti I, Reisman L. Serial evaluation of cell surface markers for immune activation after acute renal allograft rejection by urine
5 flow cytometry-correlation with clinical outcome. Transplantation. 2001; 71: 1317-1320; Woodle ES, Cronin D, Newell KA, et al. Tacrolimus therapy for refractory acute renal allograft rejection. Transplantation. 1996; 62: 906; Beckingham IJ, Nicholson ML, Bell PR. Analysis of factors associated complications following renal transplant needle core biopsy. Br J Urol. 1994; 73: 13-15.). Biopsy of the renal
10 allograft is regarded as the standard for the diagnosis of rejection and delayed graft function. However, percutaneous renal biopsy is costly and has associated morbidity and mortality. Complications include but are not limited to pain, hematuria, arteriovenous fistulas, perirenal hematomas, injury to adjacent viscera, anuria, allograft thrombosis, sepsis, shock, allograft loss, and patient death.(Beckingham IJ, Nicholson ML, Bell PR. Analysis of factors associated complications following renal
15 transplant needle core biopsy. Br J Urol. 1994; 73: 13-15; Huraib S, Goldberg H, Katz A, et al. Percutaneous needle biopsy of the trans with planted kidney: technique and complications. Am J Kidney Dis. 1989; 14: 13-17; and Benfield MR, Herrin J, Feld L, et al. Safety of kidney biopsy in pediatric transplantation: a report of the Controlled
20 Clinical Trials in Pediatric Transplantation Trial of Induction Therapy Study Group. Transplantation. 1999; 67: 544-547. Biopsies also allow for sampling errors and subsequent disparities between clinical and microscopic findings.(Curtis JJ, Julian BA, Sanders CE, et al. Dilemmas in renal transplantation: when the clinical course and histological findings differ. Am J Kidney Dis. 1996; 27: 435; and Sorof JM, Vartarian RK, Olson JL, et al. Histological concordance of paired renal allograft
25 biopsy cores. Transplantation. 1995; 60: 1215.).

There is a critical need for the identification of Biomarkers that individually or in combination with other Biomarkers or diagnostic modalities deliver the required sensitivity and specificity for early detection of kidney transplant rejection. Thus, it is
30 desirable to have a reliable and accurate method for early determination of kidney transplant rejection status in patients, the results of which can then be used to manage subject treatment. Development of a noninvasive Biomarker for renal transplant

rejection has the potential to radically change the way in which these transplant patients are managed.

SUMMARY OF THE INVENTION

5 The present invention provides sensitive and quick methods and kits that are useful for determining the kidney transplant rejection status by measuring Biomarkers of the present invention. The measurement of these Biomarkers in patient samples provides information that diagnosticians can correlate with a probable diagnosis of kidney transplant rejection or non-rejection. The Biomarkers are characterized by
10 molecular weight and/or by other protein identities. The Biomarkers can be resolved from other proteins in a sample by using a variety of fractionation techniques, *e.g.*, chromatographic separation coupled with mass spectrometry, protein capture using immobilized antibodies or by traditional immunoassays. In preferred embodiments, the method of resolution involves Surface-Enhanced Laser Desorption/Ionization
15 ("SELDI") mass spectrometry, in which the surface of the mass spectrometry probe comprises adsorbents that bind the Biomarkers.

 More specifically, forty-eight Biomarkers were discovered and subsequently identified, in accordance with the methods described and identified and referred to as
20 Biomarkers 1 through 48.

 The present invention provides a method of qualifying kidney transplant rejection status in a subject comprising (a) measuring at least one Biomarker in a sample from the subject, wherein the Biomarker is selected from the group consisting
25 Biomarkers 1 through 48 and combinations thereof, and (b) correlating the measurement with kidney transplant rejection status. In certain methods, the measuring step comprises detecting the presence or absence of Biomarkers in the sample. In other methods, the measuring step comprises quantifying the amount of Biomarker(s) in the sample. In other methods, the measuring step comprises
30 qualifying the type of bioBiomarker in the sample.

 The invention also relates to methods wherein the measuring step comprises: providing a subject sample of urine or a urine derivative; fractionating proteins in the sample on an anion exchange resin and collecting fractions that contain Biomarkers 1

through 48; and capturing Biomarkers 1 through 48 from the fractions on a surface of a substrate comprising capture reagents that bind the protein Biomarkers. In preferred embodiments, the substrate is a SELDI probe comprising an IMAC copper surface and wherein the protein Biomarkers are detected by SELDI. In other embodiments, the substrate is a SELDI probe comprising biospecific affinity reagents that bind Biomarkers 1 through 48 and wherein the protein Biomarkers are detected by SELDI. In other embodiments, the substrate is a microtiter plate comprising biospecific affinity reagents that bind Biomarkers 1 through 48 and the protein Biomarkers are detected by immunoassay.

In certain embodiments, the methods further comprise managing subject treatment based on the status determined by the method. For example, if the result of the methods of the present invention is inconclusive or there is reason that confirmation of status is necessary, the physician may order more tests. Alternatively, if the status indicates that altering immunosuppression is appropriate, the physician may schedule the patient for a change in immunosuppressive therapy. Furthermore, if the results show that the current treatment is appropriate, no further management may be necessary.

The invention also provides for such methods where the at least one Biomarker is measured again after subject management. In these instances, the step of managing subject treatment is then repeated and/or altered depending on the result obtained.

The term "kidney transplant rejection status" refers to the status of kidney function in the patient. Examples of types of kidney transplant rejection statuses include, but are not limited to, the subject's urine creatinine levels, the degree of immunosuppression, and the effectiveness of immunosuppressive treatment. Other statuses and degrees of each status are known in the art.

The present invention also relates to Biomarkers designated as Biomarkers 1 through 48. Protein Biomarkers of the invention can be characterized in one or more of several respects. In particular, in one aspect, these Biomarkers are characterized by molecular weights under the conditions specified herein, particularly as determined by

mass spectral analysis. In another aspect, the Biomarkers can be characterized by features of the Biomarkers' mass spectral signature such as size (including area) and/or shape of the Biomarkers' spectral peaks, features including proximity, size and shape of neighboring peaks, etc. In yet another aspect, the Biomarkers can be characterized by affinity binding characteristics, particularly ability to binding to an IMAC copper adsorbent under specified conditions, however, other metals, e.g., nickel, may also be used. In preferred embodiments, Biomarkers of the invention may be characterized by each of such aspects, i.e. molecular weight, mass spectral signature and IMAC-Cu absorbent binding.

For the mass values of the Biomarkers disclosed herein, the mass accuracy of the spectral instrument is considered to be about within ± 0.15 percent of the disclosed molecular weight value. Additionally, to such recognized accuracy variations of the instrument, the spectral mass determination can vary within resolution limits of from about 400 to 1000 m/dm, where m is mass and dm is the mass spectral peak width at 0.5 peak height. Those mass accuracy and resolution variances associated with the mass spectral instrument and operation thereof are reflected in the use of the term "about" in the disclosure of the mass of each of Biomarkers 1 through 48. It is also intended that such mass accuracy and resolution variances and thus meaning of the term "about" with respect to the mass of each of the Biomarkers disclosed herein is inclusive of variants of the Biomarkers as may exist due to sex, genotype and/or ethnicity of the subject and the particular cancer or origin or stage thereof.

The present invention further provides a method of qualifying kidney transplant rejection status in a subject comprising (a) measuring at least one bioBiomarker in a sample from the subject, wherein the bioBiomarker is selected from the group consisting of Biomarkers 1 through 48 and combinations thereof, and (b) correlating the measurement with kidney transplant rejection status. In certain methods, the measuring step comprises detecting the presence or absence of Biomarkers in the sample. In other methods, the measuring step comprises quantifying the amount of Biomarker(s) in the sample. In other methods, the measuring step comprises qualifying the type of bioBiomarker in the sample.

The accuracy of a diagnostic test is characterized by a Receiver Operating Characteristic curve ("ROC curve"). An ROC is a plot of the true positive rate against the false positive rate for the different possible cutpoints of a diagnostic test. An ROC curve shows the relationship between sensitivity and specificity. That is, an increase in sensitivity will be accompanied by a decrease in specificity. The closer the curve follows the left axis and then the top edge of the ROC space, the more accurate the test. Conversely, the closer the curve comes to the 45-degree diagonal of the ROC graph, the less accurate the test. The area under the ROC is a measure of test accuracy. The accuracy of the test depends on how well the test separates the group being tested into those with and without the disease in question. An area under the curve (referred to as "AUC") of 1 represents a perfect test, while an area of 0.5 represents a less useful test. Thus, preferred Biomarkers and diagnostic methods of the present invention have an AUC greater than 0.50, more preferred tests have an AUC greater than 0.60, more preferred tests have an AUC greater than 0.70.

Preferred methods of measuring the Biomarkers include use of a biochip array. Biochip arrays useful in the invention include protein and nucleic acid arrays. One or more Biomarkers are captured on the biochip array and subjected to laser ionization to detect the molecular weight of the Biomarkers. Analysis of the Biomarkers is, for example, by molecular weight of the one or more Biomarkers against a threshold intensity that is normalized against total ion current. Preferably, logarithmic transformation is used for reducing peak intensity ranges to limit the number of Biomarkers detected.

In preferred methods of the present invention, the step of correlating the measurement of the Biomarkers with kidney transplant status is performed by a software classification algorithm. Preferably, data is generated on immobilized subject samples on a biochip array, by subjecting said biochip array to laser ionization and detecting intensity of signal for mass/charge ratio; and, transforming the data into computer readable form; and executing an algorithm that classifies the data according to user input parameters, for detecting signals that represent Biomarkers present in kidney transplant rejection patients and are lacking in non-rejection patients.

Preferably the biochip surfaces are, for example, ionic, anionic, comprised of immobilized nickel ions, comprised of a mixture of positive and negative ions, comprised of one or more antibodies, single or double stranded nucleic acids, proteins, peptides or fragments thereof, amino acid probes, or phage display libraries.

5

In other preferred methods one or more of the Biomarkers are measured using laser desorption/ionization mass spectrometry, comprising providing a probe adapted for use with a mass spectrometer comprising an adsorbent attached thereto, and contacting the subject sample with the adsorbent, and; desorbing and ionizing the Biomarker or Biomarkers from the probe and detecting the deionized/ionized Biomarkers with the mass spectrometer.

10

Preferably, the laser desorption/ionization mass spectrometry comprises: providing a substrate comprising an adsorbent attached thereto; contacting the subject sample with the adsorbent; placing the substrate on a probe adapted for use with a mass spectrometer comprising an adsorbent attached thereto; and, desorbing and ionizing the Biomarker or Biomarkers from the probe and detecting the desorbed/ionized Biomarker or Biomarkers with the mass spectrometer.

15

The adsorbent can for example be hydrophobic, hydrophilic, ionic or metal chelate adsorbent, such as, nickel or an antibody, single- or double stranded oligonucleotide, amino acid, protein, peptide or fragments thereof.

20

The methods of the present invention can be performed on any type of patient sample that would be amenable to such methods, e.g., blood, serum and plasma. The preferred patient sample is urine.

25

In certain embodiments, a plurality of Biomarkers in a sample from the subject are measured, wherein the Biomarkers are selected from the group consisting of Biomarkers 1 through 48. In preferred methods, the plurality of Biomarkers consists of Biomarkers 3, 6, 14, 15, 16, 18, 19, 20, 21, 22, 23, 32 and 35. Preferably, the protein Biomarkers are measured by SELDI or immunoassay.

30

The present invention also provides kits comprising (a) a capture reagent that binds a Biomarker selected from Biomarkers 1 through 48, and combinations thereof; and (b) a container comprising at least one of the Biomarkers. In preferred embodiments, the capture reagent binds a plurality of the Biomarkers. In one
5 embodiment, the plurality comprises Biomarkers 3, 6, 14, 15, 16, 18, 19, 20, 21, 22, 23, 32 and 35. While the capture reagent can be any type of reagent, preferably the reagent is a SELDI probe. The capture reagent may also bind other known Biomarkers. In certain preferred embodiments, the kit of further comprises a second capture reagent that binds one of the Biomarkers that the first capture reagent does not
10 bind.

Further kits provided by the invention comprise (a) a first capture reagent that binds at least one Biomarker selected from Biomarkers 1 through 48, and (b) a second capture reagent that binds at least one of the Biomarkers that is not bound by the first
15 capture reagent. Preferably, at least one the capture reagent is an antibody. Certain kits further comprise an MS probe to which at least one capture reagent is attached or is attachable.

In certain kits of the present invention, the capture reagent comprises an
20 immobilized metal chelate ("IMAC").

Certain kits of the present invention further comprise a wash solution that selectively allows retention of the bound Biomarker to the capture reagent as compared with other Biomarkers after washing.
25

The invention also provides kits comprising (a) a first capture reagent that binds at least one Biomarker selected from Biomarkers 1 through 48, and (b) instructions for using the capture reagent to measure the Biomarker. In certain of these kits, the capture reagent comprises an antibody. Furthermore, some kits further
30 comprise an MS probe to which the capture reagent is attached or is attachable. In some kits, the capture reagent comprises an IMAC. The kits may also contain a wash solution that selectively allows retention of the bound Biomarker to the capture reagent as compared with other Biomarkers after washing. Preferably, the kit comprises written instructions for use of the kit for determining kidney transplant

rejection status and the instructions provide for contacting a test sample with the capture reagent and measuring one or more Biomarkers retained by the capture reagent.

5 The kit also provides for a capture reagent, which is an antibody, single or double stranded oligonucleotide, amino acid, protein, peptide or fragments thereof.

Measurement of one or more protein Biomarkers using the kit, is by mass spectrometry or immunoassays such as an ELISA.

10

Purified proteins for detection of kidney transplant rejection and/or generation of antibodies for further diagnostic assays are also provided for

Other aspects of the invention are described *infra*.

15

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 A and B represent the Receiver Operator Characteristic (ROC) Curves and data for BioBiomarker 1 having a molecular weight of about 2.5.

20

Figure 2 A and B represent the Receiver Operator Characteristic (ROC) Curves and data for BioBiomarker 2 having a molecular weight of about 2.6.

Figure 3 A and B represent the Receiver Operator Characteristic (ROC) Curves and data for BioBiomarker 3 having a molecular weight of about 3.4.

25

Figure 4 A and B represent the Receiver Operator Characteristic (ROC) Curves and data for BioBiomarker 4 having a molecular weight of about 3.5.

Figure 5 A and B represent the Receiver Operator Characteristic (ROC) Curves and data for BioBiomarker 5 having a molecular weight of about 3.8.

30

Figure 6 A and B represent the Receiver Operator Characteristic (ROC) Curves and data for BioBiomarker 6 having a molecular weight of about 4.1.

Figure 7 A and B represent the Receiver Operator Characteristic (ROC) Curves and data for BioBiomarker 7 having a molecular weight of about 4.7.

Figure 8 A and B represent the Receiver Operator Characteristic (ROC) Curves and data for BioBiomarker 8 having a molecular weight of about 4.8.

Figure 9 A and B represent the Receiver Operator Characteristic (ROC) Curves and data for BioBiomarker 9 having a molecular weight of about 5.0.

Figure 10 A and B represent the Receiver Operator Characteristic (ROC) Curves and data for BioBiomarker 10 having a molecular weight of about 5.5.

Figure 11 A and B represent the Receiver Operator Characteristic (ROC) Curves and data for BioBiomarker 11 having a molecular weight of about 5.6.

Figure 12 A and B represent the Receiver Operator Characteristic (ROC) Curves and data for BioBiomarker 12 having a molecular weight of about 6.1.

Figure 13 A and B represent the Receiver Operator Characteristic (ROC) Curves and data for BioBiomarker 13 having a molecular weight of about 6.4.

Figure 14 A and B represent the Receiver Operator Characteristic (ROC) Curves and data for BioBiomarker 14 having a molecular weight of about 6.5.

Figure 15 A and B represent the Receiver Operator Characteristic (ROC) Curves and data for BioBiomarker 15 having a molecular weight of about 6.6.

Figure 16 A and B represent the Receiver Operator Characteristic (ROC) Curves and data for BioBiomarker 16 having a molecular weight of about 6.7.

Figure 17 A and B represent the Receiver Operator Characteristic (ROC) Curves and data for BioBiomarker 17 having a molecular weight of about 6.8.

Figure 18 A and B represent the Receiver Operator Characteristic (ROC) Curves and data for BioBiomarker 18 having a molecular weight of about 7.0.

5 Figure 19 A and B represent the Receiver Operator Characteristic (ROC) Curves and data for BioBiomarker 19 having a molecular weight of about 7.1.

Figure 20 A and B represent the Receiver Operator Characteristic (ROC) Curves and data for BioBiomarker 20 having a molecular weight of about 7.3.

10 Figure 21 A and B represent the Receiver Operator Characteristic (ROC) Curves and data for BioBiomarker 21 having a molecular weight of about 7.5.

15 Figure 22 A and B represent the Receiver Operator Characteristic (ROC) Curves and data for BioBiomarker 22 having a molecular weight of about 7.8.

Figure 23 A and B represent the Receiver Operator Characteristic (ROC) Curves and data for BioBiomarker 23 having a molecular weight of about 8.0.

20 Figure 24 A and B represent the Receiver Operator Characteristic (ROC) Curves and data for BioBiomarker 24 having a molecular weight of about 8.1.

Figure 25 A and B represent the Receiver Operator Characteristic (ROC) Curves and data for BioBiomarker 25 having a molecular weight of about 9.0.

25 Figure 26 A and B represent the Receiver Operator Characteristic (ROC) Curves and data for BioBiomarker 26 having a molecular weight of about 9.1.

30 Figure 27 A and B represent the Receiver Operator Characteristic (ROC) Curves and data for BioBiomarker 27 having a molecular weight of about 9.3.

Figure 28 A and B represent the Receiver Operator Characteristic (ROC) Curves and data for BioBiomarker 28 having a molecular weight of about 9.6.

Figure 29 A and B represent the Receiver Operator Characteristic (ROC) Curves and data for BioBiomarker 29 having a molecular weight of about 9.7.

5 Figure 30 A and B represent the Receiver Operator Characteristic (ROC) Curves and data for BioBiomarker 30 having a molecular weight of about 9.8.

Figure 31 A and B represent the Receiver Operator Characteristic (ROC) Curves and data for BioBiomarker 31 having a molecular weight of about 10.0.

10 Figure 32 A and B represent the Receiver Operator Characteristic (ROC) Curves and data for BioBiomarker 32 having a molecular weight of about 10.8.

Figure 33 A and B represent the Receiver Operator Characteristic (ROC) Curves and data for BioBiomarker 33 having a molecular weight of about 10.9.
15

Figure 34 A and B represent the Receiver Operator Characteristic (ROC) Curves and data for BioBiomarker 34 having a molecular weight of about 11.3.

Figure 35 A and B represent the Receiver Operator Characteristic (ROC) Curves and data for BioBiomarker 35 having a molecular weight of about 13.4.
20

Figure 36 A and B represent the Receiver Operator Characteristic (ROC) Curves and data for BioBiomarker 36 having a molecular weight of about 13.9.

25 Figure 37 A and B represent the Receiver Operator Characteristic (ROC) Curves and data for BioBiomarker 37 having a molecular weight of about 14.7.

Figure 38 A and B represent the Receiver Operator Characteristic (ROC) Curves and data for BioBiomarker 38 having a molecular weight of about 14.8.
30

Figure 39 A and B represent the Receiver Operator Characteristic (ROC) Curves and data for BioBiomarker 39 having a molecular weight of about 15.1.

Figure 40 A and B represent the Receiver Operator Characteristic (ROC) Curves and data for BioBiomarker 40 having a molecular weight of about 15.2.

5 Figure 41 A and B represent the Receiver Operator Characteristic (ROC) Curves and data for BioBiomarker 41 having a molecular weight of about 16.1.

Figure 42 A and B represent the Receiver Operator Characteristic (ROC) Curves and data for BioBiomarker 42 having a molecular weight of about 25.0.

10 Figure 43 A and B represent the Receiver Operator Characteristic (ROC) Curves and data for BioBiomarker 43 having a molecular weight of about 28.0.

Figure 44 A and B represent the Receiver Operator Characteristic (ROC) Curves and data for BioBiomarker 44 having a molecular weight of about 50.0.
15

Figure 45 A and B represent the Receiver Operator Characteristic (ROC) Curves and data for BioBiomarker 45 having a molecular weight of about 50.1.

Figure 46 A and B represent the Receiver Operator Characteristic (ROC) Curves and data for BioBiomarker 46 having a molecular weight of about 51.1.
20

Figure 47 A and B represent the Receiver Operator Characteristic (ROC) Curves and data for BioBiomarker 47 having a molecular weight of about 51.3.

25 Figure 48 A and B represent the Receiver Operator Characteristic (ROC) Curves and data for BioBiomarker 48 having a molecular weight of about 67.0.

Figure 49 shows a sample mass spectra from nonrejection patients and rejection patients.
30

Figure 50 shows another sample mass spectra from a nonrejection patient and a rejection patient.

Figure 51 shows an illustrative ROC analysis of candidate biomarkers.

DEFINITIONS

Unless defined otherwise, all technical and scientific terms used herein have the meaning commonly understood by a person skilled in the art to which this invention belongs. The following references provide one of skill with a general
5 definition of many of the terms used in this invention: Singleton *et al.*, *Dictionary of Microbiology and Molecular Biology* (2nd ed. 1994); *The Cambridge Dictionary of Science and Technology* (Walker ed., 1988); *The Glossary of Genetics*, 5th Ed., R. Rieger *et al.* (eds.), Springer Verlag (1991); and Hale & Marham, *The Harper Collins Dictionary of Biology* (1991). As used herein, the following terms have the meanings
10 ascribed to them unless specified otherwise.

“Gas phase ion spectrometer” refers to an apparatus that detects gas phase ions. Gas phase ion spectrometers include an ion source that supplies gas phase ions. Gas phase ion spectrometers include, for example, mass spectrometers, ion mobility
15 spectrometers, and total ion current measuring devices. “Gas phase ion spectrometry” refers to the use of a gas phase ion spectrometer to detect gas phase ions.

“Mass spectrometer” refers to a gas phase ion spectrometer that measures a parameter that can be translated into mass-to-charge ratios of gas phase ions. Mass
20 spectrometers generally include an ion source and a mass analyzer. Examples of mass spectrometers are time-of-flight, magnetic sector, quadrupole filter, ion trap, ion cyclotron resonance, electrostatic sector analyzer and hybrids of these. “Mass spectrometry” refers to the use of a mass spectrometer to detect gas phase ions.

25 “Laser desorption mass spectrometer” refers to a mass spectrometer that uses laser energy as a means to desorb, volatilize, and ionize an analyte.

“Tandem mass spectrometer” refers to any mass spectrometer that is capable of performing two successive stages of m/z -based discrimination or measurement of
30 ions, including ions in an ion mixture. The phrase includes mass spectrometers having two mass analyzers that are capable of performing two successive stages of m/z -based discrimination or measurement of ions tandem-in-space. The phrase further includes mass spectrometers having a single mass analyzer that is capable of performing two successive stages of m/z -based discrimination or measurement of ions

tandem-in-time. The phrase thus explicitly includes Qq-TOF mass spectrometers, ion trap mass spectrometers, ion trap-TOF mass spectrometers, TOF-TOF mass spectrometers, Fourier transform ion cyclotron resonance mass spectrometers, electrostatic sector – magnetic sector mass spectrometers, and combinations thereof.

5

“Mass analyzer” refers to a sub-assembly of a mass spectrometer that comprises means for measuring a parameter that can be translated into mass-to-charge ratios of gas phase ions. In a time-of-flight mass spectrometer the mass analyzer comprises an ion optic assembly, a flight tube and an ion detector.

10

“Ion source” refers to a sub-assembly of a gas phase ion spectrometer that provides gas phase ions. In one embodiment, the ion source provides ions through a desorption/ionization process. Such embodiments generally comprise a probe interface that positionally engages a probe in an interrogatable relationship to a source of ionizing energy (e.g., a laser desorption/ionization source) and in concurrent communication at atmospheric or subatmospheric pressure with a detector of a gas phase ion spectrometer.

Forms of ionizing energy for desorbing/ionizing an analyte from a solid phase include, for example: (1) laser energy; (2) fast atoms (used in fast atom bombardment); (3) high energy particles generated via beta decay of radionuclides (used in plasma desorption); and (4) primary ions generating secondary ions (used in secondary ion mass spectrometry). The preferred form of ionizing energy for solid phase analytes is a laser (used in laser desorption/ionization), in particular, nitrogen lasers, Nd-Yag lasers and other pulsed laser sources. “Fluence” refers to the energy delivered per unit area of interrogated image. A high fluence source, such as a laser, will deliver about 1 mJ / mm² to 50 mJ / mm². Typically, a sample is placed on the surface of a probe, the probe is engaged with the probe interface and the probe surface is struck with the ionizing energy. The energy desorbs analyte molecules from the surface into the gas phase and ionizes them.

30

Other forms of ionizing energy for analytes include, for example: (1) electrons that ionize gas phase neutrals; (2) strong electric field to induce ionization from gas phase, solid phase, or liquid phase neutrals; and (3) a source that applies a

combination of ionization particles or electric fields with neutral chemicals to induce chemical ionization of solid phase, gas phase, and liquid phase neutrals.

“Solid support” refers to a solid material which can be derivatized with, or otherwise attached to, a capture reagent. Exemplary solid supports include probes, microtiter plates and chromatographic resins.

“Probe” in the context of this invention refers to a device adapted to engage a probe interface of a gas phase ion spectrometer (e.g., a mass spectrometer) and to present an analyte to ionizing energy for ionization and introduction into a gas phase ion spectrometer, such as a mass spectrometer. A “probe” will generally comprise a solid substrate (either flexible or rigid) comprising a sample presenting surface on which an analyte is presented to the source of ionizing energy.

“Surface-enhanced laser desorption/ionization” or “SELDI” refers to a method of desorption/ionization gas phase ion spectrometry (e.g., mass spectrometry) in which the analyte is captured on the surface of a SELDI probe that engages the probe interface of the gas phase ion spectrometer. In “SELDI MS,” the gas phase ion spectrometer is a mass spectrometer. SELDI technology is described in, e.g., U.S. patent 5,719,060 (Hutchens and Yip) and U.S. patent 6,225,047 (Hutchens and Yip).

“Surface-Enhanced Affinity Capture” or “SEAC” is a version of SELDI that involves the use of probes comprising an absorbent surface (a “SEAC probe”). “Adsorbent surface” refers to a surface to which is bound an adsorbent (also called a “capture reagent” or an “affinity reagent”). An adsorbent is any material capable of binding an analyte (e.g., a target polypeptide or nucleic acid). “Chromatographic adsorbent” refers to a material typically used in chromatography. Chromatographic adsorbents include, for example, ion exchange materials, metal chelators (e.g., nitriloacetic acid or iminodiacetic acid), immobilized metal chelates, hydrophobic interaction adsorbents, hydrophilic interaction adsorbents, dyes, simple biomolecules (e.g., nucleotides, amino acids, simple sugars and fatty acids) and mixed mode adsorbents (e.g., hydrophobic attraction/electrostatic repulsion adsorbents). “Biospecific adsorbent” refers an adsorbent comprising a biomolecule, e.g., a nucleic acid molecule (e.g., an aptamer), a polypeptide, a polysaccharide, a lipid, a steroid or

a conjugate of these (e.g., a glycoprotein, a lipoprotein, a glycolipid, a nucleic acid (e.g., DNA)-protein conjugate). In certain instances the biospecific adsorbent can be a macromolecular structure such as a multiprotein complex, a biological membrane or a virus. Examples of biospecific adsorbents are antibodies, receptor proteins and
5 nucleic acids. Biospecific adsorbents typically have higher specificity for a target analyte than chromatographic adsorbents. Further examples of adsorbents for use in SELDI can be found in U.S. Patent 6,225,047 (Hutchens and Yip, "Use of retentate chromatography to generate difference maps," May 1, 2001).

10 In some embodiments, a SEAC probe is provided as a pre-activated surface which can be modified to provide an adsorbent of choice. For example, certain probes are provided with a reactive moiety that is capable of binding a biological molecule through a covalent bond. Epoxide and carbodiimidazole are useful reactive moieties to covalently bind biospecific adsorbents such as antibodies or cellular
15 receptors.

"Adsorption" refers to detectable non-covalent binding of an analyte to an adsorbent or capture reagent.

20 "Surface-Enhanced Neat Desorption" or "SEND" is a version of SELDI that involves the use of probes comprising energy absorbing molecules chemically bound to the probe surface. ("SEND probe.") "Energy absorbing molecules" ("EAM") refer to molecules that are capable of absorbing energy from a laser desorption/ ionization source and thereafter contributing to desorption and ionization of analyte molecules in
25 contact therewith. The phrase includes molecules used in MALDI, frequently referred to as "matrix", and explicitly includes cinnamic acid derivatives, sinapinic acid ("SPA"), cyano-hydroxy-cinnamic acid ("CHCA") and dihydroxybenzoic acid, ferulic acid, hydroxyacetophenone derivatives, as well as others. It also includes EAMs used in SELDI. SEND is further described in United States patent 5,719,060
30 and United States patent application 60/408,255, filed September 4, 2002 (Kitagawa, "Monomers And Polymers Having Energy Absorbing Moieties Of Use In Desorption/Ionization Of Analytes").

“Surface-Enhanced Photolabile Attachment and Release” or “SEPAR” is a version of SELDI that involves the use of probes having moieties attached to the surface that can covalently bind an analyte, and then release the analyte through breaking a photolabile bond in the moiety after exposure to light, e.g., laser light.

5 SEPAR is further described in United States patent 5,719,060.

“Eluant” or “wash solution” refers to an agent, typically a solution, which is used to affect or modify adsorption of an analyte to an adsorbent surface and/or remove unbound materials from the surface. The elution characteristics of an eluant
10 can depend, for example, on pH, ionic strength, hydrophobicity, degree of chaotropism, detergent strength and temperature.

“Analyte” refers to any component of a sample that is desired to be detected. The term can refer to a single component or a plurality of components in the sample.
15

The “complexity” of a sample adsorbed to an adsorption surface of an affinity capture probe means the number of different protein species that are adsorbed.

“Molecular binding partners” and “specific binding partners” refer to pairs of
20 molecules, typically pairs of biomolecules that exhibit specific binding. Molecular binding partners include, without limitation, receptor and ligand, antibody and antigen, biotin and avidin, and biotin and streptavidin.

“Monitoring” refers to recording changes in a continuously varying parameter.
25

“Biochip” refers to a solid substrate having a generally planar surface to which an adsorbent is attached. Frequently, the surface of the biochip comprises a plurality of addressable locations, each of which location has the adsorbent bound there. Biochips can be adapted to engage a probe interface and, therefore, function as
30 probes.

“Protein biochip” refers to a biochip adapted for the capture of polypeptides. Many protein biochips are described in the art. These include, for example, protein biochips produced by CIPHERGEN Biosystems (Fremont, CA), Packard BioScience

Company (Meriden CT), Zyomyx (Hayward, CA) and Phylos (Lexington, MA). Examples of such protein biochips are described in the following patents or patent applications: U.S. patent 6,225,047 (Hutchens and Yip, "Use of retentate chromatography to generate difference maps," May 1, 2001); International publication WO 99/51773 (Kuimelis and Wagner, "Addressable protein arrays," October 14, 1999); U.S. patent 6,329,209 (Wagner et al., "Arrays of protein-capture agents and methods of use thereof," December 11, 2001) and International publication WO 00/56934 (Englert et al., "Continuous porous matrix arrays," September 28, 2000).

Protein biochips produced by CIPHERGEN Biosystems comprise surfaces having chromatographic or biospecific adsorbents attached thereto at addressable locations. CIPHERGEN ProteinChip® arrays include NP20, H4, H50, SAX-2, WCX-2, CM-10, IMAC-3, IMAC-30, LSAX-30, LWCX-30, IMAC-40, PS-10, PS-20 and PG-20. These protein biochips comprise an aluminum substrate in the form of a strip. The surface of the strip is coated with silicon dioxide.

In the case of the NP-20 biochip, silicon oxide functions as a hydrophilic adsorbent to capture hydrophilic proteins.

H4, H50, SAX-2, WCX-2, CM-10, IMAC-3, IMAC-30, PS-10 and PS-20 biochips further comprise a functionalized, cross-linked polymer in the form of a hydrogel physically attached to the surface of the biochip or covalently attached through a silane to the surface of the biochip. The H4 biochip has isopropyl functionalities for hydrophobic binding. The H50 biochip has nonylphenoxy-poly(ethylene glycol)methacrylate for hydrophobic binding. The SAX-2 biochip has quaternary ammonium functionalities for anion exchange. The WCX-2 and CM-10 biochips have carboxylate functionalities for cation exchange. The IMAC-3 and IMAC-30 biochips have nitriloacetic acid functionalities that adsorb transition metal ions, such as Cu^{++} and Ni^{++} , by chelation. These immobilized metal ions allow adsorption of peptide and proteins by coordinate bonding. The PS-10 biochip has carboimidazole functional groups that can react with groups on proteins for covalent binding. The PS-20 biochip has epoxide functional groups for covalent binding with proteins. The PS-series biochips are useful for binding biospecific adsorbents, such as

antibodies, receptors, lectins, heparin, Protein A, biotin/streptavidin and the like, to chip surfaces where they function to specifically capture analytes from a sample. The PG-20 biochip is a PS-20 chip to which Protein G is attached. The LSAX-30 (anion exchange), LWCX-30 (cation exchange) and IMAC-40 (metal chelate) biochips have functionalized latex beads on their surfaces. Such biochips are further described in: WO 00/66265 (Rich et al., "Probes for a Gas Phase Ion Spectrometer," November 9, 2000); WO 00/67293 (Beecher et al., "Sample Holder with Hydrophobic Coating for Gas Phase Mass Spectrometer," November 9, 2000); U.S. patent application US20030032043A1 (Pohl and Papanu, "Latex Based Adsorbent Chip," July 16, 2002) and U.S. patent application 60/350,110 (Um et al., "Hydrophobic Surface Chip," November 8, 2001).

Upon capture on a biochip, analytes can be detected by a variety of detection methods selected from, for example, a gas phase ion spectrometry method, an optical method, an electrochemical method, atomic force microscopy and a radio frequency method. Gas phase ion spectrometry methods are described herein. Of particular interest is the use of mass spectrometry and, in particular, SELDI. Optical methods include, for example, detection of fluorescence, luminescence, chemiluminescence, absorbance, reflectance, transmittance, birefringence or refractive index (e.g., surface plasmon resonance, ellipsometry, a resonant mirror method, a grating coupler waveguide method or interferometry). Optical methods include microscopy (both confocal and non-confocal), imaging methods and non-imaging methods. Immunoassays in various formats (e.g., ELISA) are popular methods for detection of analytes captured on a solid phase. Electrochemical methods include voltametry and amperometry methods. Radio frequency methods include multipolar resonance spectroscopy.

"Biomarker" in the context of the present invention refers to a polypeptide (of a particular apparent molecular weight), which is differentially present in a sample taken from patients having received a kidney transplant under rejection as compared to a patient having received a kidney transplant not under rejection.

The term "measuring" means methods which include detecting the presence or absence of Biomarker(s) in the sample, quantifying the amount of Biomarker(s) in

the sample, and/or qualifying the type of bioBiomarker. Measuring can be accomplished by methods known in the art and those further described herein, including but not limited to SELDI and immunoassay. Any suitable methods can be used to detect and measure one or more of the Biomarkers described herein. These methods include, without limitation, mass spectrometry (*e.g.*, laser desorption/ionization mass spectrometry), fluorescence (*e.g.* sandwich immunoassay), surface plasmon resonance, ellipsometry and atomic force microscopy.

The phrase "differentially present" refers to differences in the quantity and/or the frequency of a Biomarker present in a sample taken from patients having received a kidney transplant. For example, the Biomarker 6 is present at an elevated level in samples of kidney transplant rejection patients compared to samples from kidney transplant non-rejection patients. In contrast, Biomarkers 25, 29 and 30 described herein are present at a decreased level in samples of kidney transplant rejection patients compared to samples from kidney transplant non-rejection patients. Furthermore, a Biomarker can be a polypeptide, which is detected at a higher frequency or at a lower frequency in samples of kidney transplant rejection patients compared to samples from kidney transplant non-rejection patients. A Biomarker can be differentially present in terms of quantity, frequency or both.

A polypeptide is differentially present between two samples if the amount of the polypeptide in one sample is statistically significantly different from the amount of the polypeptide in the other sample. For example, a polypeptide is differentially present between the two samples if it is present at least about 120%, at least about 130%, at least about 150%, at least about 180%, at least about 200%, at least about 300%, at least about 500%, at least about 700%, at least about 900%, or at least about 1000% greater than it is present in the other sample, or if it is detectable in one sample and not detectable in the other.

Alternatively or additionally, a polypeptide is differentially present between two sets of samples if the frequency of detecting the polypeptide in the kidney transplant rejection patients' samples is statistically significantly higher or lower than in the samples from non-rejection patients. For example, a polypeptide is differentially present between the two sets of samples if it is detected at least about

120%, at least about 130%, at least about 150%, at least about 180%, at least about 200%, at least about 300%, at least about 500%, at least about 700%, at least about 900%, or at least about 1000% more frequently or less frequently observed in one set of samples than the other set of samples.

5

“Diagnostic” means identifying the presence or nature of a pathologic condition, i.e., kidney transplant rejection. Diagnostic methods differ in their sensitivity and specificity. The “sensitivity” of a diagnostic assay is the percentage of diseased individuals who test positive (percent of “true positives”). Diseased
10 individuals not detected by the assay are “false negatives.” Subjects who are not diseased and who test negative in the assay, are termed “true negatives.” The “specificity” of a diagnostic assay is 1 minus the false positive rate, where the “false positive” rate is defined as the proportion of those without the disease who test positive. While a particular diagnostic method may not provide a definitive diagnosis
15 of a condition, it suffices if the method provides a positive indication that aids in diagnosis.

A “test amount” of a Biomarker refers to an amount of a Biomarker present in a sample being tested. A test amount can be either in absolute amount (e.g., $\mu\text{g/ml}$) or
20 a relative amount (e.g., relative intensity of signals).

A “diagnostic amount” of a Biomarker refers to an amount of a Biomarker in a subject’s sample that is consistent with a diagnosis of kidney transplant rejection. A diagnostic amount can be either in absolute amount (e.g., $\mu\text{g/ml}$) or a relative amount
25 (e.g., relative intensity of signals).

A “control amount” of a Biomarker can be any amount or a range of amount, which is to be compared against a test amount of a Biomarker. For example, a control amount of a Biomarker can be the amount of a Biomarker in a person without kidney
30 transplant rejection. A control amount can be either in absolute amount (e.g., $\mu\text{g/ml}$) or a relative amount (e.g., relative intensity of signals).

“Antibody” refers to a polypeptide ligand substantially encoded by an immunoglobulin gene or immunoglobulin genes, or fragments thereof, which specifically binds and recognizes an epitope (*e.g.*, an antigen). The recognized immunoglobulin genes include the kappa and lambda light chain constant region genes, the alpha, gamma, delta, epsilon and mu heavy chain constant region genes, and the myriad immunoglobulin variable region genes. Antibodies exist, *e.g.*, as intact immunoglobulins or as a number of well-characterized fragments produced by digestion with various peptidases. This includes, *e.g.*, Fab' and F(ab)₂ fragments. The term “antibody,” as used herein, also includes antibody fragments either produced by the modification of whole antibodies or those synthesized *de novo* using recombinant DNA methodologies. It also includes polyclonal antibodies, monoclonal antibodies, chimeric antibodies, humanized antibodies, or single chain antibodies. “Fc” portion of an antibody refers to that portion of an immunoglobulin heavy chain that comprises one or more heavy chain constant region domains, CH₁, CH₂ and CH₃, but does not include the heavy chain variable region.

“Managing subject treatment” refers to the behavior of the clinician or physician subsequent to the determination of kidney transplant rejection status. For example, if the result of the methods of the present invention is inconclusive or there is reason that confirmation of status is necessary, the physician may order more tests. Alternatively, if the status indicates that altering immunosuppressive therapy is appropriate, the physician may schedule the patient for that change in treatment. Likewise, if the status is negative, *e.g.*, late stage kidney transplant rejection or if the status is acute, no further action may be warranted. Furthermore, if the results show that treatment has been successful, no further management may be necessary.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides Biomarkers generated from comparison of protein profiles from patients diagnosed with kidney transplant rejection and from patients without kidney transplant rejection, using the ProteinChip[®] Biomarker System (CIPHERGEN Biosystems, Inc., Fremont, CA). These Biomarkers, together with other known kidney transplant rejection Biomarkers, were evaluated individually and in multivariate predictive models. In particular, it is shown that these Biomarkers, used individually or preferably in combination with other Biomarkers from this group

or with other diagnostic tests, provide a novel method of determining kidney transplant rejection status in a subject.

High-throughput protein profiling combined with effective use of bioinformatics tools provides a useful approach to screening for kidney transplant rejection Biomarkers. Briefly, the system used in the present invention utilizes chromatographic ProteinChip® Arrays to assay samples using SELDI (Surface Enhanced Laser Desorption/Ionization). Proteins bound to the arrays are read in a ProteinChip® Reader, a time-of-flight mass spectrometer.

The present invention is based upon the discovery of protein Biomarkers that are differentially present in samples of kidney transplant rejection patients and kidney transplant non-rejection patients, and the application of this discovery in methods and kits for determining kidney transplant rejection status. These protein Biomarkers are found in samples from kidney transplant rejection patients at levels that are different than the levels in samples from patients without kidney transplant rejection. Accordingly, the amount of one or more Biomarkers found in a test sample compared to a control, or the presence or absence of one or more Biomarkers in the test sample provides useful information regarding the kidney transplant rejection status of the patient.

DISCOVERED RENAL TRANSPLANT REJECTION BIOMARKERS

The corresponding proteins or fragments of proteins for these bioBiomarkers are represented as intensity peaks in SELDI (surface enhanced laser desorption/ionization) protein chip/mass spectra with molecular masses centered around the following values:

- Biomarker 1: having a molecular weight of about 2.5 kD;
- Biomarker 2: having a molecular weight of about 2.6 kD;
- Biomarker 3: having a molecular weight of about 3.4 kD;
- Biomarker 4: having a molecular weight of about 3.5 kD;
- Biomarker 5: having a molecular weight of about 3.8 kD;
- Biomarker 6: having a molecular weight of about 4.1 kD;
- Biomarker 7: having a molecular weight of about 4.7 kD;

- 5 Biomarker 8: having a molecular weight of about 4.8 kD;
Biomarker 9: having a molecular weight of about 5.0 kD;
Biomarker 10: having a molecular weight of about 5.5 kD;
Biomarker 11: having a molecular weight of about 5.6 kD;
Biomarker 12: having a molecular weight of about 6.1 kD;
Biomarker 13: having a molecular weight of about 6.4 kD;
Biomarker 14: having a molecular weight of about 6.5 kD;
Biomarker 15: having a molecular weight of about 6.6 kD;
10 Biomarker 16: having a molecular weight of about 6.7 kD;
Biomarker 17: having a molecular weight of about 6.8 kD;
Biomarker 18: having a molecular weight of about 7.0 kD;
Biomarker 19: having a molecular weight of about 7.1 kD;
Biomarker 20: having a molecular weight of about 7.3 kD;
Biomarker 21: having a molecular weight of about 7.5 kD;
15 Biomarker 22: having a molecular weight of about 7.8 kD;
Biomarker 23: having a molecular weight of about 8.0 kD;
Biomarker 24: having a molecular weight of about 8.1 kD;
Biomarker 25: having a molecular weight of about 9.0 kD;
Biomarker 26: having a molecular weight of about 9.1 kD;
20 Biomarker 27: having a molecular weight of about 9.3 kD;
Biomarker 28: having a molecular weight of about 9.6 kD;
Biomarker 29: having a molecular weight of about 9.7 kD;
Biomarker 30: having a molecular weight of about 9.8 kD;
Biomarker 31: having a molecular weight of about 10.0 kD;
25 Biomarker 32: having a molecular weight of about 10.8 kD;
Biomarker 33: having a molecular weight of about 10.9 kD;
Biomarker 34: having a molecular weight of about 11.3 kD;
Biomarker 35: having a molecular weight of about 13.4 kD;
Biomarker 36: having a molecular weight of about 13.9 kD;
30 Biomarker 37: having a molecular weight of about 14.7 kD;
Biomarker 38: having a molecular weight of about 14.8 kD;
Biomarker 39: having a molecular weight of about 15.1 kD;
Biomarker 40: having a molecular weight of about 15.2 kD;
Biomarker 41: having a molecular weight of about 16.1 kD;

Biomarker 42: having a molecular weight of about 25.0 kD;
Biomarker 43: having a molecular weight of about 28.0 kD;
Biomarker 44: having a molecular weight of about 50.0 kD;
Biomarker 45: having a molecular weight of about 50.1 kD;
5 Biomarker 46: having a molecular weight of about 51.1 kD;
Biomarker 47: having a molecular weight of about 51.3 kD; and
Biomarker 48: having a molecular weight of about 67.0 kD.

10 As discussed above, Biomarkers 1 through 48 also may be characterized
based on affinity for an adsorbent, particularly binding to an immobilized chelate
(IMAC)-Cu substrate surface under the conditions specified under ProteinChip
Analysis of the General Comments of the Examples, which follow.

15 II. TEST SAMPLES

15 A) SUBJECT TYPES

Samples are collected from subjects, e.g., patients who want to establish
kidney transplant rejection status. Other patients include patients who have kidney
transplant rejection and the test is being used to determine the effectiveness of
immunosuppressive therapy or treatment they are receiving

20 B) TYPES OF SAMPLE AND PREPARATION OF THE SAMPLE

The Biomarkers can be measured in different types of biological samples. The
sample is preferably a biological fluid sample. Examples of a biological fluid sample
useful in this invention include blood, blood serum, plasma, vaginal secretions, urine,
25 tears, saliva, *etc.* Because all of the Biomarkers are found in urine, urine is a
preferred sample source for embodiments of the invention.

If desired, the sample can be prepared to enhance detectability of the
Biomarkers. For example, to increase the detectability of Biomarkers, a urine sample
30 from the subject can be preferably fractionated by, e.g., Cibacron blue agarose
chromatography and single stranded DNA affinity chromatography, anion exchange
chromatography, affinity chromatography (e.g., with antibodies) and the like. The
method of fractionation depends on the type of detection method used. Any method
that enriches for the protein of interest can be used. Sample preparations, such as pre-

fractionation protocols, are optional and may not be necessary to enhance detectability of Biomarkers depending on the methods of detection used. For example, sample preparation may be unnecessary if antibodies that specifically bind Biomarkers are used to detect the presence of Biomarkers in a sample.

5

Typically, sample preparation involves fractionation of the sample and collection of fractions determined to contain the Biomarkers. Methods of pre-fractionation include, for example, size exclusion chromatography, ion exchange chromatography, heparin chromatography, affinity chromatography, sequential
10 extraction, gel electrophoresis and liquid chromatography. The analytes also may be modified prior to detection. These methods are useful to simplify the sample for further analysis. For example, it can be useful to remove high abundance proteins, such as albumin, from blood before analysis. Examples of methods of fractionation are described in PCT/US03/00531 (incorporated herein in its entirety).

15

Preferably, the sample is pre-fractionated by anion exchange chromatography. Anion exchange chromatography allows pre-fractionation of the proteins in a sample roughly according to their charge characteristics. For example, a Q anion-exchange resin can be used (*e.g.*, Q HyperD F, Biosepra), and a sample can be sequentially
20 eluted with eluants having different pH's. Anion exchange chromatography allows separation of biomolecules in a sample that are more negatively charged from other types of biomolecules. Proteins that are eluted with an eluant having a high pH is likely to be weakly negatively charged, and a fraction that is eluted with an eluant having a low pH is likely to be strongly negatively charged. Thus, in addition to
25 reducing complexity of a sample, anion exchange chromatography separates proteins according to their binding characteristics.

30

In preferred embodiments, the urine samples are fractionated via anion exchange chromatography. Signal suppression of lower abundance proteins by high abundance proteins presents a significant challenge to SELDI mass spectrometry. Fractionation of a sample reduces the complexity of the constituents of each fraction. This method can also be used to attempt to isolate high abundance proteins into a fraction, and thereby reduce its signal suppression effect on lower abundance proteins. Anion exchange fractionation separates proteins by their isoelectric point (pI).

Proteins are comprised of amino acids, which are ambivalent-their charge changes based on the pH of the environment to which they are exposed. A protein's pI is the pH at which the protein has no net charge. A protein assumes a neutral charge when the pH of the environment is equivalent to pI of the protein. When the pH rises above the pI of the protein, the protein assumes a net negative charge. Similarly, when the pH of the environment falls below the pI of the protein, the protein has a net positive charge. The urine samples were fractionated according to the protocol set forth in the Examples below to obtain the Biomarkers described herein.

Biomolecules in a sample can also be separated by high-resolution electrophoresis, *e.g.*, one or two-dimensional gel electrophoresis. A fraction containing a Biomarker can be isolated and further analyzed by gas phase ion spectrometry. Preferably, two-dimensional gel electrophoresis is used to generate two-dimensional array of spots of biomolecules, including one or more Biomarkers. *See, e.g.*, Jungblut and Thiede, *Mass Spectr. Rev.* 16:145-162 (1997).

The two-dimensional gel electrophoresis can be performed using methods known in the art. *See, e.g.*, Deutscher ed., *Methods In Enzymology* vol. 182. Typically, biomolecules in a sample are separated by, *e.g.*, isoelectric focusing, during which biomolecules in a sample are separated in a pH gradient until they reach a spot where their net charge is zero (*i.e.*, isoelectric point). This first separation step results in one-dimensional array of biomolecules. The biomolecules in one-dimensional array is further separated using a technique generally distinct from that used in the first separation step. For example, in the second dimension, biomolecules separated by isoelectric focusing are further separated using a polyacrylamide gel, such as polyacrylamide gel electrophoresis in the presence of sodium dodecyl sulfate (SDS-PAGE). SDS-PAGE gel allows further separation based on molecular mass of biomolecules. Typically, two-dimensional gel electrophoresis can separate chemically different biomolecules in the molecular mass range from 1000-200,000 Da within complex mixtures. The pI range of these gels is about 3-10 (wide range gels).

Biomolecules in the two-dimensional array can be detected using any suitable methods known in the art. For example, biomolecules in a gel can be labeled or stained (*e.g.*, Coomassie Blue or silver staining). If gel electrophoresis generates

spots that correspond to the molecular weight of one or more Biomarkers of the invention, the spot can be further analyzed by gas phase ion spectrometry. For example, spots can be excised from the gel and analyzed by gas phase ion spectrometry. Alternatively, the gel containing biomolecules can be transferred to an inert membrane by applying an electric field. Then a spot on the membrane that approximately corresponds to the molecular weight of a Biomarker can be analyzed by gas phase ion spectrometry. In gas phase ion spectrometry, the spots can be analyzed using any suitable techniques, such as MALDI or SELDI (*e.g.*, using ProteinChip[®] array) as described herein.

Prior to gas phase ion spectrometry analysis, it may be desirable to cleave biomolecules in the spot into smaller fragments using cleaving reagents, such as proteases (*e.g.*, trypsin). The digestion of biomolecules into small fragments provides a mass fingerprint of the biomolecules in the spot, which can be used to determine the identity of Biomarkers if desired.

High performance liquid chromatography (HPLC) can also be used to separate a mixture of biomolecules in a sample based on their different physical properties, such as polarity, charge and size. HPLC instruments typically consist of a reservoir of mobile phase, a pump, an injector, a separation column, and a detector. Biomolecules in a sample are separated by injecting an aliquot of the sample onto the column. Different biomolecules in the mixture pass through the column at different rates due to differences in their partitioning behavior between the mobile liquid phase and the stationary phase. A fraction that corresponds to the molecular weight and/or physical properties of one or more Biomarkers can be collected. The fraction can then be analyzed by gas phase ion spectrometry to detect Biomarkers. For example, the spots can be analyzed using either MALDI or SELDI (*e.g.*, using ProteinChip[®] array) as described herein.

Optionally, a Biomarker can be modified before analysis to improve its resolution or to determine its identity. For example, the Biomarkers may be subject to proteolytic digestion before analysis. Any protease can be used. Proteases, such as trypsin, that are likely to cleave the Biomarkers into a discrete number of fragments

are particularly useful. The fragments that result from digestion function as a fingerprint for the Biomarkers, thereby enabling their detection indirectly. This is particularly useful where there are Biomarkers with similar molecular masses that might be confused for the Biomarker in question. Also, proteolytic fragmentation is useful for high molecular weight Biomarkers because smaller Biomarkers are more easily resolved by mass spectrometry. In another example, biomolecules can be modified to improve detection resolution. For instance, neuraminidase can be used to remove terminal sialic acid residues from glycoproteins to improve binding to an anionic adsorbent (*e.g.*, cationic exchange ProteinChip[®] arrays) and to improve detection resolution. In another example, the Biomarkers can be modified by the attachment of a tag of particular molecular weight that specifically bind to molecular Biomarkers, further distinguishing them. Optionally, after detecting such modified Biomarkers, the identity of the Biomarkers can be further determined by matching the physical and chemical characteristics of the modified Biomarkers in a protein database (*e.g.*, SwissProt).

III. CAPTURE OF BIOMARKERS

Biomarkers are preferably captured with capture reagents immobilized to a solid support, such as any biochip described herein, a multiwell microtiter plate or a resin. In particular, the Biomarkers of this invention are preferably captured on SELDI protein biochips. Capture can be on a chromatographic surface or a biospecific surface. Any of the SELDI protein biochips comprising reactive surfaces can be used to capture and detect the Biomarkers of this invention. However, the Biomarkers of this invention bind well to immobilized metal chelates. The IMAC-3 and IMAC 30 biochips, which nitriloacetic acid functionalities that adsorb transition metal ions, such as Cu^{++} and Ni^{++} , by chelation, are the preferred SELDI biochips for capturing the Biomarkers of this invention. Any of the SELDI protein biochips comprising reactive surfaces can be used to capture and detect the Biomarkers of this invention. These biochips can be derivatized with the antibodies that specifically capture the Biomarkers, or they can be derivatized with capture reagents, such as protein A or protein G that bind immunoglobulins. Then the Biomarkers can be captured in solution using specific antibodies and the captured Biomarkers isolated on chip through the capture reagent.

In general, a sample containing the Biomarkers, such as serum, is placed on the active surface of a biochip for a sufficient time to allow binding. Then, unbound molecules are washed from the surface using a suitable eluant, such as phosphate buffered saline. In general, the more stringent the eluant, the more tightly the proteins must be bound to be retained after the wash. The retained protein Biomarkers now can be detected by appropriate means.

IV. DETECTION AND MEASUREMENT OF BIOMARKERS

Once captured on a substrate, e.g., biochip or antibody, any suitable method can be used to measure a Biomarker or Biomarkers in a sample. For example, Biomarkers can be detected and/or measured by a variety of detection methods including for example, gas phase ion spectrometry methods, optical methods, electrochemical methods, atomic force microscopy and radio frequency methods. Using these methods, one or more Biomarkers can be detected.

A) SELDI

One preferred method of detection and/or measurement of the Biomarkers uses mass spectrometry and, in particular, "Surface-enhanced laser desorption/ionization" or "SELDI". SELDI refers to a method of desorption/ionization gas phase ion spectrometry (e.g., mass spectrometry) in which the analyte is captured on the surface of a SELDI probe that engages the probe interface. In "SELDI MS," the gas phase ion spectrometer is a mass spectrometer. SELDI technology is described in more detail above.

B) IMMUNOASSAY

In another embodiment, an immunoassay can be used to detect and analyze Biomarkers in a sample. This method comprises: (a) providing an antibody that specifically binds to a Biomarker; (b) contacting a sample with the antibody; and (c) detecting the presence of a complex of the antibody bound to the Biomarker in the sample.

An immunoassay is an assay that uses an antibody to specifically bind an antigen (e.g., a Biomarker). The immunoassay is characterized by the use of specific binding properties of a particular antibody to isolate, target, and/or quantify the

antigen. The phrase "specifically (or selectively) binds" to an antibody or "specifically (or selectively) immunoreactive with," when referring to a protein or peptide, refers to a binding reaction that is determinative of the presence of the protein in a heterogeneous population of proteins and other biologics. Thus, under designated immunoassay conditions, the specified antibodies bind to a particular protein at least two times the background and do not substantially bind in a significant amount to other proteins present in the sample. Specific binding to an antibody under such conditions may require an antibody that is selected for its specificity for a particular protein. For example, polyclonal antibodies raised to a Biomarker from specific species such as rat, mouse, or human can be selected to obtain only those polyclonal antibodies that are specifically immunoreactive with that Biomarker and not with other proteins, except for polymorphic variants and alleles of the Biomarker. This selection may be achieved by subtracting out antibodies that cross-react with the Biomarker molecules from other species.

Using the purified Biomarkers or their nucleic acid sequences, antibodies that specifically bind to a Biomarker can be prepared using any suitable methods known in the art. See, e.g., Coligan, *Current Protocols in Immunology* (1991); Harlow & Lane, *Antibodies: A Laboratory Manual* (1988); Goding, *Monoclonal Antibodies: Principles and Practice* (2d ed. 1986); and Kohler & Milstein, *Nature* 256:495-497 (1975). Such techniques include, but are not limited to, antibody preparation by selection of antibodies from libraries of recombinant antibodies in phage or similar vectors, as well as preparation of polyclonal and monoclonal antibodies by immunizing rabbits or mice (see, e.g., Huse *et al.*, *Science* 246:1275-1281 (1989); Ward *et al.*, *Nature* 341:544-546 (1989)). Typically a specific or selective reaction will be at least twice background signal or noise and more typically more than 10 to 100 times background.

Generally, a sample obtained from a subject can be contacted with the antibody that specifically binds the Biomarker. Optionally, the antibody can be fixed to a solid support to facilitate washing and subsequent isolation of the complex, prior to contacting the antibody with a sample. Examples of solid supports include glass or plastic in the form of, e.g., a microtiter plate, a stick, a bead, or a microbead. Antibodies can also be attached to a probe substrate or ProteinChip[®] array described above. The sample is preferably a biological fluid sample taken from a subject.

Examples of biological fluid samples include blood, serum, plasma, nipple aspirate, urine, tears, saliva *etc.* In a preferred embodiment, the biological fluid comprises blood serum. The sample can be diluted with a suitable eluant before contacting the sample to the antibody.

5

After incubating the sample with antibodies, the mixture is washed and the antibody-Biomarker complex formed can be detected. This can be accomplished by incubating the washed mixture with a detection reagent. This detection reagent may be, *e.g.*, a second antibody which is labeled with a detectable label. Exemplary
10 detectable labels include magnetic beads (*e.g.*, DYNABEADS™), fluorescent dyes, radiolabels, enzymes (*e.g.*, horse radish peroxide, alkaline phosphatase and others commonly used in an ELISA), and colorimetric labels such as colloidal gold or colored glass or plastic beads. Alternatively, the Biomarker in the sample can be detected using an indirect assay, wherein, for example, a second, labeled antibody is
15 used to detect bound Biomarker-specific antibody, and/or in a competition or inhibition assay wherein, for example, a monoclonal antibody which binds to a distinct epitope of the Biomarker is incubated simultaneously with the mixture.

Methods for measuring the amount of, or presence of, antibody-Biomarker
20 complex include, for example, detection of fluorescence, luminescence, chemiluminescence, absorbance, reflectance, transmittance, birefringence or refractive index (*e.g.*, surface plasmon resonance, ellipsometry, a resonant mirror method, a grating coupler waveguide method or interferometry). Optical methods include microscopy (both confocal and non-confocal), imaging methods and non-
25 imaging methods. Electrochemical methods include voltametry and amperometry methods. Radio frequency methods include multipolar resonance spectroscopy. Methods for performing these assays are readily known in the art. Useful assays include, for example, an enzyme immune assay (EIA) such as enzyme-linked immunosorbent assay (ELISA), a radioimmune assay (RIA), a Western blot assay, or
30 a slot blot assay. These methods are also described in, *e.g.*, *Methods in Cell Biology: Antibodies in Cell Biology*, volume 37 (Asai, ed. 1993); *Basic and Clinical Immunology* (Stites & Terr, eds., 7th ed. 1991); and Harlow & Lane, *supra*.

Throughout the assays, incubation and/or washing steps may be required after each combination of reagents. Incubation steps can vary from about 5 seconds to several hours, preferably from about 5 minutes to about 24 hours. However, the incubation time will depend upon the assay format, Biomarker, volume of solution, concentrations and the like. Usually the assays will be carried out at ambient temperature, although they can be conducted over a range of temperatures, such as 10°C to 40°C.

Immunoassays can be used to determine presence or absence of a Biomarker in a sample as well as the quantity of a Biomarker in a sample. The amount of an antibody-Biomarker complex can be determined by comparing to a standard. A standard can be, e.g., a known compound or another protein known to be present in a sample. As noted above, the test amount of Biomarker need not be measured in absolute units, as long as the unit of measurement can be compared to a control.

The methods for detecting these Biomarkers in a sample have many applications. For example, one or more Biomarkers can be measured to aid kidney transplant rejection diagnosis or prognosis. In another example, the methods for detection of the Biomarkers can be used to monitor responses in a subject to immunosuppression treatment. In another example, the methods for detecting Biomarkers can be used to assay for and to identify compounds that modulate expression of these Biomarkers *in vivo* or *in vitro*. In a preferred example, the Biomarkers are used to differentiate between the different stages of rejection progression, thus aiding in determining appropriate treatment.

V. DATA ANALYSIS

When the sample is measured and data is generated, e.g., by mass spectrometry, the data is then analyzed by a computer software program. Generally, the software can comprise code that converts signal from the mass spectrometer into computer readable form. The software also can include code that applies an algorithm to the analysis of the signal to determine whether the signal represents a "peak" in the signal corresponding to a Biomarker of this invention, or other useful Biomarkers. The software also can include code that executes an algorithm that compares signal from a test sample to a typical signal characteristic of "normal" and human cancer and

determines the closeness of fit between the two signals. The software also can include code indicating which the test sample is closest to, thereby providing a probable diagnosis.

5 In preferred methods of the present invention, multiple Biomarkers are measured. The use of multiple Biomarkers increases the predictive value of the test and provides greater utility in diagnosis, toxicology, patient stratification and patient monitoring. The process called "Pattern recognition" detects the patterns formed by multiple Biomarkers greatly improves the sensitivity and specificity of clinical
10 proteomics for predictive medicine. Subtle variations in data from clinical samples, e.g., obtained using SELDI, indicate that certain patterns of protein expression can predict phenotypes such as the presence or absence of a certain stage of rejection or a positive or adverse response to immunosuppression treatments.

15 Data generation in mass spectrometry begins with the detection of ions by an ion detector as described above. Ions that strike the detector generate an electric potential that is digitized by a high speed time-array recording device that digitally captures the analog signal. Ciphergen's ProteinChip[®] system employs an analog-to-digital converter (ADC) to accomplish this. The ADC integrates detector output at
20 regularly spaced time intervals into time-dependent bins. The time intervals typically are one to four nanoseconds long. Furthermore, the time-of-flight spectrum ultimately analyzed typically does not represent the signal from a single pulse of ionizing energy against a sample, but rather the sum of signals from a number of pulses. This reduces noise and increases dynamic range. This time-of-flight data is
25 then subject to data processing. In Ciphergen's ProteinChip[®] software, data processing typically includes TOF-to-M/Z transformation, baseline subtraction, high frequency noise filtering.

 TOF-to-M/Z transformation involves the application of an algorithm that transforms times-of-flight into mass-to-charge ratio (M/Z). In this step, the signals
30 are converted from the time domain to the mass domain. That is, each time-of-flight is converted into mass-to-charge ratio, or M/Z. Calibration can be done internally or externally. In internal calibration, the sample analyzed contains one or more analytes of known M/Z. Signal peaks at times-of-flight representing these massed analytes are assigned the known M/Z. Based on these assigned M/Z ratios, parameters are

calculated for a mathematical function that converts times-of-flight to M/Z . In external calibration, a function that converts times-of-flight to M/Z , such as one created by prior internal calibration, is applied to a time-of-flight spectrum without the use of internal calibrants.

5

Baseline subtraction improves data quantification by eliminating artificial, reproducible instrument offsets that perturb the spectrum. It involves calculating a spectrum baseline using an algorithm that incorporates parameters such as peak width, and then subtracting the baseline from the mass spectrum.

10

High frequency noise signals are eliminated by the application of a smoothing function. A typical smoothing function applies a moving average function to each time-dependent bin. In an improved version, the moving average filter is a variable width digital filter in which the bandwidth of the filter varies as a function of, e.g., peak bandwidth, generally becoming broader with increased time-of-flight. See, e.g., WO 00/70648, November 23, 2000 (Gavin et al., "Variable Width Digital Filter for Time-of-flight Mass Spectrometry").

15

Analysis generally involves the identification of peaks in the spectrum that represent signal from an analyte. Peak selection can, of course, be done by eye. However, software is available as part of Ciphergen's ProteinChip® software that can automate the detection of peaks. In general, this software functions by identifying signals having a signal-to-noise ratio above a selected threshold and labeling the mass of the peak at the centroid of the peak signal. In one useful application many spectra are compared to identify identical peaks present in some selected percentage of the mass spectra. One version of this software clusters all peaks appearing in the various spectra within a defined mass range, and assigns a mass (M/Z) to all the peaks that are near the mid-point of the mass (M/Z) cluster.

20

25

30

Peak data from one or more spectra can be subject to further analysis by, for example, creating a spreadsheet in which each row represents a particular mass spectrum, each column represents a peak in the spectra defined by mass, and each cell includes the intensity of the peak in that particular spectrum. Various statistical or pattern recognition approaches can be applied to the data.

In one example, CIPHERGEN's BioBiomarker Patterns™ Software is used to detect a pattern in the spectra that are generated. The data is classified using a pattern recognition process that uses a classification model. In general, the spectra will
5 represent samples from at least two different groups for which a classification algorithm is sought. For example, the groups can be pathological v. non-pathological (e.g., rejection v. non-rejection), drug responder v. drug non-responder, toxic response v. non-toxic response, progressor to disease state v. non-progressor to disease state, phenotypic condition present v. phenotypic condition absent.

10

The spectra that are generated in embodiments of the invention can be classified using a pattern recognition process that uses a classification model. In some embodiments, data derived from the spectra (e.g., mass spectra or time-of-flight spectra) that are generated using samples such as "known samples" can then be used
15 to "train" a classification model. A "known sample" is a sample that is pre-classified (e.g., rejection or non-rejection). Data derived from the spectra (e.g., mass spectra or time-of-flight spectra) that are generated using samples such as "known samples" can then be used to "train" a classification model. A "known sample" is a sample that is pre-classified. The data that are derived from the spectra and are used to form the
20 classification model can be referred to as a "training data set". Once trained, the classification model can recognize patterns in data derived from spectra generated using unknown samples. The classification model can then be used to classify the unknown samples into classes. This can be useful, for example, in predicting whether or not a particular biological sample is associated with a certain biological condition
25 (e.g., rejection v. non-rejection).

The training data set that is used to form the classification model may comprise raw data or pre-processed data. In some embodiments, raw data can be obtained directly from time-of-flight spectra or mass spectra, and then may be optionally "pre-processed" in any suitable manner. For example, signals above a
30 predetermined signal-to-noise ratio can be selected so that a subset of peaks in a spectrum is selected, rather than selecting all peaks in a spectrum. In another example, a predetermined number of peak "clusters" at a common value (e.g., a particular time-of-flight value or mass-to-charge ratio value) can be used to select peaks. Illustratively, if a peak at a given mass-to-charge ratio is in less than 50% of

the mass spectra in a group of mass spectra, then the peak at that mass-to-charge ratio can be omitted from the training data set. Pre-processing steps such as these can be used to reduce the amount of data that is used to train the classification model.

5 Classification models can be formed using any suitable statistical classification (or "learning") method that attempts to segregate bodies of data into classes based on objective parameters present in the data. Classification methods may be either supervised or unsupervised. Examples of supervised and unsupervised classification processes are described in Jain, "Statistical Pattern Recognition: A
10 Review", IEEE Transactions on Pattern Analysis and Machine Intelligence, Vol. 22, No. 1, January 2000, which is herein incorporated by reference in its entirety.

 In supervised classification, training data containing examples of known categories are presented to a learning mechanism, which learns one more sets of
15 relationships that define each of the known classes. New data may then be applied to the learning mechanism, which then classifies the new data using the learned relationships. Examples of supervised classification processes include linear regression processes (e.g., multiple linear regression (MLR), partial least squares (PLS) regression and principal components regression (PCR)), binary decision trees
20 (e.g., recursive partitioning processes such as CART - classification and regression trees), artificial neural networks such as backpropagation networks, discriminant analyses (e.g., Bayesian classifier or Fischer analysis), logistic classifiers, and support vector classifiers (support vector machines).

25 A preferred supervised classification method is a recursive partitioning process. Recursive partitioning processes use recursive partitioning trees to classify spectra derived from unknown samples. Further details about recursive partitioning processes are provided in U.S. 2002 0138208 A1 (Paulse et al., "Method for analyzing mass spectra," September 26, 2002.

30

 In other embodiments, the classification models that are created can be formed using unsupervised learning methods. Unsupervised classification attempts to learn classifications based on similarities in the training data set, without pre classifying the spectra from which the training data set was derived. Unsupervised learning methods

include cluster analyses. A cluster analysis attempts to divide the data into "clusters" or groups that ideally should have members that are very similar to each other, and very dissimilar to members of other clusters. Similarity is then measured using some distance metric, which measures the distance between data items, and clusters

5 together data items that are closer to each other. Clustering techniques include the MacQueen's K-means algorithm and the Kohonen's Self-Organizing Map algorithm.

Learning algorithms asserted for use in classifying biological information are described in, for example, WO 01/31580 (Barnhill et al., "Methods and devices for
10 identifying patterns in biological systems and methods of use thereof," May 3, 2001); U.S. 2002/0193950 A1 (Gavin et al., "Method or analyzing mass spectra," December 19, 2002); U.S. 2003/0004402 A1 (Hitt et al., "Process for discriminating between biological states based on hidden patterns from biological data," January 2, 2003); and U.S. 2003/ 0055615 A1 (Zhang and Zhang, "Systems and methods for processing
15 biological expression data" March 20, 2003).

Generally, the data generated from Section IV above is inputted into a diagnostic algorithm (i.e., classification algorithm as described above). The classification algorithm is then generated based on the learning algorithm. The
20 process involves developing an algorithm that can generate the classification algorithm. The methods of the present invention generate a more accurate classification algorithm by accessing a number of kidney transplant rejection and normal samples of a sufficient number based on statistical sample calculations. The samples are used as a training set of data on learning algorithm.

25 The generation of the classification, i.e., diagnostic, algorithm is dependent upon the assay protocol used to analyze samples and generate the data obtained in Section IV above. It is imperative that the protocol for the detection and/or measurement of the Biomarkers (e.g., in step IV) must be the same as that used to obtain the data used for developing the classification algorithm. The assay conditions,
30 which must be maintained throughout the training and classification systems include chip type and mass spectrometer parameters, as well as general protocols for sample preparation and testing. If the protocol for the detection and/or measurement of the Biomarkers (step IV) is changed, the learning algorithm and classification algorithm must also change. Similarly, if the learning algorithm and classification algorithm

change, then the protocol for the detection and/or measurement of Biomarkers (step IV) must also change to be consistent with that used to generate classification algorithm. Development of a new classification model would require accessing a sufficient number of kidney transplant rejection and non-rejection samples, 5 developing a new training set of data based on a new detection protocol, generating a new classification algorithm using the data and finally, verifying the classification algorithm with a multi-site study.

The classification models can be formed on and used on any suitable digital 10 computer. Suitable digital computers include micro, mini, or large computers using any standard or specialized operating system such as a Unix, Windows™ or Linux™ based operating system. The digital computer that is used may be physically separate from the mass spectrometer that is used to create the spectra of interest, or it may be coupled to the mass spectrometer. If it is separate from the mass spectrometer, the 15 data must be inputted into the computer by some other means, whether manually or automated.

The training data set and the classification models according to embodiments of the invention can be embodied by computer code that is executed or used by a 20 digital computer. The computer code can be stored on any suitable computer readable media including optical or magnetic disks, sticks, tapes, etc., and can be written in any suitable computer programming language including C, C++, visual basic, etc.

VI. EXAMPLES OF PREFERRED EMBODIMENTS.

25 In a preferred embodiment, a urine sample is collected from a patient and then fractionated using an anion exchange resin as described above. The Biomarkers in the sample are captured using an IMAC copper ProteinChip array. The Biomarkers are then detected using SELDI. The results are then entered into a computer system, which contains an algorithm that is designed using the same parameters that were 30 used in the learning algorithm and classification algorithm to originally determine the Biomarkers. The algorithm produces a diagnosis based upon the data received relating to each Biomarker.

The diagnosis is determined by examining the data produced from the SELDI tests with the classification algorithm that is developed using the Biomarkers. The classification algorithm depends on the particulars of the test protocol used to detect the Biomarkers. These particulars include, for example, sample preparation, chip type and mass spectrometer parameters. If the test parameters change, the algorithm must change. Similarly, if the algorithm changes, the test protocol must change.

In another embodiment, the sample is collected from the patient. The Biomarkers are captured using an antibody ProteinChip array as described above.

The Biomarkers are detected using a biospecific SELDI test system. The results are then entered into a computer system, which contains an algorithm that is designed using the same parameters that were used in the learning algorithm and classification algorithm to originally determine the Biomarkers. The algorithm produces a diagnosis based upon the data received relating to each Biomarker.

In yet other preferred embodiments, the Biomarkers are captured and tested using non-SELDI formats. In one example, the sample is collected from the patient. The Biomarkers are captured on a substrate using other known means, e.g., antibodies to the Biomarkers. The Biomarkers are detected using methods known in the art, e.g., optical methods and refractive index. Examples of optical methods include detection of fluorescence, e.g., ELISA. Examples of refractive index include surface plasmon resonance. The results for the Biomarkers are then subjected to an algorithm, which may or may not require artificial intelligence. The algorithm produces a diagnosis based upon the data received relating to each Biomarker.

In any of the above methods, the data from the sample may be fed directly from the detection means into a computer containing the diagnostic algorithm. Alternatively, the data obtained can be fed manually, or via an automated means, into a separate computer that contains the diagnostic algorithm.

VII. DIAGNOSIS OF SUBJECT AND DETERMINATION OF KIDNEY TRANSPLANT REJECTION STATUS

Any Biomarker, individually, is useful in aiding in the determination of kidney transplant rejection status. First, the selected Biomarker is measured in a subject sample using the methods described herein, e.g., capture on a SELDI biochip

followed by detection by mass spectrometry. Then, the measurement is compared with a diagnostic amount or control that distinguishes kidney transplant rejection status from a non-rejection status. The diagnostic amount will reflect the information herein that a particular Biomarker is up-regulated or down-regulated in a kidney transplant rejection status compared with a non-rejection status. As is well understood in the art, the particular diagnostic amount used can be adjusted to increase sensitivity or specificity of the diagnostic assay depending on the preference of the diagnostician. The test amount as compared with the diagnostic amount thus indicates kidney transplant rejection status.

While individual Biomarkers are useful diagnostic Biomarkers, it has been found that a combination of Biomarkers provides greater predictive value than single Biomarkers alone. Specifically, the detection of a plurality of Biomarkers in a sample increases the percentage of true positive and true negative diagnoses and would decrease the percentage of false positive or false negative diagnoses. Thus, preferred methods of the present invention comprise the measurement of more than one Biomarker. For example, the methods of the present invention have an AUC from ROC analysis greater than 0.50, more preferred methods have an AUC greater than 0.60, more preferred methods have an AUC greater than 0.70. Especially preferred methods have an AUC greater than 0.70 and most preferred methods have an AUC greater than 0.80.

Furthermore, using a method that measures the combination of the preferred Biomarkers of the present invention significantly improves the diagnostic performance, providing a test that has an AUC greater than 0.50, more preferred tests have an AUC greater than 0.60, more preferred tests have an AUC greater than 0.70.

In order to use the Biomarkers in combination, a logistical regression algorithm is useful. The UMSA algorithm is particularly useful to generate a diagnostic algorithm from test data. This algorithm is disclosed in Z. Zhang et al., Applying classification separability analysis to microarray data. In: Lin SM, Johnson KF, eds. Methods of Microarray data analysis: papers from CAMDA '00. Boston: Kluwer Academic Publishers, 2001:125-136; and Z. Zhang et al., Fishing Expedition – a Supervised Approach to Extract Patterns from a Compendium of Expression

Profiles. In Lin SM, Johnson, KF, eds. Microarray Data Analysis II: Papers from CAMDA '01. Boston: Kluwer Academic Publishers, 2002.

5 The learning algorithm will generate a multivariate classification (diagnostic) algorithm tuned to the particular specificity and sensitivity desired by the operator. The classification algorithm can then be used to determine kidney transplant rejection status. The method also involves measuring the selected Biomarkers in a subject sample (e.g., Biomarkers 1 through 48). These measurements are submitted to the classification algorithm. The classification algorithm generates an indicator score that
10 indicates kidney transplant rejection status.

In some embodiments, the mere presence or absence of a Biomarker, without quantifying the amount of Biomarker, is useful and can be correlated with a probable diagnosis of kidney transplant rejection. For example, Biomarker 15 can be more
15 frequently detected in human kidney transplant rejection patients than in non-rejection patients. Equally, for example, Biomarkers 29 and 30, can be less frequently detected in human kidney transplant rejection patients than in non-rejection patients. Thus, a detected presence or absence, respectively, of these Biomarkers in a subject being tested indicates that the subject has a higher probability of having kidney transplant
20 rejection.

In other embodiments, the measurement of Biomarkers can involve quantifying the Biomarkers to correlate the detection of Biomarkers with a probable diagnosis of kidney transplant rejection. Thus, if the amount of the Biomarkers
25 detected in a subject being tested is different compared to a control amount (i.e., higher or lower than the control, depending on the Biomarker), then the subject being tested has a higher probability of having kidney transplant rejection.

The correlation may take into account the amount of the Biomarker or
30 Biomarkers in the sample compared to a control amount of the Biomarker or Biomarkers (up or down regulation of the Biomarker or Biomarkers) (e.g., in normal subjects in whom human cancer is undetectable). A control can be, e.g., the average or median amount of Biomarker present in comparable samples of normal subjects in whom rejection is undetectable. The control amount is measured under the same or

substantially similar experimental conditions as in measuring the test amount. The correlation may take into account the presence or absence of the Biomarkers in a test sample and the frequency of detection of the same Biomarkers in a control. The correlation may take into account both of such factors to facilitate determination of
5 kidney transplant rejection status.

In certain embodiments of the methods of qualifying kidney transplant rejection status, the methods further comprise managing subject treatment based on the status. As aforesaid, such management describes the actions of the physician or
10 clinician subsequent to determining kidney transplant rejection status. For example, if the result of the methods of the present invention is inconclusive or there is reason that confirmation of status is necessary, the physician may order more tests. Alternatively, if the status indicates that altered immunosuppression therapy is appropriate, the physician may schedule the patient for a change in therapy. Likewise,
15 if the result is negative, e.g., the status indicates late stage kidney transplant rejection or if the status is otherwise acute, no further action may be warranted. Furthermore, if the results show that treatment has been successful, no further management may be necessary.

20 The invention also provides for such methods where the Biomarkers (or specific combination of Biomarkers) are measured again after subject management. In these cases, the methods are used to monitor the status of the rejection, e.g., response to immunosuppression treatment. Because of the ease of use of the methods and the lack of invasiveness of the methods, the methods can be repeated after each
25 treatment the patient receives. This allows the physician to follow the effectiveness of the course of treatment. If the results show that the treatment is not effective, the course of treatment can be altered accordingly. This enables the physician to be flexible in the treatment options.

30 In another example, the methods for detecting Biomarkers can be used to assay for and to identify compounds that modulate expression of these Biomarkers *in vivo* or *in vitro*.

The methods of the present invention have other applications as well. For example, the Biomarkers can be used to screen for compounds that modulate the expression of the Biomarkers *in vitro* or *in vivo*, which compounds in turn may be useful in treating or preventing kidney transplant rejection in patients. In another
5 example, the Biomarkers can be used to monitor the response to treatments for kidney transplant rejection

VIII. KITS

In yet another aspect, the present invention provides kits for qualifying kidney
10 transplant rejection status, wherein the kits can be used to measure the Biomarkers of the present invention. For example, the kits can be used to measure any one or more of the Biomarkers described herein, which Biomarkers are differentially present in samples of kidney transplant rejection patient and non-rejection patients. The kits of the invention have many applications. For example, the kits can be used to
15 differentiate if a subject has kidney transplant rejection or has a negative diagnosis, thus enabling the physician or clinician to diagnose the presence or absence of rejection. The kits can also be used to monitor the patient's response to a course of treatment, enabling the physician to modify the treatment based upon the results of the test. In another example, the kits can be used to identify compounds that modulate
20 expression of one or more of the Biomarkers in *in vitro* or *in vivo* animal models for kidney transplant rejection.

The present invention therefore provides kits comprising (a) a capture reagent that binds a Biomarker selected from Biomarkers 1 through 48, and combinations
25 thereof; and (b) a container comprising at least one of the Biomarkers. In preferred kit, the capture reagent binds a plurality of the Biomarkers. In certain preferred embodiments, the kit of further comprises a second capture reagent that binds one of the Biomarkers that the first capture reagent does not bind.

30 Further kits provided by the invention comprise (a) a first capture reagent that binds at least one Biomarker selected from Biomarkers 1 through 48 and (b) a second capture reagent that binds at least one of the Biomarkers that is not bound by the first capture reagent. Preferably, at least one of the capture reagents is an antibody.

Certain kits further comprise an MS probe to which at least one capture reagent is attached or is attachable.

While the capture reagent can be any type of reagent, preferably the reagent is a SELDI probe. In certain kits of the present invention, the capture reagent comprises an IMAC.

The invention also provides kits comprising (a) a first capture reagent that binds at least one Biomarker selected from Biomarkers 1 through 48 and (b) instructions for using the capture reagent to measure the Biomarker. In certain of these kits, the capture reagent comprises an antibody. Furthermore, some of the aforesaid kits further comprise an MS probe to which the capture reagent is attached or is attachable. In some kits, the capture reagent comprises an IMAC. Each of the Biomarkers identified here binds to the IMAC ProteinChip[®] array. Therefore, one preferred embodiment of the present invention includes a high-throughput test for early detection of kidney transplant rejection, which analyzes a patient's sample on the IMAC ProteinChip[®] array for these analytes.

In other embodiments, the kits as described herein comprise at least one capture reagent that binds at least one Biomarker selected from Biomarkers 1 through 48.

Certain kits of the present invention further comprise a wash solution, or eluant, that selectively allows retention of the bound Biomarker to the capture reagent as compared with other Biomarkers after washing. Alternatively, the kit may contain instructions for making a wash solution, wherein the combination of the adsorbent and the wash solution allows detection of the Biomarkers using gas phase ion spectrometry.

Preferably, the kit comprises written instructions for use of the kit for detection of kidney transplant rejection and the instructions provide for contacting a test sample with the capture reagent and detecting one or more Biomarkers retained by the capture reagent. For example, the kit may have standard instructions informing a technician how to wash the capture reagent (e.g., probe) after a sample of urine serum contacts the capture reagent. In another example, the kit may have

instructions for pre-fractionating a sample to reduce complexity of proteins in the sample. In another example, the kit may have instructions for automating the fractionation or other processes.

5 Such kits can be prepared from the materials described above, and the previous discussion of these materials (*e.g.*, probe substrates, capture reagents, adsorbents, washing solutions, *etc.*) is fully applicable to this section and will not be repeated.

10 In another embodiment, the kit may comprise a first substrate comprising an adsorbent thereon (*e.g.*, a particle functionalized with an adsorbent) and a second substrate onto which the first substrate can be positioned to form a probe, which is removably insertable into a gas phase ion spectrometer. In other embodiments, the kit may comprise a single substrate, which is in the form of a removably insertable probe
15 with adsorbents on the substrate. In yet another embodiment, the kit may further comprise a pre-fractionation spin column (*e.g.*, Cibacron blue agarose column, anti-HSA agarose column, K-30 size exclusion column, Q-anion exchange spin column, single stranded DNA column, lectin column, *etc.*).

20 In another embodiment, a kit comprises (a) an antibody that specifically binds to a Biomarker; and (b) a detection reagent. Such kits can be prepared from the materials described above, and the previous discussion regarding the materials (*e.g.*, antibodies, detection reagents, immobilized supports, *etc.*) is fully applicable to this section and will not be repeated. Optionally, the kit may further comprise pre-
25 fractionation spin columns. In some embodiments, the kit may further comprise instructions for suitable operation parameters in the form of a label or a separate insert.

 Optionally, the kit may further comprise a standard or control information so
30 that the test sample can be compared with the control information standard to determine if the test amount of a Biomarker detected in a sample is a diagnostic amount consistent with a diagnosis of kidney transplant rejection.

The invention also provides an article manufacture comprising at least one capture reagent bound to at least two Biomarkers selected from Biomarkers 1 through 48. Examples of articles of manufacture of the present invention include, but are not limited to, ProteinChip® Arrays, probes, microtitre plates, beads, test tubes, microtubes, and any other solid phase onto which a capture reagent can be incorporated. In an example of such an article, a ProteinChip® Array for example, will have an adsorbent that will capture Biomarkers 1 through 48. These are a few examples of such articles of manufacture. One of ordinary skill in the art would readily be able to manufacture other such articles in accordance with the teachings described herein.

The present invention also provides a system comprising a plurality of capture reagents each of which has bound to it a different Biomarker selected from Biomarkers 1 through 48. An example of such a system includes, but is not limited to, a set of ProteinChip® Arrays, which comprise adsorbents that bind one or more of the Biomarkers selected from Biomarkers 1 through 48. In this type of system, there may be one ProteinChip® Array for each of the Biomarkers. Examples of other systems include those in which the capture reagents are test tubes containing an antibody for each of the Biomarkers, either separately, or in groups. One of ordinary skill in the art would readily be able to manufacture other such articles in accordance with the teachings described herein.

The following example is offered by way of illustration, not by way of limitation. While a specific example has been provided, the above description is illustrative and not restrictive. Any one or more of the features of the previously described embodiments can be combined in any manner with one or more features of any other embodiments in the present invention. Furthermore, many variations of the invention will become apparent to those skilled in the art upon review of the specification. The scope of the invention should, therefore, be determined not with reference to the above description, but instead should be determined with reference to the appended claims along with their full scope of equivalents.

All publications and patent documents cited in this application are incorporated by reference in their entirety for all purposes to the same extent as if

each individual publication or patent document were so individually denoted. By their citation of various references in this document, Applicants do not admit any particular reference is "prior art" to their invention.

5 EXAMPLE

Materials and Methods

Patient Samples

Thirty-four urine samples were collected from 32 renal transplant patients at various stages posttransplantation. Samples were collected from 17 transplant recipients with acute rejection and 15 patients with no rejection. Two patients had paired samples collected before and during a rejection episode. Samples from patients less than 4 days posttransplant were not accepted for data analysis due to the presence of excessive inflammatory response proteins. All cases of rejection were confirmed by biopsy specimens evaluated by an independent, blinded pathologist. Banff 97 classification criteria were used for diagnosis.

Urine Processing

Specimens were centrifuged for 5 minutes at 1,000g to remove sediment.

Supernatants were aliquoted and frozen at -80°C.

20 *Surface Enhanced Laser Desorption Ionization (SELDI) Mass Spectrometry*

Processed urine samples were analyzed in triplicate using SELDI(Kuwata H, Yip TT, Yip CL, et al. Bactericidal domain of lactoferrin: detection, quantitation, and characterization of lactoferricin in serum by SELDI affinity mass spectrometry. Biochem Biophys Res Commun. 1998; 245: 764.). and ProteinChip Arrays,(Rai AJ, Zhang Z, Rosenzweig J, et al. Proteomic approaches to tumor marker discovery: Identification of biomarkers for ovarian cancer. Arch Pathol Lab Med. 2002; 126: 1518; and Li J, Zhang Z, Rosenzweig J, et al. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem. 2002; 48: 1296.) with immobilized metal affinity (IMAC-3) and hydrophobic (H4) surface chemistry. IMAC-3 chips were pretreated with 100 mmol/L CuSO₄ and phosphate-buffered saline (PBS) at pH 7.4. H4 chips were pretreated with 50%

acetonitrile. Three microliters of urine were added to each chip spot in duplicate. Chips were incubated at 37°C between applications, allowing samples to dry on the chip surface. Specimens were applied to chips in a random pattern to minimize the effects of spot-to-spot variation. Following sample application, IMAC-3 chips were washed with PBS and H4 chips were washed with 20% acetonitrile to remove nonspecific binding components. CHCA (α -cyano-4-hydroxycinnamic acid) or SPA (sinapinic acid) matrix solution (composed of energy-absorbing molecules) was then added to each chip spot in duplicate. Protein chips were analyzed on a PBS-II mass reader (Ciphergen Biosystems, Fremont, CA) with SELDI 3.0 software. Data were collected by averaging 110 laser shots, with laser intensities and detector sensitivities optimized for each combination of chip and matrix type.

Data Analysis

Mass spectra generated by SELDI mass spectrometry analysis were examined visually to select and label peaks (Fig. 50) with potential to distinguish between prerejection and rejection patients. In addition, SELDI software was used to identify and label all peaks in the spectrum data by applying a threshold to signal-to-noise values. Labeled peaks were normalized to the creatinine content of each urine specimen, through division of peak intensity by creatinine concentration in g/dL. (Lemann J Jr, Doumas BT. Proteinuria in health and disease assessed by measuring the urinary protein/creatinine ratio. Clin Chem. 1987; 23: 297; Yamaguchi T, Kadono K. Clinical evaluation of the albumin/creatinine ratio in outpatients with diabetes. Nippon Jinzo Gakkai Shi. 1991; 33: 283; and Torng S, Rigatto C, Rush DN, et al. The urine protein to creatinine ratio (P/C) as a predictor of 24-hour urine protein excretion in renal transplant patients. Transplantation. 2002; 72: 1453.). Outliers were determined statistically and removed from the triplicate data sets based on the results of T_n tests. In the T_n test, a suspected outlier is compared to the overall mean of the data set by subtracting the result in question from the overall mean and dividing by the standard deviation to obtain a T_n value. If the T_n value is greater than the critical T value (obtained from a table), then the result in question is deemed to be an outlier and not included in the average.

Both visually and computer-labeled peaks were analyzed with ProPeak software (3Z Informatics, Mt. Pleasant, SC) to statistically identify those peaks with the best ability

- to distinguish between the patient populations. ProPeak software used UMSA (Unified Maximum Separability Analysis)(Zhang Z, Page G, Zhang H. Applying classification separability analysis to microarray data. In: Lin SM, Johnson KF, eds. Methods of Microarray Data Analysis: Papers from CAMDA '00. Boston: Kluwer Academic Publishers; 2001: 25-26; and Vapnik VN. Statistical Learning Theory. New York: John Wiley & Sons; 1998: 401-440.) to identify a direction in n-dimensional space along which two data sets are optimally separated. Bootstrap selection ranked peaks according to the strength and consistency of their ability to discriminate between the sets. Peak intensities were log normalized for ProPeak analysis.
- 10 The diagnostic performance of highly ranked peaks from UMSA analysis was evaluated by receiver operator characteristic (ROC) curve analysis (Fig. 51). The ability of the peaks to distinguish between rejection and nonrejection patients was ranked by the area under the ROC curve (AUC). Peaks with AUCs greater than 0.6 were classified as peaks of interest, the highest ones of which (AUCs > 0.75) are
- 15 considered candidate biomarkers. Computer-labeled peaks were also subjected to a separate CART (Classification and Regression Tree) analysis,(Breiman L, Friedman JH, Olshen RA, et al. Classification and Regression Trees. Monterey, CA: Wadsworths & Brooks; 1984.) implemented by Ciphergen Biomarker Patterns Software, to identify patterns of biomarkers that distinguish between patient
- 20 populations.

Results

- Visual and UMSA analyses of spectra from renal transplant patients revealed 48 peaks of interest (AUCs > 0.600) that showed ability to distinguish between rejection and nonrejection urine samples. From these peaks of interest, 16 peaks (AUCs >
- 25 0.750 and $P < 0.0001$ -0.0009) showed promise as candidate biomarkers for transplant rejection. Thirteen of these peaks (3.4, 4.1, 6.5, 6.6, 6.7, 7.0, 7.1, 7.3, 7.5, 7.8, 8.0, 10.8, and 13.4 kd) were present in a majority of rejection urine samples but absent from most nonrejection specimens. Three peaks (9.0, 9.7, and 9.8) were downregulated with onset of transplant rejection.
- 30 A separate analysis using the CART algorithm in the Ciphergen Biomarker Pattern Software correctly classified 91% of the 34 specimens in the training set, giving a

sensitivity of 83% and specificity of 100% on the same training data set using two separate biomarker candidates at 10.0 kd and 3.4 kd. This result is significant because it demonstrates the potential improvement obtained by combining rejection biomarker candidates into a marker panel.

What is claimed is:

1. A method of qualifying kidney transplant rejection status in a subject comprising:

(a) measuring at least one Biomarker in a sample from the subject, wherein the

5 Biomarker is selected from the group consisting of

Biomarker 1: having a molecular weight of about 2.5 kD;

Biomarker 2: having a molecular weight of about 2.6 kD;

Biomarker 3: having a molecular weight of about 3.4 kD;

Biomarker 4: having a molecular weight of about 3.5 kD;

10 Biomarker 5: having a molecular weight of about 3.8 kD;

Biomarker 6: having a molecular weight of about 4.1 kD;

Biomarker 7: having a molecular weight of about 4.7 kD;

Biomarker 8: having a molecular weight of about 4.8 kD;

Biomarker 9: having a molecular weight of about 5.0 kD;

15 Biomarker 10: having a molecular weight of about 5.5 kD;

Biomarker 11: having a molecular weight of about 5.6 kD;

Biomarker 12: having a molecular weight of about 6.1 kD;

Biomarker 13: having a molecular weight of about 6.4 kD;

Biomarker 14: having a molecular weight of about 6.5 kD;

20 Biomarker 15: having a molecular weight of about 6.6 kD;

Biomarker 16: having a molecular weight of about 6.7 kD;

Biomarker 17: having a molecular weight of about 6.8 kD;

Biomarker 18: having a molecular weight of about 7.0 kD;

Biomarker 19: having a molecular weight of about 7.1 kD;

25 Biomarker 20: having a molecular weight of about 7.3 kD;

Biomarker 21: having a molecular weight of about 7.5 kD;

Biomarker 22: having a molecular weight of about 7.8 kD;

Biomarker 23: having a molecular weight of about 8.0 kD;

Biomarker 24: having a molecular weight of about 8.1 kD;

30 Biomarker 25: having a molecular weight of about 9.0 kD;

Biomarker 26: having a molecular weight of about 9.1 kD;

Biomarker 27: having a molecular weight of about 9.3 kD;

Biomarker 28: having a molecular weight of about 9.6 kD;

Biomarker 29: having a molecular weight of about 9.7 kD;
Biomarker 30: having a molecular weight of about 9.8 kD;
Biomarker 31: having a molecular weight of about 10.0 kD;
Biomarker 32: having a molecular weight of about 10.8 kD;
5 Biomarker 33: having a molecular weight of about 10.9 kD;
Biomarker 34: having a molecular weight of about 11.3 kD;
Biomarker 35: having a molecular weight of about 13.4 kD;
Biomarker 36: having a molecular weight of about 13.9 kD;
Biomarker 37: having a molecular weight of about 14.7 kD;
10 Biomarker 38: having a molecular weight of about 14.8 kD;
Biomarker 39: having a molecular weight of about 15.1 kD;
Biomarker 40: having a molecular weight of about 15.2 kD;
Biomarker 41: having a molecular weight of about 16.1 kD;
Biomarker 42: having a molecular weight of about 25.0 kD;
15 Biomarker 43: having a molecular weight of about 28.0 kD;
Biomarker 44: having a molecular weight of about 50.0 kD;
Biomarker 45: having a molecular weight of about 50.1 kD;
Biomarker 46: having a molecular weight of about 51.1 kD;
Biomarker 47: having a molecular weight of about 51.3 kD;
20 Biomarker 48: having a molecular weight of about 67.0 kD; and
combinations thereof, and

(b) correlating the measurement with kidney transplant rejection status.

2. The method of claim 1 further comprising:

(c) managing subject treatment based on the status.

25 3. The method of claim 2, wherein managing subject treatment is selected from ordering more tests, altering immunosuppression, and taking no further action.

4. The method of claim 2 further comprising:

(d) measuring the at least one Biomarker after subject management.

30 5. The method of claim 1 wherein the kidney transplant rejection status is selected from the group consisting of the subject's immunosuppression status and the effectiveness of immunosuppression on kidney transplant rejection.

6. A method for differentiating between a diagnosis of kidney rejection and non-rejection comprising:

(a) detecting in a subject sample an amount of at least one Biomarker selected from the group consisting of:

- 5 Biomarker 3: having a molecular weight of about 3.4 kD;
- Biomarker 6: having a molecular weight of about 4.1 kD;
- Biomarker 14: having a molecular weight of about 6.5 kD;
- Biomarker 15: having a molecular weight of about 6.6 kD;
- Biomarker 16: having a molecular weight of about 6.7 kD;
- 10 Biomarker 18: having a molecular weight of about 7.0 kD;
- Biomarker 19: having a molecular weight of about 7.1 kD;
- Biomarker 20: having a molecular weight of about 7.3 kD;
- Biomarker 21: having a molecular weight of about 7.5 kD;
- Biomarker 22: having a molecular weight of about 7.8 kD;
- 15 Biomarker 23: having a molecular weight of about 8.0 kD;
- Biomarker 32: having a molecular weight of about 10.8 kD;
- Biomarker 35: having a molecular weight of about 13.4 kD;

and

(b) correlating the amount with a diagnosis of kidney transplant
20 rejection or non-rejection.

7. A method for differentiating between a diagnosis of kidney rejection and non-rejection comprising:

(a) detecting in a subject sample an amount of at least one Biomarker selected from the group consisting of:

- 25 Biomarker 25: having a molecular weight of about 9.0 kD;
- Biomarker 29: having a molecular weight of about 9.7 kD;
- Biomarker 30: having a molecular weight of about 9.8 kD and

(b) correlating the amount with a diagnosis of kidney transplant rejection or non-rejection.

30 8. The method of any of claims 1-7 wherein the Biomarker is detected by mass spectrometry.

9. The method of any of claims 1-7 wherein the Biomarker is detected by capturing the Biomarker on a biochip having an affinity surface and detecting the captured Biomarker by SELDI.

10. The method of claim 8 wherein the affinity surface comprises
5 immobilized metal chelate of nickel.

11. The method of claim 10 wherein the biochip is IMAC3 ProteinChip®
Array.

12. The method of any one of claims 1-7 wherein the patient sample is
selected from the group consisting of blood, blood plasma, serum, urine, tissue, cells,
10 organs and seminal fluids.

13. The method of any one of claims 1-7 wherein the patient sample is
urine.

14. The method of any one of claims 1-7 comprising:
generating data on immobilized subject samples on a biochip, by subjecting
15 said biochip to laser ionization and detecting intensity of signal for mass/charge ratio;
and,

transforming the data into computer readable form;
executing an algorithm that classifies the data according to user input
parameters, for detecting signals that represent Biomarkers present in kidney
20 transplant rejection patients and are lacking in kidney transplant non-rejection
patients.

15. The method of any one of claims 1-7 wherein one or more of the
Biomarkers are detected using laser desorption/ionization mass spectrometry,
comprising:

25 providing a probe adapted for use with a mass spectrometer comprising an
adsorbent attached thereto;

contacting the subject sample with the adsorbent;

desorbing and ionizing the Biomarker or Biomarkers from the probe; and,

detecting the deionized/ionized Biomarkers with the mass spectrometer.

16. The method of claim 15, wherein the adsorbent is hydrophobic, hydrophilic, ionic or metal chelate adsorbent.

17. The method of claim 16, wherein the adsorbent is comprised of nickel.

18. The method of claim 15, wherein the adsorbent is an antibody, single-
5 or double stranded oligonucleotide, amino acid, protein, peptide or fragments thereof.

19. The method of any one of claims 1-7, wherein at least one or more protein Biomarkers are detected using immunoassays.

20. A process for purification of a Biomarker, comprising fractioning a sample comprising one or more protein Biomarkers by size-exclusion
10 chromatography and collecting a fraction that includes the one or more Biomarker; and/or fractionating a sample comprising the one or more Biomarkers by anion exchange chromatography and collecting a fraction that includes the one or more Biomarkers, wherein the Biomarker is selected from:

- 15 Biomarker 1: having a molecular weight of about 2.5 kD;
- Biomarker 2: having a molecular weight of about 2.6 kD;
- Biomarker 3: having a molecular weight of about 3.4 kD;
- Biomarker 4: having a molecular weight of about 3.5 kD;
- Biomarker 5: having a molecular weight of about 3.8 kD;
- Biomarker 6: having a molecular weight of about 4.1 kD;
- 20 Biomarker 7: having a molecular weight of about 4.7 kD;
- Biomarker 8: having a molecular weight of about 4.8 kD;
- Biomarker 9: having a molecular weight of about 5.0 kD;
- Biomarker 10: having a molecular weight of about 5.5 kD;
- Biomarker 11: having a molecular weight of about 5.6 kD;
- 25 Biomarker 12: having a molecular weight of about 6.1 kD;
- Biomarker 13: having a molecular weight of about 6.4 kD;
- Biomarker 14: having a molecular weight of about 6.5 kD;
- Biomarker 15: having a molecular weight of about 6.6 kD;
- Biomarker 16: having a molecular weight of about 6.7 kD;
- 30 Biomarker 17: having a molecular weight of about 6.8 kD;
- Biomarker 18: having a molecular weight of about 7.0 kD;

5 Biomarker 19: having a molecular weight of about 7.1 kD;
Biomarker 20: having a molecular weight of about 7.3 kD;
Biomarker 21: having a molecular weight of about 7.5 kD;
Biomarker 22: having a molecular weight of about 7.8 kD;
Biomarker 23: having a molecular weight of about 8.0 kD;
Biomarker 24: having a molecular weight of about 8.1 kD;
Biomarker 25: having a molecular weight of about 9.0 kD;
Biomarker 26: having a molecular weight of about 9.1 kD;
10 Biomarker 27: having a molecular weight of about 9.3 kD;
Biomarker 28: having a molecular weight of about 9.6 kD;
Biomarker 29: having a molecular weight of about 9.7 kD;
Biomarker 30: having a molecular weight of about 9.8 kD;
Biomarker 31: having a molecular weight of about 10.0 kD;
Biomarker 32: having a molecular weight of about 10.8 kD;
15 Biomarker 33: having a molecular weight of about 10.9 kD;
Biomarker 34: having a molecular weight of about 11.3 kD;
Biomarker 35: having a molecular weight of about 13.4 kD;
Biomarker 36: having a molecular weight of about 13.9 kD;
Biomarker 37: having a molecular weight of about 14.7 kD;
20 Biomarker 38: having a molecular weight of about 14.8 kD;
Biomarker 39: having a molecular weight of about 15.1 kD;
Biomarker 40: having a molecular weight of about 15.2 kD;
Biomarker 41: having a molecular weight of about 16.1 kD;
Biomarker 42: having a molecular weight of about 25.0 kD;
25 Biomarker 43: having a molecular weight of about 28.0 kD;
Biomarker 44: having a molecular weight of about 50.0 kD;
Biomarker 45: having a molecular weight of about 50.1 kD;
Biomarker 46: having a molecular weight of about 51.1 kD;
Biomarker 47: having a molecular weight of about 51.3 kD; and
30 Biomarker 48: having a molecular weight of about 67.0 kD.

21. The process of claim 20, wherein fractionation is monitored for purity on normal phase and immobilized nickel arrays.

22. The process of claim 20, for generating data on immobilized Biomarker fractions on an array, comprising:

subjecting said array to laser ionization and detecting intensity of signal for mass/charge ratio;

5 transforming the data into computer readable form; and
executing an algorithm that classifies the data according to user input parameters, for detecting signals that represent Biomarkers present in kidney transplant rejection patients and are lacking in kidney transplant non-rejection patients.

10 23. The process of claim 20, wherein fractions are subjected to gel electrophoresis and correlated with data generated by mass spectrometry.

24. A kit for aiding the diagnosis of kidney transplant rejection,
15 comprising:

an adsorbent attached to a substrate, wherein the adsorbent retains one or more Biomarkers selected from:

Biomarker 1: having a molecular weight of about 2.5 kD;

Biomarker 2: having a molecular weight of about 2.6 kD;

20 Biomarker 3: having a molecular weight of about 3.4 kD;

Biomarker 4: having a molecular weight of about 3.5 kD;

Biomarker 5: having a molecular weight of about 3.8 kD;

Biomarker 6: having a molecular weight of about 4.1 kD;

Biomarker 7: having a molecular weight of about 4.7 kD;

25 Biomarker 8: having a molecular weight of about 4.8 kD;

Biomarker 9: having a molecular weight of about 5.0 kD;

Biomarker 10: having a molecular weight of about 5.5 kD;

Biomarker 11: having a molecular weight of about 5.6 kD;

Biomarker 12: having a molecular weight of about 6.1 kD;

30 Biomarker 13: having a molecular weight of about 6.4 kD;

Biomarker 14: having a molecular weight of about 6.5 kD;

Biomarker 15: having a molecular weight of about 6.6 kD;

Biomarker 16: having a molecular weight of about 6.7 kD;

Biomarker 17: having a molecular weight of about 6.8 kD;

- 5 Biomarker 18: having a molecular weight of about 7.0 kD;
Biomarker 19: having a molecular weight of about 7.1 kD;
Biomarker 20: having a molecular weight of about 7.3 kD;
Biomarker 21: having a molecular weight of about 7.5 kD;
Biomarker 22: having a molecular weight of about 7.8 kD;
Biomarker 23: having a molecular weight of about 8.0 kD;
Biomarker 24: having a molecular weight of about 8.1 kD;
Biomarker 25: having a molecular weight of about 9.0 kD;
Biomarker 26: having a molecular weight of about 9.1 kD;
10 Biomarker 27: having a molecular weight of about 9.3 kD;
Biomarker 28: having a molecular weight of about 9.6 kD;
Biomarker 29: having a molecular weight of about 9.7 kD;
Biomarker 30: having a molecular weight of about 9.8 kD;
Biomarker 31: having a molecular weight of about 10.0 kD;
15 Biomarker 32: having a molecular weight of about 10.8 kD;
Biomarker 33: having a molecular weight of about 10.9 kD;
Biomarker 34: having a molecular weight of about 11.3 kD;
Biomarker 35: having a molecular weight of about 13.4 kD;
Biomarker 36: having a molecular weight of about 13.9 kD;
20 Biomarker 37: having a molecular weight of about 14.7 kD;
Biomarker 38: having a molecular weight of about 14.8 kD;
Biomarker 39: having a molecular weight of about 15.1 kD;
Biomarker 40: having a molecular weight of about 15.2 kD;
Biomarker 41: having a molecular weight of about 16.1 kD;
25 Biomarker 42: having a molecular weight of about 25.0 kD;
Biomarker 43: having a molecular weight of about 28.0 kD;
Biomarker 44: having a molecular weight of about 50.0 kD;
Biomarker 45: having a molecular weight of about 50.1 kD;
Biomarker 46: having a molecular weight of about 51.1 kD;
30 Biomarker 47: having a molecular weight of about 51.3 kD; and
Biomarker 48: having a molecular weight of about 67.0 kD.

25. The kit of claim 24, further comprising written instructions for use of the kit for detection of kidney transplant rejection.

26. The kit of claim 24, wherein the instruction provide for contacting a test sample with the absorbent and detecting one or more Biomarkers retained by the absorbent.

5 27. The kit of claim 24, wherein the substrate allows for adsorption of said adsorbent.

28. The kit of claim 24, wherein the substrate can be hydrophobic, hydrophilic, charged, polar, metal ions.

10 29. The kit of claim 24, wherein the adsorbent is an antibody, single or double stranded oligonucleotide, amino acid, protein, peptide or fragments thereof.

15 30. The kit of claim 24, wherein one or more protein Biomarkers is detected using mass spectrometry.

31. The kit of claim 24, wherein one or more protein Biomarkers is detected using immunoassays.

20 32. The kit of claim 31, wherein the immunoassay is an ELISA.

25 33. The method of claim any one of claims 1 through 17, further comprising measuring the amount of each Biomarker in the subject sample and determining the ratio of the amounts between the Biomarkers.

34. The method of any one of claims 1-7, further comprising measuring the amount of each Biomarker in the subject sample and determining the ratio of the amounts between the Biomarkers and known kidney transplant rejection Biomarkers.

30 35. The method of any one of claims 1-10, wherein the stage of kidney transplant rejection is assessed.

36. A protein purified on a biochip selected from:
Biomarker 1: having a molecular weight of about 2.5 kD;

- 5 Biomarker 2: having a molecular weight of about 2.6 kD;
Biomarker 3: having a molecular weight of about 3.4 kD;
Biomarker 4: having a molecular weight of about 3.5 kD;
Biomarker 5: having a molecular weight of about 3.8 kD;
Biomarker 6: having a molecular weight of about 4.1 kD;
Biomarker 7: having a molecular weight of about 4.7 kD;
Biomarker 8: having a molecular weight of about 4.8 kD;
Biomarker 9: having a molecular weight of about 5.0 kD;
Biomarker 10: having a molecular weight of about 5.5 kD;
10 Biomarker 11: having a molecular weight of about 5.6 kD;
Biomarker 12: having a molecular weight of about 6.1 kD;
Biomarker 13: having a molecular weight of about 6.4 kD;
Biomarker 14: having a molecular weight of about 6.5 kD;
Biomarker 15: having a molecular weight of about 6.6 kD;
15 Biomarker 16: having a molecular weight of about 6.7 kD;
Biomarker 17: having a molecular weight of about 6.8 kD;
Biomarker 18: having a molecular weight of about 7.0 kD;
Biomarker 19: having a molecular weight of about 7.1 kD;
Biomarker 20: having a molecular weight of about 7.3 kD;
20 Biomarker 21: having a molecular weight of about 7.5 kD;
Biomarker 22: having a molecular weight of about 7.8 kD;
Biomarker 23: having a molecular weight of about 8.0 kD;
Biomarker 24: having a molecular weight of about 8.1 kD;
Biomarker 25: having a molecular weight of about 9.0 kD;
25 Biomarker 26: having a molecular weight of about 9.1 kD;
Biomarker 27: having a molecular weight of about 9.3 kD;
Biomarker 28: having a molecular weight of about 9.6 kD;
Biomarker 29: having a molecular weight of about 9.7 kD;
Biomarker 30: having a molecular weight of about 9.8 kD;
30 Biomarker 31: having a molecular weight of about 10.0 kD;
Biomarker 32: having a molecular weight of about 10.8 kD;
Biomarker 33: having a molecular weight of about 10.9 kD;
Biomarker 34: having a molecular weight of about 11.3 kD;
Biomarker 35: having a molecular weight of about 13.4 kD;

Biomarker 36: having a molecular weight of about 13.9 kD;
Biomarker 37: having a molecular weight of about 14.7 kD;
Biomarker 38: having a molecular weight of about 14.8 kD;
Biomarker 39: having a molecular weight of about 15.1 kD;
5 Biomarker 40: having a molecular weight of about 15.2 kD;
Biomarker 41: having a molecular weight of about 16.1 kD;
Biomarker 42: having a molecular weight of about 25.0 kD;
Biomarker 43: having a molecular weight of about 28.0 kD;
Biomarker 44: having a molecular weight of about 50.0 kD;
10 Biomarker 45: having a molecular weight of about 50.1 kD;
Biomarker 46: having a molecular weight of about 51.1 kD;
Biomarker 47: having a molecular weight of about 51.3 kD; and
Biomarker 48: having a molecular weight of about 67.0 kD.

15 37. The purified proteins of claim 36, comprising a composition of a combination of at least two proteins.

38. The method of claim 1 wherein measuring comprises:

- (a) providing a subject sample of urine or a urine derivative;
- (b) fractionating proteins in the sample on an anion exchange resin and

20 collecting fractions that contain at least one Biomarker selected from the group consisting of Biomarkers 1 through 48; and

(c) capturing at least one Biomarker selected from the group consisting of Biomarker 1 through 48 from the fractions on a surface of a substrate comprising capture reagents that bind the protein Biomarkers.

25 39. The method of claim 38 wherein the substrate is a SELDI probe comprising an IMAC3 nickel surface and wherein the protein Biomarkers are detected by SELDI.

40. The method of claim 38 wherein the substrate is a SELDI probe comprising biospecific affinity reagents that bind at least one Biomarker selected
30 from the group consisting of Biomarkers 1 through 48 and wherein the protein Biomarkers are detected by SELDI.

41. The method of claim 38 wherein the substrate is a microtiter plate comprising biospecific affinity reagents that bind at least one Biomarker selected from the group consisting of Biomarkers 1 through 48 and the protein Biomarkers are detected by immunoassay.

5

42. The method of claim 1, wherein measuring is selected from detecting the presence or absence of the Biomarkers(s), quantifying the amount of Biomarker(s), and qualifying the type of Biomarker.

10

43. The method of claim 1 wherein at least one Biomarker is measured using a biochip array.

44. The method of claim 43 wherein the biochip array is a protein chip array.

15

45. The method of claim 43 wherein the biochip array is a nucleic acid array.

46. The method of claim 43 wherein at least one Biomarker is immobilized on the biochip array.

47. The method of claim 1 wherein the protein Biomarkers are measured by SELDI.

20

48. The method of claim 1 wherein the protein Biomarkers are measured by immunoassay.

49. The method of claim 1 wherein the correlating is performed by a software classification algorithm.

25

50. The method of claim 1 wherein the sample is selected from blood, serum and plasma.

51. A method comprising:

(a) measuring a plurality of Biomarkers in a sample from the subject, wherein the Biomarkers are selected from the group consisting of:

Biomarker 1: having a molecular weight of about 2.5 kD;

- 5 Biomarker 2: having a molecular weight of about 2.6 kD;
Biomarker 3: having a molecular weight of about 3.4 kD;
Biomarker 4: having a molecular weight of about 3.5 kD;
Biomarker 5: having a molecular weight of about 3.8 kD;
Biomarker 6: having a molecular weight of about 4.1 kD;
Biomarker 7: having a molecular weight of about 4.7 kD;
Biomarker 8: having a molecular weight of about 4.8 kD;
Biomarker 9: having a molecular weight of about 5.0 kD;
Biomarker 10: having a molecular weight of about 5.5 kD;
10 Biomarker 11: having a molecular weight of about 5.6 kD;
Biomarker 12: having a molecular weight of about 6.1 kD;
Biomarker 13: having a molecular weight of about 6.4 kD;
Biomarker 14: having a molecular weight of about 6.5 kD;
Biomarker 15: having a molecular weight of about 6.6 kD;
15 Biomarker 16: having a molecular weight of about 6.7 kD;
Biomarker 17: having a molecular weight of about 6.8 kD;
Biomarker 18: having a molecular weight of about 7.0 kD;
Biomarker 19: having a molecular weight of about 7.1 kD;
Biomarker 20: having a molecular weight of about 7.3 kD;
20 Biomarker 21: having a molecular weight of about 7.5 kD;
Biomarker 22: having a molecular weight of about 7.8 kD;
Biomarker 23: having a molecular weight of about 8.0 kD;
Biomarker 24: having a molecular weight of about 8.1 kD;
Biomarker 25: having a molecular weight of about 9.0 kD;
25 Biomarker 26: having a molecular weight of about 9.1 kD;
Biomarker 27: having a molecular weight of about 9.3 kD;
Biomarker 28: having a molecular weight of about 9.6 kD;
Biomarker 29: having a molecular weight of about 9.7 kD;
Biomarker 30: having a molecular weight of about 9.8 kD;
30 Biomarker 31: having a molecular weight of about 10.0 kD;
Biomarker 32: having a molecular weight of about 10.8 kD;
Biomarker 33: having a molecular weight of about 10.9 kD;
Biomarker 33: having a molecular weight of about 10.9 kD;
Biomarker 34: having a molecular weight of about 11.3 kD;

Biomarker 35: having a molecular weight of about 13.4 kD;
Biomarker 36: having a molecular weight of about 13.9 kD;
Biomarker 37: having a molecular weight of about 14.7 kD;
Biomarker 38: having a molecular weight of about 14.8 kD;
5 Biomarker 39: having a molecular weight of about 15.1 kD;
Biomarker 40: having a molecular weight of about 15.2 kD;
Biomarker 41: having a molecular weight of about 16.1 kD;
Biomarker 42: having a molecular weight of about 25.0 kD;
Biomarker 43: having a molecular weight of about 28.0 kD;
10 Biomarker 44: having a molecular weight of about 50.0 kD;
Biomarker 45: having a molecular weight of about 50.1 kD;
Biomarker 46: having a molecular weight of about 51.1 kD;
Biomarker 47: having a molecular weight of about 51.3 kD;
Biomarker 48: having a molecular weight of about 67.0 kD.

15 52. The method of claim 51 wherein the plurality are selected from the group consisting of:

20 Biomarker 3: having a molecular weight of about 3.4 kD;
Biomarker 6: having a molecular weight of about 4.1 kD;
Biomarker 14: having a molecular weight of about 6.5 kD;
Biomarker 15: having a molecular weight of about 6.6 kD;
Biomarker 16: having a molecular weight of about 6.7 kD;
Biomarker 18: having a molecular weight of about 7.0 kD;
Biomarker 19: having a molecular weight of about 7.1 kD;
25 Biomarker 20: having a molecular weight of about 7.3 kD;
Biomarker 21: having a molecular weight of about 7.5 kD;
Biomarker 22: having a molecular weight of about 7.8 kD;
Biomarker 23: having a molecular weight of about 8.0 kD;
Biomarker 32: having a molecular weight of about 10.8 kD;
30 Biomarker 35: having a molecular weight of about 13.4 kD.

53. The method of claim 51 wherein the plurality are selected from the group consisting of:

Biomarker 25: having a molecular weight of about 9.0 kD;

Biomarker 29: having a molecular weight of about 9.7 kD;

Biomarker 30: having a molecular weight of about 9.8 kD.

54. The method of claim 51 wherein the protein Biomarkers are detected by SELDI or immunoassay.

5 55. The method of claim 51 wherein the sample is selected from blood, serum and plasma.

56. The kit of claim 24 herein the adsorbent binds a plurality of the Biomarkers.

57. The kit of claim 24 wherein the adsorbent is a SELDI probe.

10 58. The kit of claim 24 further comprising a second adsorbent that binds one of the Biomarkers that the first adsorbent does not bind.

59. A kit comprising:

(a) a first capture reagent that binds at least one Biomarker selected from the group consisting of:

15 Biomarker 1: having a molecular weight of about 2.5 kD;

Biomarker 2: having a molecular weight of about 2.6 kD;

Biomarker 3: having a molecular weight of about 3.4 kD;

Biomarker 4: having a molecular weight of about 3.5 kD;

Biomarker 5: having a molecular weight of about 3.8 kD;

20 Biomarker 6: having a molecular weight of about 4.1 kD;

Biomarker 7: having a molecular weight of about 4.7 kD;

Biomarker 8: having a molecular weight of about 4.8 kD;

Biomarker 9: having a molecular weight of about 5.0 kD;

Biomarker 10: having a molecular weight of about 5.5 kD;

25 Biomarker 11: having a molecular weight of about 5.6 kD;

Biomarker 12: having a molecular weight of about 6.1 kD;

Biomarker 13: having a molecular weight of about 6.4 kD;

Biomarker 14: having a molecular weight of about 6.5 kD;

Biomarker 15: having a molecular weight of about 6.6 kD;

30 Biomarker 16: having a molecular weight of about 6.7 kD;

Biomarker 17: having a molecular weight of about 6.8 kD;
Biomarker 18: having a molecular weight of about 7.0 kD;
Biomarker 19: having a molecular weight of about 7.1 kD;
Biomarker 20: having a molecular weight of about 7.3 kD;
5 Biomarker 21: having a molecular weight of about 7.5 kD;
Biomarker 22: having a molecular weight of about 7.8 kD;
Biomarker 23: having a molecular weight of about 8.0 kD;
Biomarker 24: having a molecular weight of about 8.1 kD;
Biomarker 25: having a molecular weight of about 9.0 kD;
10 Biomarker 26: having a molecular weight of about 9.1 kD;
Biomarker 27: having a molecular weight of about 9.3 kD;
Biomarker 28: having a molecular weight of about 9.6 kD;
Biomarker 29: having a molecular weight of about 9.7 kD;
Biomarker 30: having a molecular weight of about 9.8 kD;
15 Biomarker 31: having a molecular weight of about 10.0 kD;
Biomarker 32: having a molecular weight of about 10.8 kD;
Biomarker 33: having a molecular weight of about 10.9 kD;
Biomarker 34: having a molecular weight of about 11.3 kD;
Biomarker 35: having a molecular weight of about 13.4 kD;
20 Biomarker 36: having a molecular weight of about 13.9 kD;
Biomarker 37: having a molecular weight of about 14.7 kD;
Biomarker 38: having a molecular weight of about 14.8 kD;
Biomarker 39: having a molecular weight of about 15.1 kD;
Biomarker 40: having a molecular weight of about 15.2 kD;
25 Biomarker 41: having a molecular weight of about 16.1 kD;
Biomarker 42: having a molecular weight of about 25.0 kD;
Biomarker 43: having a molecular weight of about 28.0 kD;
Biomarker 44: having a molecular weight of about 50.0 kD;
Biomarker 45: having a molecular weight of about 50.1 kD;
30 Biomarker 46: having a molecular weight of about 51.1 kD;
Biomarker 47: having a molecular weight of about 51.3 kD;
Biomarker 48: having a molecular weight of about 67.0 kD.; and,

(b) a second capture reagent that binds at least one of the Biomarkers that is not bound by the first capture reagent.

60. The kit of claim 59 wherein the capture reagent is an immobilized metal chelate.

61. The kit of claim 59 further comprising a wash solution that selectively allows retention of the bound Biomarker to the capture reagent as compared with
5 other Biomarkers after washing.

62. An article manufacture comprising:

(a) at least one capture reagent that binds to at least one Biomarker selected from the group consisting of:

- 10 Biomarker 1: having a molecular weight of about 2.5 kD;
- Biomarker 2: having a molecular weight of about 2.6 kD;
- Biomarker 3: having a molecular weight of about 3.4 kD;
- Biomarker 4: having a molecular weight of about 3.5 kD;
- Biomarker 5: having a molecular weight of about 3.8 kD;
- 15 Biomarker 6: having a molecular weight of about 4.1 kD;
- Biomarker 7: having a molecular weight of about 4.7 kD;
- Biomarker 8: having a molecular weight of about 4.8 kD;
- Biomarker 9: having a molecular weight of about 5.0 kD;
- Biomarker 10: having a molecular weight of about 5.5 kD;
- Biomarker 11: having a molecular weight of about 5.6 kD;
- 20 Biomarker 12: having a molecular weight of about 6.1 kD;
- Biomarker 13: having a molecular weight of about 6.4 kD;
- Biomarker 14: having a molecular weight of about 6.5 kD;
- Biomarker 15: having a molecular weight of about 6.6 kD;
- Biomarker 16: having a molecular weight of about 6.7 kD;
- 25 Biomarker 17: having a molecular weight of about 6.8 kD;
- Biomarker 18: having a molecular weight of about 7.0 kD;
- Biomarker 19: having a molecular weight of about 7.1 kD;
- Biomarker 20: having a molecular weight of about 7.3 kD;
- Biomarker 21: having a molecular weight of about 7.5 kD;
- 30 Biomarker 22: having a molecular weight of about 7.8 kD;
- Biomarker 23: having a molecular weight of about 8.0 kD;
- Biomarker 24: having a molecular weight of about 8.1 kD;

5 Biomarker 25: having a molecular weight of about 9.0 kD;
Biomarker 26: having a molecular weight of about 9.1 kD;
Biomarker 27: having a molecular weight of about 9.3 kD;
Biomarker 28: having a molecular weight of about 9.6 kD;
Biomarker 29: having a molecular weight of about 9.7 kD;
Biomarker 30: having a molecular weight of about 9.8 kD;
Biomarker 31: having a molecular weight of about 10.0 kD;
Biomarker 32: having a molecular weight of about 10.8 kD;
Biomarker 33: having a molecular weight of about 10.9 kD;
10 Biomarker 34: having a molecular weight of about 11.3 kD;
Biomarker 35: having a molecular weight of about 13.4 kD;
Biomarker 36: having a molecular weight of about 13.9 kD;
Biomarker 37: having a molecular weight of about 14.7 kD;
Biomarker 38: having a molecular weight of about 14.8 kD;
15 Biomarker 39: having a molecular weight of about 15.1 kD;
Biomarker 40: having a molecular weight of about 15.2 kD;
Biomarker 41: having a molecular weight of about 16.1 kD;
Biomarker 42: having a molecular weight of about 25.0 kD;
Biomarker 43: having a molecular weight of about 28.0 kD;
20 Biomarker 44: having a molecular weight of about 50.0 kD;
Biomarker 45: having a molecular weight of about 50.1 kD;
Biomarker 46: having a molecular weight of about 51.1 kD;
Biomarker 47: having a molecular weight of about 51.3 kD;
Biomarker 48: having a molecular weight of about 67.0 kD.

25

63. The article manufacture of claim 62 wherein the Biomarker is selected from the group consisting of:

30 Biomarker 3: having a molecular weight of about 3.4 kD;
Biomarker 6: having a molecular weight of about 4.1 kD;
Biomarker 14: having a molecular weight of about 6.5 kD;
Biomarker 15: having a molecular weight of about 6.6 kD;
Biomarker 16: having a molecular weight of about 6.7 kD;
Biomarker 18: having a molecular weight of about 7.0 kD;

Biomarker 19: having a molecular weight of about 7.1 kD;
Biomarker 20: having a molecular weight of about 7.3 kD;
Biomarker 21: having a molecular weight of about 7.5 kD;
Biomarker 22: having a molecular weight of about 7.8 kD;
5 Biomarker 23: having a molecular weight of about 8.0 kD;
Biomarker 32: having a molecular weight of about 10.8 kD;
Biomarker 35: having a molecular weight of about 13.4 kD.

64. The article manufacture of claim 62 wherein the Biomarker is selected from the group consisting of:

10 Biomarker 25: having a molecular weight of about 9.0 kD;
Biomarker 29: having a molecular weight of about 9.7 kD;
Biomarker 30: having a molecular weight of about 9.8 kD.

65. A system comprising:

15 (a) a plurality of capture reagents each of which has bound to it a different Biomarker selected from

Biomarker 1: having a molecular weight of about 2.5 kD;
Biomarker 2: having a molecular weight of about 2.6 kD;
Biomarker 3: having a molecular weight of about 3.4 kD;
Biomarker 4: having a molecular weight of about 3.5 kD;
20 Biomarker 5: having a molecular weight of about 3.8 kD;
Biomarker 6: having a molecular weight of about 4.1 kD;
Biomarker 7: having a molecular weight of about 4.7 kD;
Biomarker 8: having a molecular weight of about 4.8 kD;
Biomarker 9: having a molecular weight of about 5.0 kD;
25 Biomarker 10: having a molecular weight of about 5.5 kD;
Biomarker 11: having a molecular weight of about 5.6 kD;
Biomarker 12: having a molecular weight of about 6.1 kD;
Biomarker 13: having a molecular weight of about 6.4 kD;
Biomarker 14: having a molecular weight of about 6.5 kD;
30 Biomarker 15: having a molecular weight of about 6.6 kD;
Biomarker 16: having a molecular weight of about 6.7 kD;
Biomarker 17: having a molecular weight of about 6.8 kD;

Biomarker 18: having a molecular weight of about 7.0 kD;
Biomarker 19: having a molecular weight of about 7.1 kD;
Biomarker 20: having a molecular weight of about 7.3 kD;
Biomarker 21: having a molecular weight of about 7.5 kD;
5 Biomarker 22: having a molecular weight of about 7.8 kD;
Biomarker 23: having a molecular weight of about 8.0 kD;
Biomarker 24: having a molecular weight of about 8.1 kD;
Biomarker 25: having a molecular weight of about 9.0 kD;
Biomarker 26: having a molecular weight of about 9.1 kD;
10 Biomarker 27: having a molecular weight of about 9.3 kD;
Biomarker 28: having a molecular weight of about 9.6 kD;
Biomarker 29: having a molecular weight of about 9.7 kD;
Biomarker 30: having a molecular weight of about 9.8 kD;
Biomarker 31: having a molecular weight of about 10.0 kD;
15 Biomarker 32: having a molecular weight of about 10.8 kD;
Biomarker 33: having a molecular weight of about 10.9 kD;
Biomarker 34: having a molecular weight of about 11.3 kD;
Biomarker 35: having a molecular weight of about 13.4 kD;
Biomarker 36: having a molecular weight of about 13.9 kD;
20 Biomarker 37: having a molecular weight of about 14.7 kD;
Biomarker 38: having a molecular weight of about 14.8 kD;
Biomarker 39: having a molecular weight of about 15.1 kD;
Biomarker 40: having a molecular weight of about 15.2 kD;
Biomarker 41: having a molecular weight of about 16.1 kD;
25 Biomarker 42: having a molecular weight of about 25.0 kD;
Biomarker 43: having a molecular weight of about 28.0 kD;
Biomarker 44: having a molecular weight of about 50.0 kD;
Biomarker 45: having a molecular weight of about 50.1 kD;
Biomarker 46: having a molecular weight of about 51.1 kD;
30 Biomarker 47: having a molecular weight of about 51.3 kD;
Biomarker 48: having a molecular weight of about 67.0 kD.

Test Receiver Operator Characteristic (ROC) curves

M2570_53 by SAMP_GRP


Performed by Benjamin Silverman

Date 15 August 2002

n 37

SAMP_GRP	n
0	15
1	22

Curve	Area	SE	p	95% CI of Area	SAMP_GRP = 1
M2570_53	0.679	0.0893	0.0226	0.504 to 0.854	have higher values



M2570_53 (abnormals above cut-off)	Sensitivity	Specificity	TP	TN	FP	FN
-2.269465893	95.5%	0.0%	21	0	15	1

FIGURE 1A

Test		Receiver Operator Characteristic (ROC) curves					
		M2570_53 by SAMP_GRP					
Performed by	Benjamin Silverman					Date	15 August 2002
-1.951002658	90.9%	0.0%	20	0	15	2	
-1.83330003	90.9%	6.7%	20	1	14	2	
-1.269532325	86.4%	6.7%	19	1	14	3	
-0.749250767	86.4%	13.3%	19	2	13	3	
-0.686191804	86.4%	20.0%	19	3	12	3	
-0.480561789	86.4%	26.7%	19	4	11	3	
-0.24696523	86.4%	33.3%	19	5	10	3	
-0.164089193	81.8%	33.3%	18	5	10	4	
2.081687311	81.8%	40.0%	18	6	9	4	
3.295632696	77.3%	40.0%	17	6	9	5	
3.365034205	72.7%	40.0%	16	6	9	6	
3.59872779	72.7%	46.7%	16	7	8	6	
3.616006133	72.7%	53.3%	16	8	7	6	
3.817845849	72.7%	60.0%	16	9	6	6	
3.83625841	68.2%	60.0%	15	9	6	7	
3.939338679	63.6%	60.0%	14	9	6	8	
4.158036338	63.6%	66.7%	14	10	5	8	
4.708928058	63.6%	73.3%	14	11	4	8	
4.720146774	63.6%	80.0%	14	12	3	8	
4.848737034	59.1%	80.0%	13	12	3	9	
4.883287628	54.5%	80.0%	12	12	3	10	
5.58382828	50.0%	80.0%	11	12	3	11	
5.63657289	45.5%	80.0%	10	12	3	12	
5.97481079	40.9%	80.0%	9	12	3	13	
6.303358832	36.4%	80.0%	8	12	3	14	
7.678719546	31.8%	80.0%	7	12	3	15	
8.0975886	31.8%	86.7%	7	13	2	15	
8.927745106	31.8%	93.3%	7	14	1	15	
9.115824471	27.3%	93.3%	6	14	1	16	
9.841141821	27.3%	100.0%	6	15	0	16	
9.880647941	22.7%	100.0%	5	15	0	17	
10.02241699	18.2%	100.0%	4	15	0	18	
10.07505391	13.6%	100.0%	3	15	0	19	
10.65260521	9.1%	100.0%	2	15	0	20	
16.80229123	4.5%	100.0%	1	15	0	21	
102.3283407	0.0%	100.0%	0	15	0	22	

FIGURE 1B

Test Receiver Operator Characteristic (ROC) curves

M2606_59 by SAMP_GRP


Performed by Benjamin Silverman

Date 14 August 2002

n 37

SAMP_GRP	n
0	15
1	22

Curve	Area	SE	p	95% CI of Area	SAMP_GRP = 1
M2606_59	0.655	0.0941	0.0502	0.470 to 0.839	have higher values



M2606_59 (abnormals above cut-off)	Sensitivity	Specificity	TP	TN	FP	FN
-1.080932112	95.5%	0.0%	21	0	15	1

FIGURE 2A

Test Receiver Operator Characteristic (ROC) curves

M2606_59 by SAMP_GRP							
Performed by	Benjamin Silverman					Date	14 August 2002
0.027827364	95.5%	6.7%	21	1	14	1	
0.683141072	95.5%	13.3%	21	2	13	1	
1.149352525	95.5%	20.0%	21	3	12	1	
2.01440388	95.5%	26.7%	21	4	11	1	
2.950097316	90.9%	26.7%	20	4	11	2	
3.291169441	86.4%	26.7%	19	4	11	3	
3.426174559	86.4%	33.3%	19	5	10	3	
5.038025584	81.8%	33.3%	18	5	10	4	
5.08703796	81.8%	40.0%	18	6	9	4	
5.543285249	77.3%	40.0%	17	6	9	5	
6.109528354	72.7%	40.0%	16	6	9	6	
6.138626935	72.7%	46.7%	16	7	8	6	
7.607489067	72.7%	53.3%	16	8	7	6	
7.910857563	68.2%	53.3%	15	8	7	7	
8.75882275	68.2%	60.0%	15	9	6	7	
8.819047007	68.2%	66.7%	15	10	5	7	
8.980914241	63.6%	66.7%	14	10	5	8	
9.709094998	59.1%	66.7%	13	10	5	9	
10.08745897	54.5%	68.7%	12	10	5	10	
11.04608025	50.0%	66.7%	11	10	5	11	
11.63267593	45.5%	66.7%	10	10	5	12	
12.49374817	45.5%	73.3%	10	11	4	12	
12.60732604	45.5%	80.0%	10	12	3	12	
13.50273042	40.9%	80.0%	9	12	3	13	
13.82143605	40.9%	86.7%	9	13	2	13	
16.7254242	36.4%	86.7%	8	13	2	14	
17.41424302	31.8%	86.7%	7	13	2	15	
18.06049443	27.3%	86.7%	6	13	2	16	
18.20894302	22.7%	86.7%	5	13	2	17	
23.27328015	18.2%	86.7%	4	13	2	18	
24.08280508	13.6%	86.7%	3	13	2	19	
25.98483956	13.6%	93.3%	3	14	1	19	
26.57746175	9.1%	93.3%	2	14	1	20	
28.83048001	4.5%	93.3%	1	14	1	21	
47.62329377	4.5%	100.0%	1	15	0	21	
166.8780076	0.0%	100.0%	0	15	0	22	

FIGURE 2B

Test Receiver Operator Characteristic (ROC) curves

M3388_17 by SAMP_GRP


Performed by Benjamin Silverman

Date 14 August 2002

n 37

SAMP_GRP	n
0	15
1	22

Curve	Area	SE	p	95% CI of Area	SAMP_GRP = 1
M3388_17	0.773	0.0782	0.0002	0.620 to 0.926	have higher values



M3388_17 (abnormals above cut-off)	Sensitivity	Specificity	TP	TN	FP	FN
6.069828529	100.0%	6.7%	22	1	14	0

FIGURE 3A

Test Receiver Operator Characteristic (ROC) curves

M3388_17 by SAMP_GRP

Performed by Benjamin Silverman

Date

14 August 2002

7.207024304	100.0%	13.3%	22	2	13	0
9.922083432	100.0%	20.0%	22	3	12	0
10.17708081	100.0%	26.7%	22	4	11	0
10.56576285	100.0%	33.3%	22	5	10	0
10.59455925	95.5%	33.3%	21	5	10	1
10.91545247	95.5%	40.0%	21	6	9	1
12.29222011	95.5%	46.7%	21	7	8	1
13.37211543	90.9%	46.7%	20	7	8	2
13.55951694	90.9%	53.3%	20	8	7	2
13.91148758	86.4%	53.3%	19	8	7	3
15.27682835	81.8%	53.3%	18	8	7	4
17.64519175	77.3%	53.3%	17	8	7	5
19.34493728	77.3%	60.0%	17	9	6	5
21.08732753	72.7%	60.0%	16	9	6	6
22.76287936	68.2%	60.0%	15	9	6	7
25.28009079	68.2%	66.7%	15	10	5	7
28.47442488	63.6%	66.7%	14	10	5	8
29.29347057	59.1%	66.7%	13	10	5	9
32.64837117	54.5%	66.7%	12	10	5	10
33.79327766	54.5%	73.3%	12	11	4	10
34.64644181	54.5%	80.0%	12	12	3	10
35.2582956	50.0%	80.0%	11	12	3	11
43.35388576	45.5%	80.0%	10	12	3	12
44.33466793	40.9%	80.0%	9	12	3	13
57.15728342	40.9%	86.7%	9	13	2	13
57.34024544	40.9%	93.3%	9	14	1	13
58.57318233	40.9%	100.0%	9	15	0	13
67.95461705	36.4%	100.0%	8	15	0	14
73.51997985	31.8%	100.0%	7	15	0	15
81.8346206	27.3%	100.0%	6	15	0	16
84.87048686	22.7%	100.0%	5	15	0	17
95.23399501	18.2%	100.0%	4	15	0	18
111.3451323	13.6%	100.0%	3	15	0	19
135.2673113	9.1%	100.0%	2	15	0	20
163.0844717	4.5%	100.0%	1	15	0	21
244.1203177	0.0%	100.0%	0	15	0	22

FIGURE 3B

Test Receiver Operator Characteristic (ROC) curves

M3504_43 by SAMP_GRP


Performed by Benjamin Silverman

Date 14 August 2002

n 37

SAMP_GRP	n
0	15
1	22

Curve	Area	SE	p	95% CI of Area	SAMP_GRP = 1
M3504_43	0.733	0.0845	0.0029	0.568 to 0.899	have higher values



M3504_43 (abnormals above cut-off)	Sensitivity	Specificity	TP	TN	FP	FN
2.065567969	100.0%	6.7%	22	1	14	0

FIGURE 4A

Test Receiver Operator Characteristic (ROC) curves

M3504_43 by SAMP_GRP

Performed by Benjamin Silverman

Date

14 August 2002

4.147177377	100.0%	13.3%	22	2	13	0
4.346483678	95.5%	13.3%	21	2	13	1
5.179027946	95.5%	20.0%	21	3	12	1
6.233060653	90.9%	20.0%	20	3	12	2
6.38602063	90.9%	26.7%	20	4	11	2
6.501021458	90.9%	33.3%	20	5	10	2
6.546230005	90.9%	40.0%	20	6	9	2
6.937741113	90.9%	46.7%	20	7	8	2
7.284313736	86.4%	46.7%	19	7	8	3
7.518206292	86.4%	53.3%	19	8	7	3
9.33476608	86.4%	60.0%	19	9	6	3
9.532246496	81.8%	60.0%	18	9	6	4
9.781221999	77.3%	60.0%	17	9	6	5
9.866035899	72.7%	60.0%	16	9	6	6
16.00820213	68.2%	60.0%	15	9	6	7
18.92475045	68.2%	66.7%	15	10	5	7
19.75003398	63.6%	66.7%	14	10	5	8
19.79855126	59.1%	66.7%	13	10	5	9
20.02273661	54.5%	66.7%	12	10	5	10
24.21285993	50.0%	66.7%	11	10	5	11
29.87738742	50.0%	73.3%	11	11	4	11
30.43190207	45.5%	73.3%	10	11	4	12
31.64180193	40.9%	73.3%	9	11	4	13
39.09458711	40.9%	80.0%	9	12	3	13
40.19759412	40.9%	86.7%	9	13	2	13
42.40377564	36.4%	86.7%	8	13	2	14
44.91866348	36.4%	93.3%	8	14	1	14
53.46082451	31.8%	93.3%	7	14	1	15
57.85160936	31.8%	100.0%	7	15	0	15
61.00249637	27.3%	100.0%	6	15	0	16
72.50725155	22.7%	100.0%	5	15	0	17
80.1429293	18.2%	100.0%	4	15	0	18
81.42966987	13.6%	100.0%	3	15	0	19
94.0633764	9.1%	100.0%	2	15	0	20
102.5370068	4.5%	100.0%	1	15	0	21
131.0417084	0.0%	100.0%	0	15	0	22

Figure 4B

Test Receiver Operator Characteristic (ROC) curves

M3752_32 by SAMP_GRP


Performed by Benjamin Silverman

Date 14 August 2002

n 37

SAMP_GRP	n
0	15
1	22

Curve	Area	SE	p	95% CI of Area	SAMP_GRP = 1
M3752_32	0.739	0.0892	0.0036	0.565 to 0.914	have higher values



M3752_32 (abnormals above cut-off)	Sensitivity	Specificity	TP	TN	FP	FN
0.714340764	100.0%	6.7%	22	1	14	0

FIGURE 5 A

Test Receiver Operator Characteristic (ROC) curves

M3752_32 by SAMP_GRP						
Performed by	Benjamin Silverman			Date		
14 August 2002						
0.785473552	100.0%	13.3%	22	2	13	0
0.804835056	100.0%	20.0%	22	3	12	0
0.911664591	95.5%	20.0%	21	3	12	1
0.993546146	95.5%	26.7%	21	4	11	1
1.284810251	95.5%	33.3%	21	5	10	1
1.899316275	95.5%	40.0%	21	6	9	1
2.13389516	95.5%	46.7%	21	7	8	1
2.135426092	95.5%	53.3%	21	8	7	1
2.248975521	90.9%	53.3%	20	8	7	2
2.255384199	90.9%	60.0%	20	9	6	2
2.268580024	86.4%	60.0%	19	9	6	3
2.457235214	81.8%	60.0%	18	9	6	4
2.717744608	77.3%	60.0%	17	9	6	5
2.742493088	72.7%	60.0%	16	9	6	6
3.681569815	72.7%	66.7%	16	10	5	6
3.760595586	68.2%	66.7%	15	10	5	7
3.921438128	63.6%	66.7%	14	10	5	8
3.923444827	59.1%	66.7%	13	10	5	9
5.041232984	59.1%	73.3%	13	11	4	9
6.358798622	54.5%	73.3%	12	11	4	10
7.002814369	50.0%	73.3%	11	11	4	11
9.580198204	45.5%	73.3%	10	11	4	12
9.886882747	40.9%	73.3%	9	11	4	13
9.974385279	36.4%	73.3%	8	11	4	14
10.91867031	31.8%	73.3%	7	11	4	15
12.63788422	31.8%	80.0%	7	12	3	15
12.76021924	31.8%	86.7%	7	13	2	15
12.8746397	31.8%	93.3%	7	14	1	15
14.37204906	27.3%	93.3%	6	14	1	16
18.58403843	22.7%	93.3%	5	14	1	17
19.32278085	18.2%	93.3%	4	14	1	18
32.53093819	13.6%	93.3%	3	14	1	19
40.25804091	13.6%	100.0%	3	15	0	19
41.91052271	9.1%	100.0%	2	15	0	20
48.69019397	4.5%	100.0%	1	15	0	21
49.70161731	0.0%	100.0%	0	15	0	22

Figure 58

Test Receiver Operator Characteristic (ROC) curves

M4101_08 by SAMP_GRP


Performed by Benjamin Silverman

Date 14 August 2002

n 37

SAMP_GRP	n
0	15
1	22

Curve	Area	SE	p	95% CI of Area	SAMP_GRP = 1
M4101_08	0.788	0.0806	0.0002	0.630 to 0.946	have higher values



M4101_08 (abnormals above cut-off)	Sensitivity	Specificity	TP	TN	FP	FN
0.791227317	100.0%	6.7%	22	1	14	0

FIGURE 6A

Test Receiver Operator Characteristic (ROC) curves

M4101_08 by SAMP_GRP

Performed by Benjamin Silverman

Date

14 August 2002

1.777024145	100.0%	13.3%	22	2	13	0
1.864611445	100.0%	20.0%	22	3	12	0
2.229038148	100.0%	26.7%	22	4	11	0
2.42141698	100.0%	33.3%	22	5	10	0
2.565874221	100.0%	40.0%	22	6	9	0
2.702019221	95.5%	40.0%	21	6	9	1
2.843449311	95.5%	46.7%	21	7	8	1
2.982981073	90.9%	46.7%	20	7	8	2
3.090587735	90.9%	53.3%	20	8	7	2
3.241431653	86.4%	53.3%	19	8	7	3
3.60744697	81.8%	53.3%	18	8	7	4
4.562443603	77.3%	53.3%	17	8	7	5
4.903502945	77.3%	60.0%	17	9	6	5
5.177222365	72.7%	60.0%	16	9	6	6
5.181713211	72.7%	66.7%	16	10	5	6
5.857837737	72.7%	73.3%	16	11	4	6
6.977510421	68.2%	73.3%	15	11	4	7
7.386528126	68.2%	80.0%	15	12	3	7
8.779791432	63.6%	80.0%	14	12	3	8
9.459555394	63.6%	86.7%	14	13	2	8
10.7072921	59.1%	86.7%	13	13	2	9
12.08088057	54.5%	86.7%	12	13	2	10
14.15204918	50.0%	86.7%	11	13	2	11
16.11396822	45.5%	86.7%	10	13	2	12
17.28550508	40.9%	86.7%	9	13	2	13
17.80691034	36.4%	86.7%	8	13	2	14
18.43405031	36.4%	93.3%	8	14	1	14
18.47433197	31.8%	93.3%	7	14	1	15
22.34250211	27.3%	93.3%	6	14	1	16
27.29265602	22.7%	93.3%	5	14	1	17
28.67121222	18.2%	93.3%	4	14	1	18
29.03664973	13.6%	93.3%	3	14	1	19
36.20675533	9.1%	93.3%	2	14	1	20
38.54127644	4.5%	93.3%	1	14	1	21
43.59268294	4.5%	100.0%	1	15	0	21
144.7568822	0.0%	100.0%	0	15	0	22

Figure 6B

Test Receiver Operator Characteristic (ROC) curves

M4740_77 by SAMP_GRP


Performed by Benjamin Silverman

Date 14 August 2002

n 37

SAMP_GRP	n
0	15
1	22

Curve	Area	SE	p	95% CI of Area	SAMP_GRP = 1
M4740_77	0.703	0.0885	0.0109	0.530 to 0.877	have lower values



M4740_77 (abnormals below cut-off)	Sensitivity	Specificity	TP	TN	FP	FN
1.782471733	0.0%	100.0%	0	15	0	22

FIGURE 7A

Test		Receiver Operator Characteristic (ROC) curves					
		M4740_77 by SAMP_GRP					
Performed by	Benjamin Silverman					Date	14 August 2002
3.46751317	4.5%	100.0%	1	15	0	21	
3.703141299	9.1%	100.0%	2	15	0	20	
3.822882864	13.6%	100.0%	3	15	0	19	
4.213531318	18.2%	100.0%	4	15	0	18	
5.861586364	18.2%	93.3%	4	14	1	18	
6.537592438	22.7%	93.3%	5	14	1	17	
6.544283701	27.3%	93.3%	6	14	1	18	
6.937836678	27.3%	86.7%	6	13	2	16	
7.396949195	31.8%	86.7%	7	13	2	15	
7.581156967	36.4%	86.7%	8	13	2	14	
7.622572721	40.9%	86.7%	9	13	2	13	
7.996831339	45.5%	86.7%	10	13	2	12	
8.128229641	45.5%	80.0%	10	12	3	12	
8.555890869	50.0%	80.0%	11	12	3	11	
9.035229021	50.0%	73.3%	11	11	4	11	
10.52413657	54.5%	73.3%	12	11	4	10	
10.76436616	54.5%	66.7%	12	10	5	10	
12.18334212	59.1%	66.7%	13	10	5	9	
13.34623356	63.6%	66.7%	14	10	5	8	
14.48398405	68.2%	66.7%	15	10	5	7	
14.76122649	72.7%	66.7%	16	10	5	6	
19.24801943	77.3%	66.7%	17	10	5	5	
21.76687704	81.8%	66.7%	18	10	5	4	
22.89440092	81.8%	60.0%	18	9	6	4	
23.72554368	81.8%	53.3%	18	8	7	4	
26.31956137	81.8%	46.7%	18	7	8	4	
27.15591038	81.8%	40.0%	18	6	9	4	
27.27126289	81.8%	33.3%	18	5	10	4	
30.41172213	81.8%	26.7%	18	4	11	4	
31.68687668	86.4%	26.7%	19	4	11	3	
38.40570882	86.4%	20.0%	19	3	12	3	
43.33855943	90.9%	20.0%	20	3	12	2	
46.45290679	90.9%	13.3%	20	2	13	2	
55.29038899	90.9%	6.7%	20	1	14	2	
121.5530544	95.5%	6.7%	21	1	14	1	
156.6316898	100.0%	6.7%	22	1	14	0	

Figure 1B

Test Receiver Operator Characteristic (ROC) curves

M4774_79 by SAMP_GRP


Performed by Benjamin Silverman

Date 14 August 2002

n 37

SAMP_GRP	n
0	15
1	22

Curve	Area	SE	p	95% CI of Area	SAMP_GRP = 1
M4774_79	0.700	0.0888	0.0121	0.526 to 0.874	have lower values



M4774_79 (abnormals below cut-off)	Sensitivity	Specificity	TP	TN	FP	FN
1.628203756	0.0%	100.0%	0	15	0	22

FIGURE 8 A

Test Receiver Operator Characteristic (ROC) curves

M4774_79 by SAMP_GRP

Performed by	Benjamin Silverman			Date		14 August 2002
1.827155531	4.5%	100.0%	1	15	0	21
2.770794786	4.5%	93.3%	1	14	1	21
3.279957997	9.1%	93.3%	2	14	1	20
3.627411737	13.6%	93.3%	3	14	1	19
3.70851809	18.2%	93.3%	4	14	1	18
3.72785582	22.7%	93.3%	5	14	1	17
4.32411472	27.3%	93.3%	6	14	1	16
4.598018454	31.8%	93.3%	7	14	1	15
5.008617117	36.4%	93.3%	8	14	1	14
5.399934701	36.4%	86.7%	8	13	2	14
5.487403027	40.9%	86.7%	9	13	2	13
6.267387571	45.5%	86.7%	10	13	2	12
6.538557684	50.0%	86.7%	11	13	2	11
6.773605908	54.5%	86.7%	12	13	2	10
6.838166538	54.5%	80.0%	12	12	3	10
7.621667577	59.1%	80.0%	13	12	3	9
7.659773747	59.1%	73.3%	13	11	4	9
7.770546548	59.1%	66.7%	13	10	5	9
10.02116644	63.6%	66.7%	14	10	5	8
10.45039825	68.2%	66.7%	15	10	5	7
11.02281238	68.2%	60.0%	15	9	6	7
11.03992967	72.7%	60.0%	16	9	6	6
11.62998313	72.7%	53.3%	16	8	7	6
11.85826753	77.3%	53.3%	17	8	7	5
12.63500235	77.3%	46.7%	17	7	8	5
12.78702516	77.3%	40.0%	17	6	9	5
13.37119084	77.3%	33.3%	17	5	10	5
15.17345082	81.8%	33.3%	18	5	10	4
15.41808818	81.8%	26.7%	18	4	11	4
16.5708956	81.8%	20.0%	18	3	12	4
18.03957309	86.4%	20.0%	19	3	12	3
20.67017237	90.9%	20.0%	20	3	12	2
21.15863159	95.5%	20.0%	21	3	12	1
21.773702	100.0%	20.0%	22	3	12	0
23.69309466	100.0%	13.3%	22	2	13	0
37.43292643	100.0%	6.7%	22	1	14	0

Figure 8B

Test Receiver Operator Characteristic (ROC) curves

M4991_74 by SAMP_GRP


Performed by Benjamin Silverman

Date 14 August 2002

n 37

SAMP_GRP	n
0	15
1	22

Curve	Area	SE	p	95% CI of Area	SAMP_GRP = 1
M4991_74	0.661	0.0937	0.0433	0.477 to 0.844	have lower values



M4991_74 (abnormals below cut-off)	Sensitivity	Specificity	TP	TN	FP	FN
-0.196979745	0.0%	100.0%	0	15	0	22

FIGURE 9A

Test		Receiver Operator Characteristic (ROC) curves					
		M4991_74 by SAMP_GRP					
Performed by	Benjamin Silverman					Date	14 August 2002
0.996208662	4.5%	100.0%	1	15	0	21	
1.730046597	9.1%	100.0%	2	15	0	20	
1.952680607	13.6%	100.0%	3	15	0	19	
1.979642763	13.6%	93.3%	3	14	1	19	
2.211947172	13.6%	86.7%	3	13	2	19	
2.607265204	18.2%	86.7%	4	13	2	18	
2.805527099	22.7%	86.7%	5	13	2	17	
2.829625782	22.7%	80.0%	5	12	3	17	
3.649138621	27.3%	80.0%	6	12	3	16	
3.687307965	31.8%	80.0%	7	12	3	15	
4.267439352	36.4%	80.0%	8	12	3	14	
4.39521336	40.9%	80.0%	9	12	3	13	
4.427187555	45.5%	80.0%	10	12	3	12	
4.885644148	50.0%	80.0%	11	12	3	11	
5.450333293	54.5%	80.0%	12	12	3	10	
5.787831795	54.5%	73.3%	12	11	4	10	
6.089175257	54.5%	66.7%	12	10	5	10	
6.361118832	59.1%	66.7%	13	10	5	9	
6.427173334	63.6%	66.7%	14	10	5	8	
6.863028781	68.2%	66.7%	15	10	5	7	
6.882342458	68.2%	60.0%	15	9	6	7	
7.411521486	72.7%	60.0%	16	9	6	6	
8.606578814	72.7%	53.3%	16	8	7	6	
9.297640803	77.3%	53.3%	17	8	7	5	
10.25714603	77.3%	46.7%	17	7	8	5	
11.967552	81.8%	46.7%	18	7	8	4	
13.12548723	81.8%	40.0%	18	6	9	4	
14.28048117	81.8%	33.3%	18	5	10	4	
16.55161704	86.4%	33.3%	19	5	10	3	
26.30451983	86.4%	26.7%	19	4	11	3	
28.08294583	86.4%	20.0%	19	3	12	3	
32.11852956	86.4%	13.3%	19	2	13	3	
34.21013343	90.9%	13.3%	20	2	13	2	
34.36097865	95.5%	13.3%	21	2	13	1	
35.89149782	95.5%	6.7%	21	1	14	1	
42.64837465	95.5%	0.0%	21	0	15	1	

Figure 9B

Test Receiver Operator Characteristic (ROC) curves

M5536_29 by SAMP_GRP


Performed by Benjamin Silverman

Date 14 August 2002

n 37

SAMP_GRP	n
0	15
1	22

Curve	Area	SE	p	95% CI of Area	SAMP_GRP = 1
M5536_29	0.615	0.0950	0.1129	0.429 to 0.801	have higher values



M5536_29 (abnormals above cut-off)	Sensitivity	Specificity	TP	TN	FP	FN
2.476873773	100.0%	6.7%	22	1	14	0

FIGURE 10A

Test Receiver Operator Characteristic (ROC) curves

M5536_29 by SAMP_GRP

Performed by Benjamin Silverman

Date

14 August 2002

2.735239337	95.5%	6.7%	21	1	14	1
3.120351652	95.5%	13.3%	21	2	13	1
3.38479814	95.5%	20.0%	21	3	12	1
3.997539986	95.5%	26.7%	21	4	11	1
4.095493334	90.9%	26.7%	20	4	11	2
4.263146482	86.4%	26.7%	19	4	11	3
4.594284377	81.8%	26.7%	18	4	11	4
5.972410264	77.3%	26.7%	17	4	11	5
6.664831963	77.3%	33.3%	17	5	10	5
6.817705332	72.7%	33.3%	16	5	10	6
8.141308021	68.2%	33.3%	15	5	10	7
8.480803777	68.2%	40.0%	15	6	9	7
8.987766361	68.2%	46.7%	15	7	8	7
9.231911097	68.2%	53.3%	15	8	7	7
9.552062697	63.6%	53.3%	14	8	7	8
10.55353177	59.1%	53.3%	13	8	7	9
13.97374817	59.1%	60.0%	13	9	6	9
14.02278422	59.1%	66.7%	13	10	5	9
14.88280435	54.5%	66.7%	12	10	5	10
15.23628909	50.0%	66.7%	11	10	5	11
23.4978088	45.5%	66.7%	10	10	5	12
25.14900037	40.9%	66.7%	9	10	5	13
26.02066777	36.4%	66.7%	8	10	5	14
30.6345416	36.4%	73.3%	8	11	4	14
30.77622328	31.8%	73.3%	7	11	4	15
31.94867944	31.8%	80.0%	7	12	3	15
34.49611418	31.8%	86.7%	7	13	2	15
35.08171775	27.3%	86.7%	6	13	2	16
36.99180982	27.3%	93.3%	6	14	1	16
38.61874069	22.7%	93.3%	5	14	1	17
41.37427345	18.2%	93.3%	4	14	1	18
43.17627664	13.6%	93.3%	3	14	1	19
44.48204224	9.1%	93.3%	2	14	1	20
52.94519269	9.1%	100.0%	2	15	0	20
62.35890391	4.5%	100.0%	1	15	0	21
65.07263487	0.0%	100.0%	0	15	0	22

Figure 10f

Test Receiver Operator Characteristic (ROC) curves

M5632_34 by SAMP_GRP


Performed by Benjamin Silverman

Date 14 August 2002

n 37

SAMP_GRP	n
0	15
1	22

Curve	Area	SE	p	95% CI of Area	SAMP_GRP = 1
M5632_34	0.706	0.0896	0.0107	0.530 to 0.882	have higher values



M5632_34 (abnormals above cut-off)	Sensitivity	Specificity	TP	TN	FP	FN
-0.66241178	95.5%	0.0%	21	0	15	1

FIGURE 11A

Test Receiver Operator Characteristic (ROC) curves

M5632_34 by SAMP_GRP

Performed by	Benjamin Silverman				Date	14 August 2002
-0.504040134	90.9%	0.0%	20	0	15	2
0.388898772	90.9%	6.7%	20	1	14	2
0.653349603	90.9%	13.3%	20	2	13	2
0.77842974	90.9%	20.0%	20	3	12	2
0.825697867	90.9%	26.7%	20	4	11	2
0.968687382	90.9%	33.3%	20	5	10	2
0.998569141	86.4%	33.3%	19	5	10	3
1.077108899	81.8%	33.3%	18	5	10	4
1.107048847	81.8%	40.0%	18	6	9	4
1.126856905	81.8%	46.7%	18	7	8	4
1.314607138	77.3%	46.7%	17	7	8	5
1.596204729	77.3%	53.3%	17	8	7	5
1.932708548	72.7%	53.3%	16	8	7	6
1.975900376	72.7%	60.0%	16	9	6	6
2.238214852	72.7%	66.7%	16	10	5	6
2.251560917	72.7%	73.3%	16	11	4	6
2.352154965	68.2%	73.3%	15	11	4	7
2.521548392	68.2%	80.0%	15	12	3	7
2.854528318	63.6%	80.0%	14	12	3	8
3.024417527	59.1%	80.0%	13	12	3	9
3.122910575	54.5%	80.0%	12	12	3	10
3.488196703	50.0%	80.0%	11	12	3	11
3.61290495	45.5%	80.0%	10	12	3	12
3.841931455	40.9%	80.0%	9	12	3	13
3.873274722	40.9%	86.7%	9	13	2	13
4.550969293	36.4%	86.7%	8	13	2	14
4.687454232	31.8%	86.7%	7	13	2	15
5.820357958	27.3%	86.7%	6	13	2	16
5.840106731	27.3%	93.3%	6	14	1	16
6.139408278	22.7%	93.3%	5	14	1	17
6.675787665	18.2%	93.3%	4	14	1	18
10.06276664	13.6%	93.3%	3	14	1	19
13.41667655	9.1%	93.3%	2	14	1	20
14.98079515	9.1%	100.0%	2	15	0	20
20.80876033	4.5%	100.0%	1	15	0	21
28.92874487	0.0%	100.0%	0	15	0	22

Figure 11B

Test Receiver Operator Characteristic (ROC) curves

M6083_96 by SAMP_GRP


Performed by Benjamin Silverman

Date 14 August 2002

n 37

SAMP_GRP	n
0	15
1	22

Curve	Area	SE	p	95% CI of Area	SAMP_GRP = 1
M6083_96	0.636	0.1018	0.0903	0.437 to 0.836	have higher values



M6083_96 (abnormals above cut-off)	Sensitivity	Specificity	TP	TN	FP	FN
-1.209303384	95.5%	0.0%	21	0	15	1

FIGURE 12A

Test Receiver Operator Characteristic (ROC) curves

M6083_96 by SAMP_GRP

Performed by Benjamin Silverman

Date

14 August 2002

-0.840532557	90.9%	0.0%	20	0	15	2
0.051463134	90.9%	6.7%	20	1	14	2
0.706431918	90.9%	13.3%	20	2	13	2
1.124512015	90.9%	20.0%	20	3	12	2
1.591362646	90.9%	26.7%	20	4	11	2
1.683209049	90.9%	33.3%	20	5	10	2
1.788481249	90.9%	40.0%	20	6	9	2
2.481609046	86.4%	40.0%	19	6	9	3
2.51886446	86.4%	46.7%	19	7	8	3
2.55797428	86.4%	53.3%	19	8	7	3
2.605058174	81.8%	53.3%	18	8	7	4
2.885215545	81.8%	60.0%	18	9	6	4
3.197459448	77.3%	60.0%	17	9	6	5
3.365272297	72.7%	60.0%	16	9	6	6
3.671798165	68.2%	60.0%	15	9	6	7
3.90007016	63.6%	60.0%	14	9	6	8
4.039270694	59.1%	60.0%	13	9	6	9
4.436064311	54.5%	60.0%	12	9	6	10
4.617136392	54.5%	66.7%	12	10	5	10
5.115352999	50.0%	66.7%	11	10	5	11
6.353216703	50.0%	73.3%	11	11	4	11
6.4912197	45.5%	73.3%	10	11	4	12
7.441252266	40.9%	73.3%	9	11	4	13
8.792126385	36.4%	73.3%	8	11	4	14
11.29691249	31.8%	73.3%	7	11	4	15
13.30488137	31.8%	80.0%	7	12	3	15
13.92938769	27.3%	80.0%	6	12	3	16
15.8894186	22.7%	80.0%	5	12	3	17
15.99529578	18.2%	80.0%	4	12	3	18
17.73356817	18.2%	86.7%	4	13	2	18
20.46026717	13.6%	86.7%	3	13	2	19
21.31066896	9.1%	86.7%	2	13	2	20
23.17512833	4.5%	86.7%	1	13	2	21
29.15341734	0.0%	86.7%	0	13	2	22
37.84621415	0.0%	93.3%	0	14	1	22
43.82802395	0.0%	100.0%	0	15	0	22

Figure 12b

Test Receiver Operator Characteristic (ROC) curves

M6406_04 by SAMP_GRP

Performed by Benjamin Silverman


Date

14 August 2002

n | 37

SAMP_GRP	n
0	15
1	22

Curve	Area	SE	p	95% CI of Area	SAMP_GRP = 1
M6406_04	0.667	0.0918	0.0348	0.487 to 0.847	have higher values



M6406_04 (abnormals above cut-off)	Sensitivity	Specificity	TP	TN	FP	FN
0.207686614	95.5%	0.0%	21	0	15	1

FIGURE 13A

Test Receiver Operator Characteristic (ROC) curves

M6406_04 by SAMP_GRP

Performed by Benjamin Silverman

Date

14 August 2002

0.923420696	95.5%	6.7%	21	1	14	1
1.234313198	95.5%	13.3%	21	2	13	1
1.494874412	90.9%	13.3%	20	2	13	2
1.625003803	90.9%	20.0%	20	3	12	2
1.783038312	90.9%	26.7%	20	4	11	2
2.266399527	90.9%	33.3%	20	5	10	2
2.694941007	86.4%	33.3%	19	5	10	3
2.886712812	81.8%	33.3%	18	5	10	4
3.057125428	81.8%	40.0%	18	6	9	4
3.078671506	77.3%	40.0%	17	6	9	5
3.136138812	77.3%	46.7%	17	7	8	5
3.37282052	77.3%	53.3%	17	8	7	5
3.386309735	77.3%	60.0%	17	9	6	5
3.470325094	72.7%	60.0%	16	9	6	6
3.510408777	68.2%	60.0%	15	9	6	7
3.702964632	63.6%	60.0%	14	9	6	8
4.134558043	63.6%	66.7%	14	10	5	8
4.418528395	59.1%	66.7%	13	10	5	9
4.626183014	54.5%	66.7%	12	10	5	10
6.199219603	50.0%	66.7%	11	10	5	11
6.643154701	45.5%	66.7%	10	10	5	12
6.801405828	45.5%	73.3%	10	11	4	12
8.678907807	45.5%	80.0%	10	12	3	12
8.928059882	40.9%	80.0%	9	12	3	13
9.547872707	36.4%	80.0%	8	12	3	14
9.740209204	31.8%	80.0%	7	12	3	15
11.50928318	27.3%	80.0%	6	12	3	16
11.64666186	27.3%	86.7%	6	13	2	16
16.68248737	22.7%	86.7%	5	13	2	17
18.36670762	22.7%	93.3%	5	14	1	17
20.99571285	18.2%	93.3%	4	14	1	18
26.53742371	18.2%	100.0%	4	15	0	18
28.29947448	13.6%	100.0%	3	15	0	19
48.99553133	9.1%	100.0%	2	15	0	20
75.56336781	4.5%	100.0%	1	15	0	21
727.9817302	0.0%	100.0%	0	15	0	22

Figure 13B

Test Receiver Operator Characteristic (ROC) curves

M6468_89 by SAMP_GRP


Performed by Benjamin Silverman

Date 14 August 2002

n 37

SAMP_GRP	n
0	15
1	22

Curve	Area	SE	p	95% CI of Area	SAMP_GRP = 1
M6468_89	0.824	0.0679	<0.0001	0.691 to 0.957	have higher values



M6468_89 (abnormals above cut-off)	Sensitivity	Specificity	TP	TN	FP	FN
0.091826597	100.0%	6.7%	22	1	14	0

FIGURE 14 A

Test Receiver Operator Characteristic (ROC) curves

M6468_89 by SAMP_GRP

Performed by Benjamin Silverman

Date

14 August 2002

0.835563258	100.0%	13.3%	22	2	13	0
0.93219296	100.0%	20.0%	22	3	12	0
1.074969489	100.0%	26.7%	22	4	11	0
1.133243299	100.0%	33.3%	22	5	10	0
1.518080502	100.0%	40.0%	22	6	9	0
1.825078341	95.5%	40.0%	21	6	9	1
1.918368848	95.5%	46.7%	21	7	8	1
2.230152821	90.9%	46.7%	20	7	8	2
2.375750164	86.4%	46.7%	19	7	8	3
2.641109179	86.4%	53.3%	19	8	7	3
3.094798916	86.4%	60.0%	19	9	6	3
3.811488644	86.4%	66.7%	19	10	5	3
4.500641184	81.8%	66.7%	18	10	5	4
4.783912451	77.3%	66.7%	17	10	5	5
4.794961294	72.7%	66.7%	16	10	5	6
4.934982572	72.7%	73.3%	16	11	4	6
5.034285335	68.2%	73.3%	15	11	4	7
5.077822723	63.6%	73.3%	14	11	4	8
5.983764713	59.1%	73.3%	13	11	4	9
7.45907997	59.1%	80.0%	13	12	3	9
7.491795742	54.5%	80.0%	12	12	3	10
8.139771712	50.0%	80.0%	11	12	3	11
8.555474896	50.0%	86.7%	11	13	2	11
9.467190147	50.0%	93.3%	11	14	1	11
9.887556218	50.0%	100.0%	11	15	0	11
12.78727407	45.5%	100.0%	10	15	0	12
14.99572961	40.9%	100.0%	9	15	0	13
15.17972908	36.4%	100.0%	8	15	0	14
16.21889052	31.8%	100.0%	7	15	0	15
16.78423313	27.3%	100.0%	6	15	0	16
17.96332953	22.7%	100.0%	5	15	0	17
26.72227163	18.2%	100.0%	4	15	0	18
31.20758175	13.6%	100.0%	3	15	0	19
57.91100778	9.1%	100.0%	2	15	0	20
107.7567031	4.5%	100.0%	1	15	0	21
426.7508851	0.0%	100.0%	0	15	0	22

Figure 14B

Test Receiver Operator Characteristic (ROC) curves

M6602_76 by SAMP_GRP


Performed by Benjamin Silverman

Date 14 August 2002

n 37

SAMP_GRP	n
0	15
1	22

Curve	Area	SE	p	95% CI of Area	SAMP_GRP = 1
M6602_76	0.776	0.0792	0.0002	0.621 to 0.931	have higher values



M6602_76 (abnormals above cut-off)	Sensitivity	Specificity	TP	TN	FP	FN
0.820083574	95.5%	0.0%	21	0	15	1

FIGURE 15A

Test Receiver Operator Characteristic (ROC) curves

M6602_76 by SAMP_GRP

Performed by Benjamin Silverman

Date

14 August 2002

1.145943829	95.5%	6.7%	21	1	14	1
1.271587635	95.5%	13.3%	21	2	13	1
1.319340027	95.5%	20.0%	21	3	12	1
1.413613659	90.9%	20.0%	20	3	12	2
1.430941938	90.9%	26.7%	20	4	11	2
1.499030655	90.9%	33.3%	20	5	10	2
2.982147717	90.9%	40.0%	20	6	9	2
3.310303594	90.9%	46.7%	20	7	8	2
3.583311101	90.9%	53.3%	20	8	7	2
3.910654764	90.9%	60.0%	20	9	6	2
4.106539181	86.4%	60.0%	19	9	6	3
4.146892007	81.8%	60.0%	18	9	6	4
4.504318001	77.3%	60.0%	17	9	6	5
5.125117622	77.3%	66.7%	17	10	5	5
6.118715467	77.3%	73.3%	17	11	4	5
6.530734839	72.7%	73.3%	16	11	4	6
8.485693053	68.2%	73.3%	15	11	4	7
8.701819799	63.6%	73.3%	14	11	4	8
8.938297048	63.6%	80.0%	14	12	3	8
11.54358186	59.1%	80.0%	13	12	3	9
11.77637501	54.5%	80.0%	12	12	3	10
13.17815594	50.0%	80.0%	11	12	3	11
14.70426566	45.5%	80.0%	10	12	3	12
18.11626496	40.9%	80.0%	9	12	3	13
20.74477865	40.9%	86.7%	9	13	2	13
21.72001082	40.9%	93.3%	9	14	1	13
22.61295945	36.4%	93.3%	8	14	1	14
28.44256416	31.8%	93.3%	7	14	1	15
28.59767222	31.8%	100.0%	7	15	0	15
31.1639502	27.3%	100.0%	6	15	0	16
34.82375034	22.7%	100.0%	5	15	0	17
36.530145	18.2%	100.0%	4	15	0	18
68.51218679	13.6%	100.0%	3	15	0	19
72.06446204	9.1%	100.0%	2	15	0	20
76.93895384	4.5%	100.0%	1	15	0	21
1132.766318	0.0%	100.0%	0	15	0	22

Figure 15b

Test Receiver Operator Characteristic (ROC) curves

M6678_13 by SAMP_GRP


Performed by Benjamin Silverman

Date 14 August 2002

n 37

SAMP_GRP	n
0	15
1	22

Curve	Area	SE	p	95% CI of Area	SAMP_GRP = 1
M6678_13	0.821	0.0683	<0.0001	0.687 to 0.955	have higher values



M6678_13 (abnormals above cut-off)	Sensitivity	Specificity	TP	TN	FP	FN
0.172067082	100.0%	6.7%	22	1	14	0

FIGURE 16A

Test Receiver Operator Characteristic (ROC) curves

M6678_13 by SAMP_GRP

Performed by Benjamin Silverman

Date

14 August 2002

0.804078156	100.0%	13.3%	22	2	13	0
0.947881336	100.0%	20.0%	22	3	12	0
1.776830937	100.0%	26.7%	22	4	11	0
1.815583274	100.0%	33.3%	22	5	10	0
1.87952221	100.0%	40.0%	22	6	9	0
2.215304578	95.5%	40.0%	21	6	9	1
2.686887113	90.9%	40.0%	20	6	9	2
3.418198784	90.9%	46.7%	20	7	8	2
3.569813842	90.9%	53.3%	20	8	7	2
4.140555716	90.9%	60.0%	20	9	6	2
4.854915071	86.4%	60.0%	19	9	6	3
4.910729785	81.8%	60.0%	18	9	6	4
7.495729351	77.3%	60.0%	17	9	6	5
7.529526451	77.3%	66.7%	17	10	5	5
8.141631464	72.7%	66.7%	16	10	5	6
8.894175505	68.2%	66.7%	15	10	5	7
9.897687452	68.2%	73.3%	15	11	4	7
10.70496756	63.6%	73.3%	14	11	4	8
11.04636753	63.6%	80.0%	14	12	3	8
11.87418655	59.1%	80.0%	13	12	3	9
12.11700223	59.1%	86.7%	13	13	2	9
12.99470979	54.5%	86.7%	12	13	2	10
15.29949571	50.0%	86.7%	11	13	2	11
15.49869338	45.5%	86.7%	10	13	2	12
17.01670817	45.5%	93.3%	10	14	1	12
17.39670531	45.5%	100.0%	10	15	0	12
21.15304525	40.9%	100.0%	9	15	0	13
25.24524975	36.4%	100.0%	8	15	0	14
26.35790954	31.8%	100.0%	7	15	0	15
40.71351756	27.3%	100.0%	6	15	0	16
49.3578222	22.7%	100.0%	5	15	0	17
54.7182916	18.2%	100.0%	4	15	0	18
62.09784715	13.6%	100.0%	3	15	0	19
66.98593778	9.1%	100.0%	2	15	0	20
112.5819998	4.5%	100.0%	1	15	0	21
421.1384813	0.0%	100.0%	0	15	0	22

Figure 16B

Test Receiver Operator Characteristic (ROC) curves

M6812_97 by SAMP_GRP						
Performed by	Benjamin Silverman				Date	14 August 2002
0.083697961	100.0%	13.3%	22	2	13	0
0.10179494	95.5%	13.3%	21	2	13	1
0.525080407	95.5%	20.0%	21	3	12	1
0.570354396	90.9%	20.0%	20	3	12	2
0.753188459	90.9%	26.7%	20	4	11	2
1.11285706	86.4%	26.7%	19	4	11	3
1.325208389	81.8%	26.7%	18	4	11	4
1.617507376	77.3%	26.7%	17	4	11	5
1.80310697	77.3%	33.3%	17	5	10	5
1.839397793	77.3%	40.0%	17	6	9	5
1.883035656	77.3%	46.7%	17	7	8	5
2.134774398	77.3%	53.3%	17	8	7	5
2.549415178	77.3%	60.0%	17	9	6	5
2.737012635	72.7%	60.0%	16	9	6	6
3.440345493	68.2%	60.0%	15	9	6	7
3.760823507	68.2%	66.7%	15	10	5	7
4.001239542	63.6%	66.7%	14	10	5	8
4.235485182	63.6%	73.3%	14	11	4	8
4.984817763	59.1%	73.3%	13	11	4	9
5.108312165	54.5%	73.3%	12	11	4	10
5.445686923	50.0%	73.3%	11	11	4	11
6.569652629	50.0%	80.0%	11	12	3	11
8.295531625	50.0%	86.7%	11	13	2	11
10.26293153	45.5%	86.7%	10	13	2	12
10.41860259	45.5%	93.3%	10	14	1	12
10.54561463	45.5%	100.0%	10	15	0	12
10.93678783	40.9%	100.0%	9	15	0	13
13.079319	36.4%	100.0%	8	15	0	14
14.73918594	31.8%	100.0%	7	15	0	15
15.85800335	27.3%	100.0%	6	15	0	16
17.43916435	22.7%	100.0%	5	15	0	17
21.54469853	18.2%	100.0%	4	15	0	18
26.33373752	13.6%	100.0%	3	15	0	19
34.98959324	9.1%	100.0%	2	15	0	20
78.8916841	4.5%	100.0%	1	15	0	21
349.5455888	0.0%	100.0%	0	15	0	22

Figure 17B

Test Receiver Operator Characteristic (ROC) curves

M6995_07 by SAMP_GRP


Performed by Benjamin Silverman

Date 14 August 2002

n 37

SAMP_GRP	n
0	15
1	22

Curve	Area	SE	p	95% CI of Area	SAMP_GRP = 1
M6995_07	0.788	0.0754	<0.0001	0.640 to 0.936	have higher values



M6995_07 (abnormals above cut-off)	Sensitivity	Specificity	TP	TN	FP	FN
1.491443956	100.0%	6.7%	22	1	14	0

FIGURE 18A

Test Receiver Operator Characteristic (ROC) curves

M8995_07 by SAMP_GRP

Performed by Benjamin Silverman

Date

14 August 2002

3.064382087	100.0%	13.3%	22	2	13	0
3.211056923	95.5%	13.3%	21	2	13	1
3.575587562	95.5%	20.0%	21	3	12	1
3.590078119	95.5%	26.7%	21	4	11	1
3.64230464	95.5%	33.3%	21	5	10	1
3.810235534	95.5%	40.0%	21	6	9	1
6.561735067	95.5%	46.7%	21	7	8	1
6.569795399	90.9%	46.7%	20	7	8	2
6.985274137	90.9%	53.3%	20	8	7	2
7.844524644	86.4%	53.3%	19	8	7	3
8.233274241	81.8%	53.3%	18	8	7	4
8.552871855	81.8%	60.0%	18	9	6	4
8.581003414	77.3%	60.0%	17	9	6	5
9.276961217	77.3%	66.7%	17	10	5	5
9.71746827	72.7%	66.7%	16	10	5	6
10.65779175	72.7%	73.3%	16	11	4	6
12.8063091	68.2%	73.3%	15	11	4	7
14.37145601	63.6%	73.3%	14	11	4	8
14.46510595	59.1%	73.3%	13	11	4	9
14.51627012	54.5%	73.3%	12	11	4	10
14.94070151	50.0%	73.3%	11	11	4	11
17.48944524	50.0%	80.0%	11	12	3	11
20.38931912	50.0%	86.7%	11	13	2	11
20.4113395	45.5%	86.7%	10	13	2	12
25.92763801	45.5%	93.3%	10	14	1	12
26.40659722	40.9%	93.3%	9	14	1	13
26.74725392	36.4%	93.3%	8	14	1	14
32.42243868	36.4%	100.0%	8	15	0	14
38.44615454	31.8%	100.0%	7	15	0	15
39.5757897	27.3%	100.0%	6	15	0	16
42.93915647	22.7%	100.0%	5	15	0	17
44.44568121	18.2%	100.0%	4	15	0	18
44.51626947	13.6%	100.0%	3	15	0	19
95.0004203	9.1%	100.0%	2	15	0	20
141.0738233	4.5%	100.0%	1	15	0	21
3147.932227	0.0%	100.0%	0	15	0	22

Figure 18D

Test Receiver Operator Characteristic (ROC) curves

M7092_76 by SAMP_GRP


Performed by Benjamin Silverman

Date 14 August 2002

n 37

SAMP_GRP	n
0	15
1	22

Curve	Area	SE	p	95% CI of Area	SAMP_GRP = 1
M7092_76	0.806	0.0814	<0.0001	0.647 to 0.968	have higher values



M7092_76 (abnormals above cut-off)	Sensitivity	Specificity	TP	TN	FP	FN
0.116985513	100.0%	6.7%	22	1	14	0

FIGURE 19A

Test Receiver Operator Characteristic (ROC) curves							
M7092_76 by SAMP_GRP							
Performed by	Benjamin Silverman						Date
							14 August 2002
1.862910226	100.0%	13.3%	22	2	13	0	
2.957763417	100.0%	20.0%	22	3	12	0	
3.222148121	95.5%	20.0%	21	3	12	1	
3.27231959	95.5%	26.7%	21	4	11	1	
3.282820708	95.5%	33.3%	21	5	10	1	
4.001971072	95.5%	40.0%	21	6	9	1	
4.04949334	95.5%	46.7%	21	7	8	1	
4.153630114	90.9%	46.7%	20	7	8	2	
4.497343511	90.9%	53.3%	20	8	7	2	
4.918339938	90.9%	60.0%	20	9	6	2	
5.151284095	90.9%	66.7%	20	10	5	2	
5.334167589	90.9%	73.3%	20	11	4	2	
5.552935622	86.4%	73.3%	19	11	4	3	
5.901348367	81.8%	73.3%	18	11	4	4	
6.449491292	77.3%	73.3%	17	11	4	5	
8.769308501	72.7%	73.3%	16	11	4	6	
8.803059652	68.2%	73.3%	15	11	4	7	
8.919510428	68.2%	80.0%	15	12	3	7	
10.19427001	63.6%	80.0%	14	12	3	8	
10.45580495	63.6%	86.7%	14	13	2	8	
12.59614789	59.1%	86.7%	13	13	2	9	
16.83451689	54.5%	86.7%	12	13	2	10	
22.00466543	50.0%	86.7%	11	13	2	11	
23.47247801	45.5%	86.7%	10	13	2	12	
26.17734222	40.9%	86.7%	9	13	2	13	
27.02830203	36.4%	86.7%	8	13	2	14	
29.83138707	31.8%	86.7%	7	13	2	15	
39.98526477	27.3%	86.7%	6	13	2	16	
44.65059349	27.3%	93.3%	6	14	1	16	
46.65430614	22.7%	93.3%	5	14	1	17	
54.13737253	18.2%	93.3%	4	14	1	18	
100.3851762	13.6%	93.3%	3	14	1	19	
110.8760403	9.1%	93.3%	2	14	1	20	
153.059446	4.5%	93.3%	1	14	1	21	
168.4616351	4.5%	100.0%	1	15	0	21	
426.5909767	0.0%	100.0%	0	15	0	22	

Figure 19B

Test Receiver Operator Characteristic (ROC) curves

M7314_17 by SAMP_GRP


Performed by Benjamin Silverman

Date 14 August 2002

n 37

SAMP_GRP	n
0	15
1	22

Curve	Area	SE	p	95% CI of Area	SAMP_GRP = 1
M7314_17	0.773	0.0867	0.0008	0.603 to 0.943	have higher values



M7314_17 (abnormals above cut-off)	Sensitivity	Specificity	TP	TN	FP	FN
1.114997332	100.0%	6.7%	22	1	14	0

FIGURE 20A

Test Receiver Operator Characteristic (ROC) curves

M7314_17 by SAMP_GRP

Performed by Benjamin Silverman

Date

14 August 2002

1.180169107	100.0%	13.3%	22	2	13	0
1.224623102	100.0%	20.0%	22	3	12	0
1.326553822	100.0%	26.7%	22	4	11	0
1.709052162	95.5%	26.7%	21	4	11	1
1.77348404	90.9%	26.7%	20	4	11	2
2.236875714	90.9%	33.3%	20	5	10	2
2.240777654	86.4%	33.3%	19	5	10	3
2.352830697	86.4%	40.0%	19	6	9	3
2.475113163	86.4%	46.7%	19	7	8	3
2.834024541	86.4%	53.3%	19	8	7	3
2.919756862	86.4%	60.0%	19	9	6	3
2.964311998	81.8%	60.0%	18	9	6	4
2.98055665	81.8%	66.7%	18	10	5	4
3.310074994	81.8%	73.3%	18	11	4	4
3.873756225	77.3%	73.3%	17	11	4	5
5.048148574	72.7%	73.3%	16	11	4	6
5.051833408	72.7%	80.0%	16	12	3	6
6.248643692	68.2%	80.0%	15	12	3	7
6.682066684	68.2%	86.7%	15	13	2	7
8.598671796	63.6%	86.7%	14	13	2	8
9.39521205	59.1%	86.7%	13	13	2	9
10.56821695	54.5%	86.7%	12	13	2	10
13.53952374	50.0%	86.7%	11	13	2	11
14.17616623	45.5%	86.7%	10	13	2	12
15.60825923	40.9%	86.7%	9	13	2	13
17.90393685	36.4%	86.7%	8	13	2	14
19.91147186	31.8%	86.7%	7	13	2	15
25.18734431	27.3%	86.7%	6	13	2	16
27.36118714	22.7%	86.7%	5	13	2	17
32.78098195	18.2%	86.7%	4	13	2	18
34.78889153	18.2%	93.3%	4	14	1	18
43.45506451	13.6%	93.3%	3	14	1	19
59.53332127	9.1%	93.3%	2	14	1	20
63.66042898	4.5%	93.3%	1	14	1	21
69.34508241	0.0%	93.3%	0	14	1	22
73.87428099	0.0%	100.0%	0	15	0	22

Figure 20

Test Receiver Operator Characteristic (ROC) curves

M7512_62 by SAMP_GRP


Performed by Benjamin Silverman

Date 14 August 2002

n 37

SAMP_GRP	n
0	15
1	22

Curve	Area	SE	p	95% CI of Area	SAMP_GRP = 1
M7512_62	0.773	0.0871	0.0009	0.602 to 0.943	have higher values



M7512_62 (abnormals above cut-off)	Sensitivity	Specificity	TP	TN	FP	FN
0.625410695	95.5%	0.0%	21	0	15	1

FIGURE 21 A

Test Receiver Operator Characteristic (ROC) curves

M7512_62 by SAMP_GRP

Performed by Benjamin Silverman

Date

14 August 2002

0.762104663	95.5%	6.7%	21	1	14	1
1.122272393	95.5%	13.3%	21	2	13	1
1.378372019	95.5%	20.0%	21	3	12	1
1.546262948	95.5%	26.7%	21	4	11	1
1.643886277	95.5%	33.3%	21	5	10	1
1.661108564	95.5%	40.0%	21	6	9	1
3.058893486	95.5%	46.7%	21	7	8	1
3.78575016	95.5%	53.3%	21	8	7	1
3.846409634	95.5%	60.0%	21	9	6	1
3.907858158	95.5%	66.7%	21	10	5	1
4.753500925	90.9%	66.7%	20	10	5	2
4.94581107	86.4%	66.7%	19	10	5	3
5.833371244	81.8%	66.7%	18	10	5	4
5.872789172	77.3%	66.7%	17	10	5	5
5.879481156	72.7%	66.7%	16	10	5	6
6.660721221	72.7%	73.3%	16	11	4	6
7.500832279	68.2%	73.3%	15	11	4	7
7.675599479	63.6%	73.3%	14	11	4	8
7.972317528	63.6%	80.0%	14	12	3	8
10.66838021	59.1%	80.0%	13	12	3	9
11.59554514	54.5%	80.0%	12	12	3	10
12.97571036	50.0%	80.0%	11	12	3	11
14.88590508	45.5%	80.0%	10	12	3	12
17.39851187	40.9%	80.0%	9	12	3	13
20.28527567	36.4%	80.0%	8	12	3	14
21.55862835	31.8%	80.0%	7	12	3	15
24.05640739	27.3%	80.0%	6	12	3	16
25.55057933	22.7%	80.0%	5	12	3	17
25.57183388	22.7%	86.7%	5	13	2	17
28.47338716	22.7%	93.3%	5	14	1	17
31.73736348	22.7%	100.0%	5	15	0	17
51.03701678	18.2%	100.0%	4	15	0	18
55.37243893	13.6%	100.0%	3	15	0	19
91.83881699	9.1%	100.0%	2	15	0	20
126.9859246	4.5%	100.0%	1	15	0	21
165.9115088	0.0%	100.0%	0	15	0	22

Figure 21P

Test Receiver Operator Characteristic (ROC) curves

M7794_82 by SAMP_GRP

Performed by Benjamin Silverman


Date

14 August 2002

n | 37

SAMP_GRP	n
0	15
1	22

Curve	Area	SE	p	95% CI of Area	SAMP_GRP = 1
M7794_82	0.742	0.0938	0.0049	0.559 to 0.926	have higher values



M7794_82 (abnormals above cut-off)	Sensitivity	Specificity	TP	TN	FP	FN
-0.08627241	100.0%	6.7%	22	1	14	0

FIGURE 22A

Test Receiver Operator Characteristic (ROC) curves

M7794_82 by SAMP_GRP

Performed by Benjamin Silverman

Date

14 August 2002

0.013815951	100.0%	13.3%	22	2	13	0
0.049455599	100.0%	20.0%	22	3	12	0
0.095260382	95.5%	20.0%	21	3	12	1
0.109513792	95.5%	26.7%	21	4	11	1
0.186117689	95.5%	33.3%	21	5	10	1
0.402645583	95.5%	40.0%	21	6	9	1
0.452914233	95.5%	46.7%	21	7	8	1
0.484984253	90.9%	46.7%	20	7	8	2
0.536323113	90.9%	53.3%	20	8	7	2
0.563391393	90.9%	60.0%	20	9	6	2
0.693832415	90.9%	66.7%	20	10	5	2
0.765652442	86.4%	66.7%	19	10	5	3
0.783555475	81.8%	66.7%	18	10	5	4
0.858183653	77.3%	66.7%	17	10	5	5
0.888201349	77.3%	73.3%	17	11	4	5
0.902269861	72.7%	73.3%	16	11	4	6
0.908749925	68.2%	73.3%	15	11	4	7
0.954138409	63.6%	73.3%	14	11	4	8
0.956932268	59.1%	73.3%	13	11	4	9
1.040190836	54.5%	73.3%	12	11	4	10
1.38805676	50.0%	73.3%	11	11	4	11
1.462958498	45.5%	73.3%	10	11	4	12
1.565809169	40.9%	73.3%	9	11	4	13
1.639589588	36.4%	73.3%	8	11	4	14
1.659493689	31.8%	73.3%	7	11	4	15
1.797384017	31.8%	80.0%	7	12	3	15
1.821160291	27.3%	80.0%	6	12	3	16
1.958973143	22.7%	80.0%	5	12	3	17
2.138566227	22.7%	86.7%	5	13	2	17
2.14742124	22.7%	93.3%	5	14	1	17
2.880841629	18.2%	93.3%	4	14	1	18
3.76104205	13.6%	93.3%	3	14	1	19
5.412710799	9.1%	93.3%	2	14	1	20
11.82552702	4.5%	93.3%	1	14	1	21
23.67610979	4.5%	100.0%	1	15	0	21
44.68965421	0.0%	100.0%	0	15	0	22

Figure 22B

Test Receiver Operator Characteristic (ROC) curves

M8008_80 by SAMP_GRP


Performed by Benjamin Silverman

Date 14 August 2002

n 37

SAMP_GRP	n
0	15
1	22

Curve	Area	SE	p	95% CI of Area	SAMP_GRP = 1
M8008_80	0.748	0.0901	0.0029	0.572 to 0.925	have higher values



M8008_80 (abnormals above cut-off)	Sensitivity	Specificity	TP	TN	FP	FN
1.11982771	100.0%	6.7%	22	1	14	0

FIGURE 23 A

Test Receiver Operator Characteristic (ROC) curves

M8008_80 by SAMP_GRP

Performed by Benjamin Silverman

Date

14 August 2002

1.359759553	100.0%	13.3%	22	2	13	0
2.654253558	100.0%	20.0%	22	3	12	0
2.808461046	100.0%	26.7%	22	4	11	0
3.26845117	100.0%	33.3%	22	5	10	0
3.528811365	100.0%	40.0%	22	6	9	0
3.536888491	95.5%	40.0%	21	6	9	1
3.690604924	95.5%	46.7%	21	7	8	1
3.846135566	95.5%	53.3%	21	8	7	1
4.063516487	95.5%	60.0%	21	9	6	1
4.968072731	90.9%	60.0%	20	9	6	2
5.11309322	86.4%	60.0%	19	9	6	3
5.244061045	81.8%	60.0%	18	9	6	4
5.519460219	77.3%	60.0%	17	9	6	5
5.746787228	77.3%	66.7%	17	10	5	5
5.888803285	72.7%	66.7%	16	10	5	6
6.029356242	68.2%	66.7%	15	10	5	7
6.808604885	63.6%	66.7%	14	10	5	8
7.221723174	59.1%	66.7%	13	10	5	9
9.085606959	54.5%	66.7%	12	10	5	10
9.917829533	54.5%	73.3%	12	11	4	10
9.97218851	50.0%	73.3%	11	11	4	11
11.13193439	45.5%	73.3%	10	11	4	12
12.52006708	40.9%	73.3%	9	11	4	13
14.11770896	36.4%	73.3%	8	11	4	14
14.2002752	36.4%	80.0%	8	12	3	14
14.48384235	31.8%	80.0%	7	12	3	15
14.97244447	31.8%	86.7%	7	13	2	15
22.61737089	27.3%	86.7%	6	13	2	16
22.63182262	27.3%	93.3%	6	14	1	16
38.86081226	22.7%	93.3%	5	14	1	17
44.85462631	18.2%	93.3%	4	14	1	18
45.65159336	13.6%	93.3%	3	14	1	19
57.40336361	9.1%	93.3%	2	14	1	20
71.56935595	9.1%	100.0%	2	15	0	20
80.11117489	4.5%	100.0%	1	15	0	21
85.83353633	0.0%	100.0%	0	15	0	22

Figure 23B

Test Receiver Operator Characteristic (ROC) curves

M8126_49 by SAMP_GRP


Performed by Benjamin Silverman

Date 14 August 2002

n 37

SAMP_GRP	n
0	15
1	22

Curve	Area	SE	p	95% CI of Area	SAMP_GRP = 1
M8126_49	0.742	0.0842	0.0020	0.577 to 0.907	have higher values



M8126_49 (abnormals above cut-off)	Sensitivity	Specificity	TP	TN	FP	FN
-0.242649757	100.0%	6.7%	22	1	14	0

FIGURE 24 A

Test Receiver Operator Characteristic (ROC) curves

M8126_49 by SAMP_GRP

Performed by Benjamin Silverman

Date

14 August 2002

0.530442832	100.0%	13.3%	22	2	13	0
0.644223404	100.0%	20.0%	22	3	12	0
0.885640373	95.5%	20.0%	21	3	12	1
1.433559793	95.5%	26.7%	21	4	11	1
1.794431151	90.9%	26.7%	20	4	11	2
1.818318183	86.4%	26.7%	19	4	11	3
2.079303745	86.4%	33.3%	19	5	10	3
2.114695472	81.8%	33.3%	18	5	10	4
2.300483675	81.8%	40.0%	18	6	9	4
2.557169627	77.3%	40.0%	17	6	9	5
2.691146289	77.3%	46.7%	17	7	8	5
2.8048776	77.3%	53.3%	17	8	7	5
2.971536888	72.7%	53.3%	16	8	7	6
3.295574013	72.7%	60.0%	16	9	6	6
3.625766821	68.2%	60.0%	15	9	6	7
3.644660813	68.2%	66.7%	15	10	5	7
3.736933608	68.2%	73.3%	15	11	4	7
3.737652044	68.2%	80.0%	15	12	3	7
3.79710601	68.2%	86.7%	15	13	2	7
3.806135483	63.6%	86.7%	14	13	2	8
4.042986903	59.1%	86.7%	13	13	2	9
4.074173818	54.5%	86.7%	12	13	2	10
4.688852396	50.0%	86.7%	11	13	2	11
4.796496576	45.5%	86.7%	10	13	2	12
4.965020089	40.9%	86.7%	9	13	2	13
5.066333812	40.9%	93.3%	9	14	1	13
5.576272551	36.4%	93.3%	8	14	1	14
6.491330575	31.8%	93.3%	7	14	1	15
6.795353009	27.3%	93.3%	6	14	1	16
7.076142913	22.7%	93.3%	5	14	1	17
22.76210615	18.2%	93.3%	4	14	1	18
25.8590526	13.6%	93.3%	3	14	1	19
28.51064176	9.1%	93.3%	2	14	1	20
42.61452812	9.1%	100.0%	2	15	0	20
65.64727304	4.5%	100.0%	1	15	0	21
129.1652158	0.0%	100.0%	0	15	0	22

Figure 24B

Test Receiver Operator Characteristic (ROC) curves

M9032_41 by SAMP_GRP


Performed by Benjamin Silverman

Date 14 August 2002

n 37

SAMP_GRP	n
0	15
1	22

Curve	Area	SE	p	95% CI of Area	SAMP_GRP = 1
M9032_41	0.758	0.0800	0.0008	0.601 to 0.914	have lower values



M9032_41 (abnormals below cut-off)	Sensitivity	Specificity	TP	TN	FP	FN
0.301214127	0.0%	100.0%	0	15	0	22

FIGURE 25/A

Test Receiver Operator Characteristic (ROC) curves

M9032_41 by SAMP_GRP						Date	14 August 2002
Performed by	Benjamin Silverman						
0.803405811	4.5%	100.0%	1	15	0	21	
0.998249125	9.1%	100.0%	2	15	0	20	
1.176635111	13.6%	100.0%	3	15	0	19	
1.292732389	18.2%	100.0%	4	15	0	18	
1.37399724	22.7%	100.0%	5	15	0	17	
1.374238023	27.3%	100.0%	6	15	0	16	
1.469324005	31.8%	100.0%	7	15	0	15	
1.495648575	36.4%	100.0%	8	15	0	14	
1.666667202	40.9%	100.0%	9	15	0	13	
1.712649617	45.5%	100.0%	10	15	0	12	
1.920543547	45.5%	93.3%	10	14	1	12	
2.133352538	50.0%	93.3%	11	14	1	11	
2.28590313	50.0%	86.7%	11	13	2	11	
2.329098269	54.5%	86.7%	12	13	2	10	
2.490115349	59.1%	86.7%	13	13	2	9	
2.562278576	63.6%	86.7%	14	13	2	8	
2.924448973	68.2%	86.7%	15	13	2	7	
3.201543343	68.2%	80.0%	15	12	3	7	
3.24060916	72.7%	80.0%	16	12	3	6	
4.080807466	72.7%	73.3%	16	11	4	6	
4.120817587	72.7%	66.7%	16	10	5	6	
4.392505873	72.7%	60.0%	16	9	6	6	
4.794477164	72.7%	53.3%	16	8	7	6	
4.79606144	72.7%	46.7%	16	7	8	6	
5.425100163	72.7%	40.0%	16	6	9	6	
5.938344901	77.3%	40.0%	17	6	9	5	
6.31378122	81.8%	40.0%	18	6	9	4	
6.591704626	81.8%	33.3%	18	5	10	4	
8.267892434	81.8%	26.7%	18	4	11	4	
8.671042606	86.4%	26.7%	19	4	11	3	
10.61510852	90.9%	26.7%	20	4	11	2	
12.72350271	90.9%	20.0%	20	3	12	2	
13.23403263	90.9%	13.3%	20	2	13	2	
23.24713623	95.5%	13.3%	21	2	13	1	
30.65382604	95.5%	6.7%	21	1	14	1	
90.70489507	95.5%	0.0%	21	0	15	1	

Figure 25B

Test | Receiver Operator Characteristic (ROC) curves

M9134_84 by SAMP_GRP


Performed by | Benjamin Silverman

Date | 14 August 2002

n | 37

SAMP_GRP	n
0	15
1	22

Curve	Area	SE	p	95% CI of Area	SAMP_GRP = 1
M9134_84	0.682	0.0904	0.0221	0.505 to 0.859	have lower values



M9134_84 (abnormals below cut-off)	Sensitivity	Specificity	TP	TN	FP	FN
-0.230457138	0.0%	100.0%	0	15	0	22

FIGURE 26A

Test Receiver Operator Characteristic (ROC) curves

M9134_84 by SAMP_GRP


Performed by	Benjamin Silverman				Date	14 August 2002
0.303716546	4.5%	100.0%	1	15	0	21
0.422909754	4.5%	93.3%	1	14	1	21
0.679789975	9.1%	93.3%	2	14	1	20
1.15660303	13.6%	93.3%	3	14	1	19
1.185904471	18.2%	93.3%	4	14	1	18
1.247739984	22.7%	93.3%	5	14	1	17
1.284010996	27.3%	93.3%	6	14	1	16
1.37596149	31.8%	93.3%	7	14	1	15
1.576186258	31.8%	86.7%	7	13	2	15
1.851196687	36.4%	86.7%	8	13	2	14
1.878772545	40.9%	86.7%	9	13	2	13
1.897908011	40.9%	80.0%	9	12	3	13
2.290261208	45.5%	80.0%	10	12	3	12
2.575036839	50.0%	80.0%	11	12	3	11
2.580613336	50.0%	73.3%	11	11	4	11
2.736807216	54.5%	73.3%	12	11	4	10
2.812866946	59.1%	73.3%	13	11	4	9
2.878357233	63.6%	73.3%	14	11	4	8
3.489262381	63.6%	66.7%	14	10	5	8
3.739002718	68.2%	66.7%	15	10	5	7
4.129794763	68.2%	60.0%	15	9	6	7
4.256950328	72.7%	60.0%	16	9	6	6
4.378021704	72.7%	53.3%	16	8	7	6
4.389813191	72.7%	46.7%	16	7	8	6
4.775583174	77.3%	46.7%	17	7	8	5
6.554049654	77.3%	40.0%	17	6	9	5
6.738969207	81.8%	40.0%	18	6	9	4
7.172153745	81.8%	33.3%	18	5	10	4
7.571982855	86.4%	33.3%	19	5	10	3
8.817682331	86.4%	26.7%	19	4	11	3
14.6752361	86.4%	20.0%	19	3	12	3
15.48975496	90.9%	20.0%	20	3	12	2
15.79923578	95.5%	20.0%	21	3	12	1
17.61892743	95.5%	13.3%	21	2	13	1
30.84421482	95.5%	6.7%	21	1	14	1
89.35626416	95.5%	0.0%	21	0	15	1

Figure 26P

Test | Receiver Operator Characteristic (ROC) curves
M9259_73 by SAMP_GRP
Performed by | Benjamin Silverman
Date | 16 August 2002
n | 37

SAMP_GRP	n
0	15
1	22

Curve	Area	SE	p	95% CI of Area	SAMP_GRP = 1
M9259_73	0.615	0.0949	0.1124	0.429 to 0.801	have lower values



M9259_73 (abnormals below cut-off)	Sensitivity	Specificity	TP	TN	FP	FN
-0.313072149	0.0%	100.0%	0	15	0	22

FIGURE 27A

Test Receiver Operator Characteristic (ROC) curves

M9259_73 by SAMP_GRP

Performed by Benjamin Silverman

Date

16 August 2002

-0.090034929	0.0%	93.3%	0	14	1	22
-0.087657336	4.5%	93.3%	1	14	1	21
0.025059587	9.1%	93.3%	2	14	1	20
0.0890659	13.6%	93.3%	3	14	1	19
0.137712694	18.2%	93.3%	4	14	1	18
0.39484115	22.7%	93.3%	5	14	1	17
0.441429925	27.3%	93.3%	6	14	1	16
0.443883635	31.8%	93.3%	7	14	1	15
0.537223872	31.8%	86.7%	7	13	2	15
0.573660892	36.4%	86.7%	8	13	2	14
0.587299677	40.9%	86.7%	9	13	2	13
1.141788822	40.9%	80.0%	9	12	3	13
1.288678045	45.5%	80.0%	10	12	3	12
1.497411002	50.0%	80.0%	11	12	3	11
1.504448557	54.5%	80.0%	12	12	3	10
1.553203734	54.5%	73.3%	12	11	4	10
1.697719129	54.5%	66.7%	12	10	5	10
1.740725515	59.1%	66.7%	13	10	5	9
1.789909879	59.1%	60.0%	13	9	6	9
1.800103417	63.6%	60.0%	14	9	6	8
1.890731101	63.6%	53.3%	14	8	7	8
2.089011337	68.2%	53.3%	15	8	7	7
2.450853521	68.2%	46.7%	15	7	8	7
3.183220714	68.2%	40.0%	15	6	9	7
3.601972595	68.2%	33.3%	15	5	10	7
4.117866168	68.2%	26.7%	15	4	11	7
4.834268435	72.7%	26.7%	16	4	11	6
5.638919739	72.7%	20.0%	16	3	12	6
6.10658428	77.3%	20.0%	17	3	12	5
6.841923307	81.8%	20.0%	18	3	12	4
8.231907094	86.4%	20.0%	19	3	12	3
10.42225494	90.9%	20.0%	20	3	12	2
15.5536609	90.9%	13.3%	20	2	13	2
16.22326061	90.9%	6.7%	20	1	14	2
53.13230616	90.9%	0.0%	20	0	15	2
69.60587743	95.5%	0.0%	21	0	15	1

Figure 27B

Test Receiver Operator Characteristic (ROC) curves

M9612_27 by SAMP_GRP

Performed by Benjamin Silverman

Date

14 August 2002

0.758601683	4.5%	100.0%	1	15	0	21
1.180865799	9.1%	100.0%	2	15	0	20
1.274578224	13.6%	100.0%	3	15	0	19
1.483956338	18.2%	100.0%	4	15	0	18
1.493244123	22.7%	100.0%	5	15	0	17
1.555852667	27.3%	100.0%	6	15	0	16
2.105803209	31.8%	100.0%	7	15	0	15
2.369291433	36.4%	100.0%	8	15	0	14
2.40902558	40.9%	100.0%	9	15	0	13
2.861582232	45.5%	100.0%	10	15	0	12
3.208838829	50.0%	100.0%	11	15	0	11
4.314256863	54.5%	100.0%	12	15	0	10
5.123782783	54.5%	93.3%	12	14	1	10
5.206522974	54.5%	86.7%	12	13	2	10
5.392504287	59.1%	86.7%	13	13	2	9
5.627164435	59.1%	80.0%	13	12	3	9
7.347091898	63.6%	80.0%	14	12	3	8
7.614016057	68.2%	80.0%	15	12	3	7
7.780212345	68.2%	73.3%	15	11	4	7
8.066501227	68.2%	66.7%	15	10	5	7
8.189857251	68.2%	60.0%	15	9	6	7
8.879133228	68.2%	53.3%	15	8	7	7
9.452288319	72.7%	53.3%	16	8	7	6
10.02350022	72.7%	46.7%	16	7	8	6
11.09534531	77.3%	46.7%	17	7	8	5
13.60423119	81.8%	46.7%	18	7	8	4
13.97510631	81.8%	40.0%	18	6	9	4
14.24114764	81.8%	33.3%	18	5	10	4
14.30357042	81.8%	26.7%	18	4	11	4
14.66718773	86.4%	26.7%	19	4	11	3
16.79245222	86.4%	20.0%	19	3	12	3
17.49682083	90.9%	20.0%	20	3	12	2
32.76755785	95.5%	20.0%	21	3	12	1
35.34829908	95.5%	13.3%	21	2	13	1
49.72699286	95.5%	6.7%	21	1	14	1
74.09042786	100.0%	6.7%	22	1	14	0

Figure 28B

Test Receiver Operator Characteristic (ROC) curves

M9746_54 by SAMP_GRP


Performed by Benjamin Silverman

Date 14 August 2002

n 37

SAMP_GRP	n
0	15
1	22

Curve	Area	SE	p	95% CI of Area	SAMP_GRP = 1
M9746_54	0.809	0.0718	<0.0001	0.668 to 0.950	have lower values



M9746_54 (abnormals below cut-off)	Sensitivity	Specificity	TP	TN	FP	FN
0.27462008	0.0%	100.0%	0	15	0	22

FIGURE 29A

Test Receiver Operator Characteristic (ROC) curves

M9746_54 by SAMP_GRP

Performed by Benjamin Silverman

Date

14 August 2002

0.944941397	4.5%	100.0%	1	15	0	21
1.429602659	9.1%	100.0%	2	15	0	20
1.860367717	13.6%	100.0%	3	15	0	19
2.156058253	18.2%	100.0%	4	15	0	18
2.163995771	22.7%	100.0%	5	15	0	17
2.230258934	27.3%	100.0%	6	15	0	16
2.244471438	31.8%	100.0%	7	15	0	15
3.928575765	36.4%	100.0%	8	15	0	14
4.89314159	40.9%	100.0%	9	15	0	13
5.001978398	40.9%	93.3%	9	14	1	13
5.395387778	45.5%	93.3%	10	14	1	12
5.591140256	50.0%	93.3%	11	14	1	11
5.705310247	54.5%	93.3%	12	14	1	10
6.346787733	59.1%	93.3%	13	14	1	9
6.900258793	63.6%	93.3%	14	14	1	8
9.925793863	68.2%	93.3%	15	14	1	7
10.99991811	72.7%	93.3%	16	14	1	6
12.12215213	72.7%	86.7%	16	13	2	6
12.15934553	72.7%	80.0%	16	12	3	6
12.53847818	72.7%	73.3%	16	11	4	6
12.7064395	72.7%	66.7%	16	10	5	6
13.41035628	77.3%	66.7%	17	10	5	5
13.44152165	77.3%	60.0%	17	9	6	5
13.65324412	77.3%	53.3%	17	8	7	5
14.17991663	77.3%	46.7%	17	7	8	5
15.57075291	81.8%	46.7%	18	7	8	4
18.04349193	81.8%	40.0%	18	6	9	4
22.3977826	86.4%	40.0%	19	6	9	3
23.32377482	90.9%	40.0%	20	6	9	2
24.62590135	90.9%	33.3%	20	5	10	2
24.70430526	90.9%	26.7%	20	4	11	2
27.58682672	90.9%	20.0%	20	3	12	2
31.43474846	95.5%	20.0%	21	3	12	1
33.81750113	95.5%	13.3%	21	2	13	1
40.01851039	100.0%	13.3%	22	2	13	0
54.47066069	100.0%	6.7%	22	1	14	0

Figure 29B

Test Receiver Operator Characteristic (ROC) curves

M9782_13 by SAMP_GRP


Performed by Benjamin Silverman

Date 14 August 2002

n | 37

SAMP_GRP	n
0	15
1	22

Curve	Area	SE	p	95% CI of Area	SAMP_GRP = 1
M9782_13	0.812	0.0699	<0.0001	0.675 to 0.949	have lower values



M9782_13 (abnormals below cut-off)	Sensitivity	Specificity	TP	TN	FP	FN
0.187949677	0.0%	100.0%	0	15	0	22

FIGURE 30A

Test Receiver Operator Characteristic (ROC) curves

M9782_13 by SAMP_GRP

Performed by Benjamin Silverman

Date

14 August 2002

0.311940904	4.5%	100.0%	1	15	0	21
0.320787249	9.1%	100.0%	2	15	0	20
0.588458192	13.6%	100.0%	3	15	0	19
0.827319355	18.2%	100.0%	4	15	0	18
0.964527145	22.7%	100.0%	5	15	0	17
1.303108694	27.3%	100.0%	6	15	0	16
1.440991138	31.8%	100.0%	7	15	0	15
1.911425052	36.4%	100.0%	8	15	0	14
1.977973759	40.9%	100.0%	9	15	0	13
2.704541978	45.5%	100.0%	10	15	0	12
3.18696848	50.0%	100.0%	11	15	0	11
3.264391167	54.5%	100.0%	12	15	0	10
3.649763174	59.1%	100.0%	13	15	0	9
4.050829847	59.1%	93.3%	13	14	1	9
4.367868931	59.1%	86.7%	13	13	2	9
5.033974153	63.6%	86.7%	14	13	2	8
5.632684713	68.2%	86.7%	15	13	2	7
5.735939585	68.2%	80.0%	15	12	3	7
6.576947242	72.7%	80.0%	16	12	3	6
6.700781868	72.7%	73.3%	16	11	4	6
6.825206697	72.7%	66.7%	16	10	5	6
8.182420851	72.7%	60.0%	16	9	6	6
8.312179556	72.7%	53.3%	16	8	7	6
8.461231786	77.3%	53.3%	17	8	7	5
8.604240794	81.8%	53.3%	18	8	7	4
10.6034531	81.8%	46.7%	18	7	8	4
11.69847523	86.4%	46.7%	19	7	8	3
12.95334106	86.4%	40.0%	19	6	9	3
14.37960511	90.9%	40.0%	20	6	9	2
14.55501121	90.9%	33.3%	20	5	10	2
22.8775234	95.5%	33.3%	21	5	10	1
24.59587908	95.5%	26.7%	21	4	11	1
32.89066637	95.5%	20.0%	21	3	12	1
44.04188758	95.5%	13.3%	21	2	13	1
47.67700209	95.5%	6.7%	21	1	14	1
65.79597195	100.0%	6.7%	22	1	14	0

Figure 30B

Test Receiver Operator Characteristic (ROC) curves

M9986_39 by SAMP_GRP


Performed by Benjamin Silverman

Date 14 August 2002

n 37

SAMP_GRP	n
0	15
1	22

Curve	Area	SE	p	95% CI of Area	SAMP_GRP = 1
M9986_39	0.776	0.0767	0.0002	0.625 to 0.926	have lower values



M9986_39 (abnormals below cut-off)	Sensitivity	Specificity	TP	TN	FP	FN
-0.295256429	0.0%	100.0%	0	15	0	22

FIGURE 31A

Test Receiver Operator Characteristic (ROC) curves

M9986_39 by SAMP_GRP			Date		14 August 2002	
Performed by	Benjamin Silverman					
1.008835146	4.5%	100.0%	1	15	0	21
1.165659121	9.1%	100.0%	2	15	0	20
1.256851909	13.6%	100.0%	3	15	0	19
2.241283084	18.2%	100.0%	4	15	0	18
2.28786077	22.7%	100.0%	5	15	0	17
2.567899944	27.3%	100.0%	6	15	0	16
2.915542456	31.8%	100.0%	7	15	0	15
2.946087861	36.4%	100.0%	8	15	0	14
3.515636808	40.9%	100.0%	9	15	0	13
3.61887364	45.5%	100.0%	10	15	0	12
4.081298473	50.0%	100.0%	11	15	0	11
4.589735775	54.5%	100.0%	12	15	0	10
5.266312315	59.1%	100.0%	13	15	0	9
7.217859829	59.1%	93.3%	13	14	1	9
8.318176705	63.6%	93.3%	14	14	1	8
8.878907369	63.6%	86.7%	14	13	2	8
9.456901691	63.6%	80.0%	14	12	3	8
10.28999424	63.6%	73.3%	14	11	4	8
14.37846263	63.6%	66.7%	14	10	5	8
16.99313275	63.6%	60.0%	14	9	6	8
18.82439633	68.2%	60.0%	15	9	6	7
19.58359542	68.2%	53.3%	15	8	7	7
20.13834584	72.7%	53.3%	16	8	7	6
22.48639367	77.3%	53.3%	17	8	7	5
23.08411608	77.3%	46.7%	17	7	8	5
25.85315832	81.8%	46.7%	18	7	8	4
29.21510714	86.4%	46.7%	19	7	8	3
30.74984161	86.4%	40.0%	19	6	9	3
32.56932974	86.4%	33.3%	19	5	10	3
37.00175626	90.9%	33.3%	20	5	10	2
40.65070508	90.9%	26.7%	20	4	11	2
46.36510251	90.9%	20.0%	20	3	12	2
59.92837427	95.5%	20.0%	21	3	12	1
60.68808134	95.5%	13.3%	21	2	13	1
97.93584835	95.5%	6.7%	21	1	14	1
104.5984281	95.5%	0.0%	21	0	15	1

Figure 31B

Test Receiver Operator Characteristic (ROC) curves

M10823_4 by SAMP_GRP

Performed by Benjamin Silverman

Date 14 August 2002


Performed by	Benjamin Silverman	Date	14 August 2002
0.671006585	100.0%	13.3%	22
0.673951205	100.0%	20.0%	22
0.85034147	100.0%	26.7%	22
1.091235144	95.5%	26.7%	21
1.499560539	95.5%	33.3%	21
1.6038729	90.9%	33.3%	20
1.689901778	86.4%	33.3%	19
1.873136627	81.8%	33.3%	18
1.873452486	81.8%	40.0%	18
1.911010945	81.8%	46.7%	18
2.024488057	81.8%	53.3%	18
2.566194201	81.8%	60.0%	18
2.828797509	81.8%	66.7%	18
2.900653046	77.3%	66.7%	17
2.924282124	72.7%	66.7%	16
3.48601262	72.7%	73.3%	16
3.508487988	68.2%	73.3%	15
4.080371763	68.2%	80.0%	15
4.336801503	63.6%	80.0%	14
4.685772237	59.1%	80.0%	13
5.846072901	54.5%	80.0%	12
5.927676181	50.0%	80.0%	11
6.051455083	50.0%	86.7%	11
6.178395098	45.5%	86.7%	10
6.452067205	40.9%	86.7%	9
6.802498183	36.4%	86.7%	8
8.451155445	31.8%	86.7%	7
8.46425216	27.3%	86.7%	6
11.36753199	22.7%	86.7%	5
15.67369003	22.7%	93.3%	5
19.34606204	18.2%	93.3%	4
20.10344319	13.6%	93.3%	3
20.51485771	9.1%	93.3%	2
32.081559	4.5%	93.3%	1
44.91333527	0.0%	93.3%	0
54.23581573	0.0%	100.0%	0

Figure 32B

Test | Receiver Operator Characteristic (ROC) curves
M10860_5 by SAMP_GRP
Performed by | Benjamin Silverman
Date | 14 August 2002
n | 37

SAMP_GRP	n
0	15
1	22

Curve	Area	SE	p	95% CI of Area	SAMP_GRP = 1
M10860_5	0.691	0.0920	0.0190	0.511 to 0.871	have higher values



M10860_5 (abnormals above cut-off)	Sensitivity	Specificity	TP	TN	FP	FN
0.625449592	95.5%	0.0%	21	0	15	1

FIGURE 33 *A*

Test Receiver Operator Characteristic (ROC) curves

M10860_5 by SAMP_GRP

Performed by Benjamin Silverman

Date

14 August 2002

0.649659093	95.5%	6.7%	21	1	14	1
0.75660742	95.5%	13.3%	21	2	13	1
0.827850575	90.9%	13.3%	20	2	13	2
0.874557025	86.4%	13.3%	19	2	13	3
0.942458079	86.4%	20.0%	19	3	12	3
1.299508596	81.8%	20.0%	18	3	12	4
1.477528139	81.8%	26.7%	18	4	11	4
1.741733474	77.3%	26.7%	17	4	11	5
2.442650232	77.3%	33.3%	17	5	10	5
2.49969861	77.3%	40.0%	17	6	9	5
2.854472279	72.7%	40.0%	16	6	9	6
3.637781801	72.7%	46.7%	16	7	8	6
4.026034745	72.7%	53.3%	16	8	7	6
4.373739534	72.7%	60.0%	16	9	6	6
4.412232967	72.7%	66.7%	16	10	5	6
5.243094923	72.7%	73.3%	16	11	4	6
5.879200077	68.2%	73.3%	15	11	4	7
7.832574741	68.2%	80.0%	15	12	3	7
7.983245257	63.6%	80.0%	14	12	3	8
8.502650675	59.1%	80.0%	13	12	3	9
9.277844369	59.1%	86.7%	13	13	2	9
9.98032986	54.5%	86.7%	12	13	2	10
10.446093	50.0%	86.7%	11	13	2	11
11.40028173	45.5%	86.7%	10	13	2	12
11.96785354	40.9%	86.7%	9	13	2	13
13.7323821	36.4%	86.7%	8	13	2	14
13.92963359	31.8%	86.7%	7	13	2	15
18.38409613	31.8%	93.3%	7	14	1	15
21.12109901	27.3%	93.3%	6	14	1	16
23.08340021	22.7%	93.3%	5	14	1	17
25.98323228	18.2%	93.3%	4	14	1	18
28.89121952	13.6%	93.3%	3	14	1	19
55.22611991	9.1%	93.3%	2	14	1	20
131.6364922	4.5%	93.3%	1	14	1	21
194.5375406	0.0%	93.3%	0	14	1	22
251.7598007	0.0%	100.0%	0	15	0	22

Figure 33E

Test Receiver Operator Characteristic (ROC) curves

M11298_6 by SAMP_GRP


Performed by Benjamin Silverman

Date 14 August 2002

n 37

SAMP_GRP	n
0	15
1	22

Curve	Area	SE	p	95% CI of Area	SAMP_GRP = 1
M11298_6	0.630	0.1058	0.1091	0.423 to 0.838	have higher values



M11298_6 (abnormals above cut-off)	Sensitivity	Specificity	TP	TN	FP	FN
0.069735482	100.0%	6.7%	22	1	14	0

FIGURE 34 A

Test	Receiver Operator Characteristic (ROC) curves					
	M11298_8 by SAMP_GRP					
Performed by	Benjamin Silverman				Date	14 August 2002
0.149582527	100.0%	13.3%	22	2	13	0
0.223497018	100.0%	20.0%	22	3	12	0
0.288031269	100.0%	26.7%	22	4	11	0
0.392039963	95.5%	26.7%	21	4	11	1
0.482206326	95.5%	33.3%	21	5	10	1
0.493313078	95.5%	40.0%	21	6	9	1
0.567621858	90.9%	40.0%	20	6	9	2
0.581373026	90.9%	46.7%	20	7	8	2
0.68372028	86.4%	46.7%	19	7	8	3
0.705154358	81.8%	46.7%	18	7	8	4
1.022125197	81.8%	53.3%	18	8	7	4
1.396624672	77.3%	53.3%	17	8	7	5
1.626040888	72.7%	53.3%	16	8	7	6
1.75309758	68.2%	53.3%	15	8	7	7
1.78154363	63.6%	53.3%	14	8	7	8
1.907771234	59.1%	53.3%	13	8	7	9
1.971133683	54.5%	53.3%	12	8	7	10
2.262083652	54.5%	60.0%	12	9	6	10
2.529965406	54.5%	66.7%	12	10	5	10
2.604054361	50.0%	66.7%	11	10	5	11
3.647733064	50.0%	73.3%	11	11	4	11
4.380208717	45.5%	73.3%	10	11	4	12
6.698383023	40.9%	73.3%	9	11	4	13
6.760494031	36.4%	73.3%	8	11	4	14
7.443587208	31.8%	73.3%	7	11	4	15
8.262329904	27.3%	73.3%	6	11	4	16
9.003081752	22.7%	73.3%	5	11	4	17
11.5832935	18.2%	73.3%	4	11	4	18
11.61282227	18.2%	80.0%	4	12	3	18
18.74142022	13.6%	80.0%	3	12	3	19
19.38284104	9.1%	80.0%	2	12	3	20
24.23295792	4.5%	80.0%	1	12	3	21
26.16048385	4.5%	86.7%	1	13	2	21
26.36644348	0.0%	86.7%	0	13	2	22
32.88581786	0.0%	93.3%	0	14	1	22
39.19350134	0.0%	100.0%	0	15	0	22

Figure 34E

Test Receiver Operator Characteristic (ROC) curves

M13386_4 by SAMP_GRP


Performed by Benjamin Silverman

Date 14 August 2002

n 37

SAMP_GRP	n
0	15
1	22

Curve	Area	SE	p	95% CI of Area	SAMP_GRP = 1
M13386_4	0.782	0.0758	<0.0001	0.634 to 0.930	have higher values



M13386_4 (abnormals above cut-off)	Sensitivity	Specificity	TP	TN	FP	FN
0.09381789	100.0%	6.7%	22	1	14	0

FIGURE 35A

Test	Receiver Operator Characteristic (ROC) curves						
	M13388_4 by SAMP_GRP						
Performed by	Benjamin Silverman					Date	14 August 2002
0.124670465	100.0%	13.3%	22	2	13	0	
0.343871165	100.0%	20.0%	22	3	12	0	
0.411768114	100.0%	26.7%	22	4	11	0	
0.447501692	100.0%	33.3%	22	5	10	0	
0.501984192	95.5%	33.3%	21	5	10	1	
0.506229615	95.5%	40.0%	21	6	9	1	
0.670561066	90.9%	40.0%	20	6	9	2	
0.716216281	90.9%	46.7%	20	7	8	2	
0.795109612	90.9%	53.3%	20	8	7	2	
0.97373317	86.4%	53.3%	19	8	7	3	
1.287597984	81.8%	53.3%	18	8	7	4	
1.321319393	77.3%	53.3%	17	8	7	5	
1.327346283	77.3%	60.0%	17	9	6	5	
1.342282679	72.7%	60.0%	16	9	6	6	
1.438354391	68.2%	60.0%	15	9	6	7	
1.921057278	63.6%	60.0%	14	9	6	8	
2.235552923	63.6%	66.7%	14	10	5	8	
2.377677685	63.6%	73.3%	14	11	4	8	
2.448569037	59.1%	73.3%	13	11	4	9	
2.521570151	54.5%	73.3%	12	11	4	10	
2.534695052	54.5%	80.0%	12	12	3	10	
2.557062659	54.5%	86.7%	12	13	2	10	
2.563776641	50.0%	86.7%	11	13	2	11	
2.76281867	45.5%	86.7%	10	13	2	12	
2.822205414	45.5%	93.3%	10	14	1	12	
2.942739621	40.9%	93.3%	9	14	1	13	
3.176759363	36.4%	93.3%	8	14	1	14	
3.56705507	36.4%	100.0%	8	15	0	14	
3.697507784	31.8%	100.0%	7	15	0	15	
4.162756708	27.3%	100.0%	6	15	0	16	
7.154094102	22.7%	100.0%	5	15	0	17	
7.264484986	18.2%	100.0%	4	15	0	18	
10.74768511	13.6%	100.0%	3	15	0	19	
12.02456743	9.1%	100.0%	2	15	0	20	
24.85498921	4.5%	100.0%	1	15	0	21	
35.76220463	0.0%	100.0%	0	15	0	22	

Figure 35

Test Receiver Operator Characteristic (ROC) curves

M13893_9 by SAMP_GRP


Performed by Benjamin Silverman

Date 14 August 2002

n 37

SAMP_GRP	n
0	15
1	22

Curve	Area	SE	p	95% CI of Area	SAMP_GRP = 1
M13893_9	0.615	0.1028	0.1313	0.414 to 0.817	have higher values



M13893_9 (abnormals above cut-off)	Sensitivity	Specificity	TP	TN	FP	FN
0.628842989	100.0%	6.7%	22	1	14	0

FIGURE 36 A

Test Receiver Operator Characteristic (ROC) curves

M13893_9 by SAMP_GRP

Performed by Benjamin Silverman

Date

14 August 2002

0.743225364	100.0%	13.3%	22	2	13	0
1.030426576	100.0%	20.0%	22	3	12	0
1.380127971	95.5%	20.0%	21	3	12	1
1.426474539	95.5%	26.7%	21	4	11	1
2.152972601	95.5%	33.3%	21	5	10	1
2.608056213	90.9%	33.3%	20	5	10	2
2.630865033	90.9%	40.0%	20	6	9	2
2.659269738	86.4%	40.0%	19	6	9	3
3.259037701	86.4%	46.7%	19	7	8	3
3.270230475	81.8%	46.7%	18	7	8	4
3.291970055	81.8%	53.3%	18	8	7	4
3.900053221	77.3%	53.3%	17	8	7	5
4.191044639	72.7%	53.3%	16	8	7	6
6.145344315	68.2%	53.3%	15	8	7	7
6.644038085	63.6%	53.3%	14	8	7	8
8.02492889	59.1%	53.3%	13	8	7	9
8.320312383	54.5%	53.3%	12	8	7	10
8.499048941	50.0%	53.3%	11	8	7	11
8.831927477	45.5%	53.3%	10	8	7	12
9.856140439	45.5%	60.0%	10	9	6	12
10.62746905	40.9%	60.0%	9	9	6	13
10.82610414	36.4%	60.0%	8	9	6	14
12.54454288	31.8%	60.0%	7	9	6	15
13.90470058	31.8%	66.7%	7	10	5	15
14.27519579	27.3%	66.7%	6	10	5	16
14.81217871	27.3%	73.3%	6	11	4	16
15.05367835	27.3%	80.0%	6	12	3	16
15.93348534	22.7%	80.0%	5	12	3	17
17.30998863	22.7%	86.7%	5	13	2	17
21.0557198	18.2%	86.7%	4	13	2	18
21.90739293	13.6%	86.7%	3	13	2	19
22.91996482	13.6%	93.3%	3	14	1	19
27.95243119	9.1%	93.3%	2	14	1	20
29.69045585	4.5%	93.3%	1	14	1	21
36.34488613	4.5%	100.0%	1	15	0	21
127.7527799	0.0%	100.0%	0	15	0	22

Figure 36B

Test Receiver Operator Characteristic (ROC) curves

M14664_5 by SAMP_GRP


Performed by Benjamin Silverman

Date 14 August 2002

n 37

SAMP_GRP	n
0	15
1	22

Curve	Area	SE	p	95% CI of Area	SAMP_GRP = 1
M14664_5	0.612	0.0959	0.1211	0.424 to 0.800	have higher values



M14664_5 (abnormals above cut-off)	Sensitivity	Specificity	TP	TN	FP	FN
0.061220273	100.0%	6.7%	22	1	14	0

FIGURE 37A

Test Receiver Operator Characteristic (ROC) curves

M14684_5 by SAMP_GRP

Performed by	Benjamin Silverman				Date	14 August 2002
0.141560818	95.5%	6.7%	21	1	14	1
0.420364231	90.9%	6.7%	20	1	14	2
0.460694086	86.4%	6.7%	19	1	14	3
0.651725392	81.8%	6.7%	18	1	14	4
0.669942947	81.8%	13.3%	18	2	13	4
0.676613432	81.8%	20.0%	18	3	12	4
0.716768642	77.3%	20.0%	17	3	12	5
0.831765072	77.3%	26.7%	17	4	11	5
0.86823056	77.3%	33.3%	17	5	10	5
0.8845323	77.3%	40.0%	17	6	9	5
1.170116981	77.3%	46.7%	17	7	8	5
1.213470147	77.3%	53.3%	17	8	7	5
1.220792267	72.7%	53.3%	16	8	7	6
1.237617785	72.7%	60.0%	16	9	6	6
1.348864013	68.2%	60.0%	15	9	6	7
1.48726478	63.6%	60.0%	14	9	6	8
1.531760922	59.1%	60.0%	13	9	6	9
1.586845037	59.1%	66.7%	13	10	5	9
1.666566621	54.5%	66.7%	12	10	5	10
1.724981193	50.0%	66.7%	11	10	5	11
3.302147733	45.5%	66.7%	10	10	5	12
3.486304719	45.5%	73.3%	10	11	4	12
3.551218748	40.9%	73.3%	9	11	4	13
3.916000499	36.4%	73.3%	8	11	4	14
4.994468705	36.4%	80.0%	8	12	3	14
7.660385297	31.8%	80.0%	7	12	3	15
8.303404038	27.3%	80.0%	6	12	3	16
8.332740901	27.3%	86.7%	6	13	2	16
10.53190359	22.7%	86.7%	5	13	2	17
11.0878473	18.2%	86.7%	4	13	2	18
14.9303935	18.2%	93.3%	4	14	1	18
20.5759742	13.6%	93.3%	3	14	1	19
21.51370471	9.1%	93.3%	2	14	1	20
30.15332726	9.1%	100.0%	2	15	0	20
56.92785582	4.5%	100.0%	1	15	0	21
166.0183046	0.0%	100.0%	0	15	0	22

Figure 310

Test Receiver Operator Characteristic (ROC) curves

M14786_8 by SAMP_GRP

Performed by	Benjamin Silverman				Date	14 August 2002
0.023475635	100.0%	13.3%	22	2	13	0
0.179128407	100.0%	20.0%	22	3	12	0
0.267044214	100.0%	26.7%	22	4	11	0
0.439943972	100.0%	33.3%	22	5	10	0
0.747059995	95.5%	33.3%	21	5	10	1
0.803327362	95.5%	40.0%	21	6	9	1
0.944758506	95.5%	46.7%	21	7	8	1
1.088580369	90.9%	46.7%	20	7	8	2
1.16040567	90.9%	53.3%	20	8	7	2
1.232976867	86.4%	53.3%	19	8	7	3
1.328282419	81.8%	53.3%	18	8	7	4
1.737456748	81.8%	60.0%	18	9	6	4
1.862991377	77.3%	60.0%	17	9	6	5
2.618800454	72.7%	60.0%	16	9	6	6
3.190489507	72.7%	66.7%	16	10	5	6
3.593950342	68.2%	66.7%	15	10	5	7
3.992662117	63.6%	66.7%	14	10	5	8
4.292351631	63.6%	73.3%	14	11	4	8
5.173824392	59.1%	73.3%	13	11	4	9
5.435998972	54.5%	73.3%	12	11	4	10
6.130557824	50.0%	73.3%	11	11	4	11
6.430648786	45.5%	73.3%	10	11	4	12
6.804374645	40.9%	73.3%	9	11	4	13
6.894913459	36.4%	73.3%	8	11	4	14
7.090966562	31.8%	73.3%	7	11	4	15
7.664042534	31.8%	80.0%	7	12	3	15
7.846086851	31.8%	86.7%	7	13	2	15
9.148478696	27.3%	86.7%	6	13	2	16
11.37402216	22.7%	86.7%	5	13	2	17
12.34702758	22.7%	93.3%	5	14	1	17
17.16718737	18.2%	93.3%	4	14	1	18
20.98234151	13.6%	93.3%	3	14	1	19
32.06067547	13.6%	100.0%	3	15	0	19
35.35146295	9.1%	100.0%	2	15	0	20
42.47069795	4.5%	100.0%	1	15	0	21
281.2400752	0.0%	100.0%	0	15	0	22

Figure 38e

Test Receiver Operator Characteristic (ROC) curves

M15111_4 by SAMP_GRP


Performed by Benjamin Silverman

Date 14 August 2002

n 37

SAMP_GRP	n
0	15
1	22

Curve	Area	SE	p	95% CI of Area	SAMP_GRP = 1
M15111_4	0.603	0.1038	0.1604	0.400 to 0.806	have higher values



M15111_4 (abnormals above cut-off)	Sensitivity	Specificity	TP	TN	FP	FN
-0.129346634	100.0%	6.7%	22	1	14	0

FIGURE 39A

Test Receiver Operator Characteristic (ROC) curves

M15111_4 by SAMP_GRP

Performed by Benjamin Silverman

Date

14 August 2002

-0.082272482	100.0%	13.3%	22	2	13	0
-0.051647397	100.0%	20.0%	22	3	12	0
0.083955483	100.0%	26.7%	22	4	11	0
0.103130253	95.5%	26.7%	21	4	11	1
0.156015035	95.5%	33.3%	21	5	10	1
0.24131824	90.9%	33.3%	20	5	10	2
0.30192565	86.4%	33.3%	19	5	10	3
0.357009516	86.4%	40.0%	19	6	9	3
0.418122078	81.8%	40.0%	18	6	9	4
0.501114979	81.8%	46.7%	18	7	8	4
0.506992262	77.3%	46.7%	17	7	8	5
0.591501	72.7%	46.7%	16	7	8	6
0.625650143	68.2%	46.7%	15	7	8	7
0.626384321	63.6%	46.7%	14	7	8	8
0.632164126	63.6%	53.3%	14	8	7	8
0.63531719	63.6%	60.0%	14	9	6	8
0.645259109	59.1%	60.0%	13	9	6	9
0.678909306	54.5%	60.0%	12	9	6	10
0.840789629	50.0%	60.0%	11	9	6	11
0.864326107	45.5%	60.0%	10	9	6	12
0.961140158	40.9%	60.0%	9	9	6	13
1.035335892	40.9%	66.7%	9	10	5	13
1.36632823	36.4%	66.7%	8	10	5	14
1.380299287	31.8%	66.7%	7	10	5	15
1.803915729	27.3%	66.7%	6	10	5	16
1.918985561	27.3%	73.3%	6	11	4	16
1.959011122	22.7%	73.3%	5	11	4	17
2.266327269	22.7%	80.0%	5	12	3	17
2.75618663	22.7%	86.7%	5	13	2	17
3.050300348	18.2%	86.7%	4	13	2	18
4.376056415	13.6%	86.7%	3	13	2	19
4.817121905	9.1%	86.7%	2	13	2	20
7.363790965	4.5%	86.7%	1	13	2	21
9.744086366	0.0%	86.7%	0	13	2	22
39.88240945	0.0%	93.3%	0	14	1	22
161.5535104	0.0%	100.0%	0	15	0	22


Figure 39B

Test	Receiver Operator Characteristic (ROC) curves		
	M15236_2 by SAMP_GRP		
Performed by	Benjamin Silverman	Date	16 August 2002

n | 37

SAMP_GRP	n
0	15
1	22

Curve	Area	SE	p	95% CI of Area	SAMP_GRP = 1
M15236_2	0.685	0.0954	0.0263	0.498 to 0.872	have higher values



M15236_2 (abnormals above cut-off)	Sensitivity	Specificity	TP	TN	FP	FN
0.177481002	100.0%	6.7%	22	1	14	0

FIGURE 40A

Test Receiver Operator Characteristic (ROC) curves

M16116_7 by SAMP_GRP


Performed by Benjamin Silverman

Date 16 August 2002

n 37

SAMP_GRP	n
0	15
1	22

Curve	Area	SE	p	95% CI of Area	SAMP_GRP = 1
M16116_7	0.615	0.1011	0.1273	0.417 to 0.813	have higher values



M16116_7 (abnormals above cut-off)	Sensitivity	Specificity	TP	TN	FP	FN
-0.110846445	100.0%	6.7%	22	1	14	0

FIGURE 41A

Test Receiver Operator Characteristic (ROC) curves

M16116_7 by SAMP_GRP

Performed by Benjamin Silverman

Date

16 August 2002

-0.080009221	95.5%	6.7%	21	1	14	1
0.13243982	90.9%	6.7%	20	1	14	2
0.132569031	90.9%	13.3%	20	2	13	2
0.132897016	90.9%	20.0%	20	3	12	2
0.141616725	90.9%	26.7%	20	4	11	2
0.191151907	90.9%	33.3%	20	5	10	2
0.242371361	90.9%	40.0%	20	6	9	2
0.292459979	86.4%	40.0%	19	6	9	3
0.373858157	86.4%	46.7%	19	7	8	3
0.401639082	86.4%	53.3%	19	8	7	3
0.461780418	81.8%	53.3%	18	8	7	4
0.472465163	77.3%	53.3%	17	8	7	5
0.499106112	72.7%	53.3%	16	8	7	6
0.504270861	68.2%	53.3%	15	8	7	7
0.62504857	63.6%	53.3%	14	8	7	8
0.720128095	59.1%	53.3%	13	8	7	9
0.724831498	54.5%	53.3%	12	8	7	10
0.899794601	54.5%	60.0%	12	9	6	10
0.931865595	50.0%	60.0%	11	9	6	11
0.9363429	45.5%	60.0%	10	9	6	12
0.995489407	40.9%	60.0%	9	9	6	13
1.135442279	40.9%	66.7%	9	10	5	13
1.18410198	40.9%	73.3%	9	11	4	13
1.280101252	36.4%	73.3%	8	11	4	14
1.510623299	31.8%	73.3%	7	11	4	15
1.519705578	27.3%	73.3%	6	11	4	16
1.739130465	22.7%	73.3%	5	11	4	17
1.739313948	22.7%	80.0%	5	12	3	17
1.77708523	22.7%	86.7%	5	13	2	17
2.036891128	18.2%	86.7%	4	13	2	18
2.867780521	13.6%	86.7%	3	13	2	19
3.247367684	13.6%	93.3%	3	14	1	19
3.500757425	9.1%	93.3%	2	14	1	20
4.574331216	4.5%	93.3%	1	14	1	21
6.042793811	0.0%	93.3%	0	14	1	22
222.0484769	0.0%	100.0%	0	15	0	22

Figure 41B

Test Receiver Operator Characteristic (ROC) curves

M25041_2 by SAMP_GRP


Performed by Benjamin Silverman

Date 14 August 2002

n 37

SAMP_GRP	n
0	15
1	22

Curve	Area	SE	p	95% CI of Area	SAMP_GRP = 1
M25041_2	0.639	0.0933	0.0675	0.457 to 0.822	have higher values



M25041_2 (abnormals above cut-off)	Sensitivity	Specificity	TP	TN	FP	FN
0.793645654	95.5%	0.0%	21	0	15	1

FIGURE 42 A

Test Receiver Operator Characteristic (ROC) curves

M25041_2 by SAMP_GRP

Performed by Benjamin Silverman

Date

14 August 2002

0.817153162	95.5%	6.7%	21	1	14	1
1.082548537	90.9%	6.7%	20	1	14	2
1.141165731	90.9%	13.3%	20	2	13	2
1.237989017	90.9%	20.0%	20	3	12	2
1.25499662	86.4%	20.0%	19	3	12	3
1.343229757	81.8%	20.0%	18	3	12	4
1.349329152	81.8%	26.7%	18	4	11	4
2.081998999	81.8%	33.3%	18	5	10	4
2.20479043	77.3%	33.3%	17	5	10	5
2.232456456	72.7%	33.3%	16	5	10	6
2.436031979	68.2%	33.3%	15	5	10	7
2.577796281	68.2%	40.0%	15	6	9	7
3.022638023	68.2%	46.7%	15	7	8	7
3.292505173	63.6%	46.7%	14	7	8	8
3.378232079	63.6%	53.3%	14	8	7	8
3.569749296	63.6%	60.0%	14	9	6	8
3.947644366	63.6%	66.7%	14	10	5	8
4.017402491	59.1%	66.7%	13	10	5	9
4.025797474	54.5%	66.7%	12	10	5	10
4.641249207	54.5%	73.3%	12	11	4	10
4.672013348	54.5%	80.0%	12	12	3	10
5.0163702	54.5%	86.7%	12	13	2	10
5.51431751	50.0%	86.7%	11	13	2	11
6.121226492	45.5%	86.7%	10	13	2	12
6.421619338	40.9%	86.7%	9	13	2	13
6.493739417	36.4%	86.7%	8	13	2	14
7.12459442	31.8%	86.7%	7	13	2	15
9.376347689	27.3%	86.7%	6	13	2	16
11.87108569	22.7%	86.7%	5	13	2	17
12.68431208	18.2%	86.7%	4	13	2	18
12.84424644	18.2%	93.3%	4	14	1	18
16.49781271	13.6%	93.3%	3	14	1	19
18.59015054	9.1%	93.3%	2	14	1	20
23.26913367	9.1%	100.0%	2	15	0	20
26.37159816	4.5%	100.0%	1	15	0	21
34.36259113	0.0%	100.0%	0	15	0	22

Figure 42b

Test Receiver Operator Characteristic (ROC) curves

M28013_1 by SAMP_GRP

Performed by Benjamin Silverman


Date

14 August 2002

n | 37

SAMP_GRP	n
0	15
1	22

Curve	Area	SE	p	95% CI of Area	SAMP_GRP = 1
M28013_1	0.603	0.0954	0.1401	0.416 to 0.790	have higher values



M28013_1 (abnormals above cut-off)	Sensitivity	Specificity	TP	TN	FP	FN
-0.095035313	95.5%	0.0%	21	0	15	1

FIGURE 43A

Test Receiver Operator Characteristic (ROC) curves

M28013_1 by SAMP_GRP

Performed by Benjamin Silverman

Date

14 August 2002

0.008319371	95.5%	6.7%	21	1	14	1
0.010549266	95.5%	13.3%	21	2	13	1
0.102216294	95.5%	20.0%	21	3	12	1
0.113828147	90.9%	20.0%	20	3	12	2
0.1191118	86.4%	20.0%	19	3	12	3
0.126751464	81.8%	20.0%	18	3	12	4
0.139219149	81.8%	26.7%	18	4	11	4
0.143262373	77.3%	26.7%	17	4	11	5
0.159400568	77.3%	33.3%	17	5	10	5
0.175599876	72.7%	33.3%	16	5	10	6
0.237338251	68.2%	33.3%	15	5	10	7
0.253741367	63.6%	33.3%	14	5	10	8
0.261407068	63.6%	40.0%	14	6	9	8
0.275595468	63.6%	46.7%	14	7	8	8
0.282158382	63.6%	53.3%	14	8	7	8
0.297729343	63.6%	60.0%	14	9	6	8
0.313257239	63.6%	66.7%	14	10	5	8
0.323071775	59.1%	66.7%	13	10	5	9
0.414240943	54.5%	66.7%	12	10	5	10
0.431505021	50.0%	66.7%	11	10	5	11
0.4509231	50.0%	73.3%	11	11	4	11
0.46992756	45.5%	73.3%	10	11	4	12
0.560326976	40.9%	73.3%	9	11	4	13
0.697047262	36.4%	73.3%	8	11	4	14
0.8010417	31.8%	73.3%	7	11	4	15
1.017133662	27.3%	73.3%	6	11	4	16
1.019696331	27.3%	80.0%	6	12	3	16
1.023129053	27.3%	86.7%	6	13	2	16
1.053132432	27.3%	93.3%	6	14	1	16
1.26765639	22.7%	93.3%	5	14	1	17
2.161821389	18.2%	93.3%	4	14	1	18
2.231947361	13.6%	93.3%	3	14	1	19
2.681779385	9.1%	93.3%	2	14	1	20
4.009571403	9.1%	100.0%	2	15	0	20
5.061125972	4.5%	100.0%	1	15	0	21
21.26275531	0.0%	100.0%	0	15	0	22

Figure 43B

Test Receiver Operator Characteristic (ROC) curves

M49972_1 by SAMP_GRP


Performed by Benjamin Silverman

Date 14 August 2002

n | 37

SAMP_GRP	n
0	15
1	22

Curve	Area	SE	p	95% CI of Area	SAMP_GRP = 1
M49972_1	0.703	0.0924	0.0140	0.522 to 0.884	have higher values



M49972_1 (abnormals above cut-off)	Sensitivity	Specificity	TP	TN	FP	FN
0.119948701	100.0%	6.7%	22	1	14	0

FIGURE 44A

Test Receiver Operator Characteristic (ROC) curves

M49972_1 by SAMP_GRP

Performed by Benjamin Silverman

Date

14 August 2002

0.132950234	100.0%	13.3%	22	2	13	0
0.141985312	100.0%	20.0%	22	3	12	0
0.246235855	95.5%	20.0%	21	3	12	1
0.287564918	95.5%	26.7%	21	4	11	1
0.293882443	95.5%	33.3%	21	5	10	1
0.306783535	95.5%	40.0%	21	6	9	1
0.349275179	95.5%	46.7%	21	7	8	1
0.372101499	90.9%	46.7%	20	7	8	2
0.523240205	86.4%	46.7%	19	7	8	3
0.529789658	81.8%	46.7%	18	7	8	4
0.532304145	77.3%	46.7%	17	7	8	5
0.565558298	77.3%	53.3%	17	8	7	5
0.615696638	72.7%	53.3%	16	8	7	6
0.655358293	72.7%	60.0%	16	9	6	6
0.708502864	68.2%	60.0%	15	9	6	7
0.820163109	63.6%	60.0%	14	9	6	8
0.829209887	59.1%	60.0%	13	9	6	9
0.889935695	59.1%	66.7%	13	10	5	9
0.900952491	59.1%	73.3%	13	11	4	9
0.952218444	54.5%	73.3%	12	11	4	10
0.963450793	50.0%	73.3%	11	11	4	11
1.053272294	50.0%	80.0%	11	12	3	11
1.115031656	45.5%	80.0%	10	12	3	12
1.117385785	40.9%	80.0%	9	12	3	13
1.231643564	36.4%	80.0%	8	12	3	14
1.369123003	36.4%	86.7%	8	13	2	14
1.421508865	31.8%	86.7%	7	13	2	15
1.460854582	27.3%	86.7%	6	13	2	16
1.795777414	22.7%	86.7%	5	13	2	17
1.92994641	18.2%	86.7%	4	13	2	18
2.206108575	13.6%	86.7%	3	13	2	19
2.278575727	13.6%	93.3%	3	14	1	19
2.610392714	9.1%	93.3%	2	14	1	20
2.849559837	4.5%	93.3%	1	14	1	21
5.589760177	4.5%	100.0%	1	15	0	21
27.19836861	0.0%	100.0%	0	15	0	22

Figure 44B

Test Receiver Operator Characteristic (ROC) curves

M50078_2 by SAMP_GRP


Performed by Benjamin Silverman

Date 14 August 2002

n 37

SAMP_GRP	n
0	15
1	22

Curve	Area	SE	p	95% CI of Area	SAMP_GRP = 1
M50078_2	0.824	0.0966	0.0993	0.435 to 0.814	have higher values



M50078_2 (abnormals above cut-off)	Sensitivity	Specificity	TP	TN	FP	FN
0.083771249	100.0%	6.7%	22	1	14	0

FIGURE 45A

Test Receiver Operator Characteristic (ROC) curves

M50078_2 by SAMP_GRP

Performed by	Benjamin Silverman				Date	14 August 2002
0.112192966	95.5%	6.7%	21	1	14	1
0.187614661	95.5%	13.3%	21	2	13	1
0.249307343	90.9%	13.3%	20	2	13	2
0.263981414	90.9%	20.0%	20	3	12	2
0.306532284	86.4%	20.0%	19	3	12	3
0.338598049	86.4%	26.7%	19	4	11	3
0.345538383	81.8%	26.7%	18	4	11	4
0.39682968	81.8%	33.3%	18	5	10	4
0.418253613	81.8%	40.0%	18	6	9	4
0.433207988	81.8%	46.7%	18	7	8	4
0.442596153	77.3%	46.7%	17	7	8	5
0.523921441	77.3%	53.3%	17	8	7	5
0.533559718	72.7%	53.3%	16	8	7	6
0.580795124	68.2%	53.3%	15	8	7	7
0.591320318	63.6%	53.3%	14	8	7	8
0.66716828	59.1%	53.3%	13	8	7	9
0.673010393	59.1%	60.0%	13	9	6	9
0.749027671	54.5%	60.0%	12	9	6	10
0.762425926	54.5%	66.7%	12	10	5	10
0.795540626	54.5%	73.3%	12	11	4	10
0.841469072	50.0%	73.3%	11	11	4	11
0.887016568	45.5%	73.3%	10	11	4	12
0.936274853	40.9%	73.3%	9	11	4	13
1.151312518	36.4%	73.3%	8	11	4	14
1.511400676	31.8%	73.3%	7	11	4	15
1.530864328	27.3%	73.3%	6	11	4	16
1.698991556	27.3%	80.0%	6	12	3	16
1.701630079	22.7%	80.0%	5	12	3	17
1.738942865	22.7%	86.7%	5	13	2	17
1.742833851	18.2%	86.7%	4	13	2	18
1.752666622	18.2%	93.3%	4	14	1	18
2.427706313	13.6%	93.3%	3	14	1	19
2.677791701	9.1%	93.3%	2	14	1	20
2.690070914	4.5%	93.3%	1	14	1	21
2.911184998	4.5%	100.0%	1	15	0	21
18.44471648	0.0%	100.0%	0	15	0	22

Figure 451

Test Receiver Operator Characteristic (ROC) curves

M51107_4 by SAMP_GRP


Performed by Benjamin Silverman

Date 14 August 2002

n 37

SAMP_GRP	n
0	15
1	22

Curve	Area	SE	p	95% CI of Area	SAMP_GRP = 1
M51107_4	0.682	0.0934	0.0258	0.499 to 0.865	have higher values



M51107_4 (abnormals above cut-off)	Sensitivity	Specificity	TP	TN	FP	FN
0.074699264	100.0%	6.7%	22	1	14	0

FIGURE 46A

Test	Receiver Operator Characteristic (ROC) curves					
	M51107_4 by SAMP_GRP					
Performed by	Benjamin Silverman				Date	14 August 2002
0.152211743	100.0%	13.3%	22	2	13	0
0.168812127	100.0%	20.0%	22	3	12	0
0.173776748	100.0%	26.7%	22	4	11	0
0.183833926	100.0%	33.3%	22	5	10	0
0.214125809	95.5%	33.3%	21	5	10	1
0.327567348	90.9%	33.3%	20	5	10	2
0.345779351	90.9%	40.0%	20	6	9	2
0.349354919	86.4%	40.0%	19	6	9	3
0.37344561	86.4%	46.7%	19	7	8	3
0.379220583	81.8%	46.7%	18	7	8	4
0.394515757	77.3%	46.7%	17	7	8	5
0.410858999	72.7%	46.7%	16	7	8	6
0.434554869	68.2%	46.7%	15	7	8	7
0.482603327	68.2%	53.3%	15	8	7	7
0.519551206	63.6%	53.3%	14	8	7	8
0.568891448	59.1%	53.3%	13	8	7	9
0.578992423	59.1%	60.0%	13	9	6	9
0.579319445	59.1%	66.7%	13	10	5	9
0.628011587	59.1%	73.3%	13	11	4	9
0.638395862	54.5%	73.3%	12	11	4	10
0.641159015	50.0%	73.3%	11	11	4	11
0.647907617	45.5%	73.3%	10	11	4	12
0.676375996	45.5%	80.0%	10	12	3	12
0.716268209	40.9%	80.0%	9	12	3	13
0.779127187	36.4%	80.0%	8	12	3	14
0.81686344	31.8%	80.0%	7	12	3	15
0.91401114	31.8%	86.7%	7	13	2	15
1.005058602	27.3%	86.7%	6	13	2	16
1.162282129	22.7%	86.7%	5	13	2	17
1.995799971	18.2%	86.7%	4	13	2	18
2.301850974	13.6%	86.7%	3	13	2	19
2.427576247	13.6%	93.3%	3	14	1	19
2.45915745	9.1%	93.3%	2	14	1	20
2.774302208	9.1%	100.0%	2	15	0	20
3.670288528	4.5%	100.0%	1	15	0	21
24.85935987	0.0%	100.0%	0	15	0	22

Figure 46B

Test Receiver Operator Characteristic (ROC) curves

M51349_5 by SAMP_GRP


Performed by Benjamin Silverman

Date 14 August 2002

n 37

SAMP_GRP	n
0	15
1	22

Curve	Area	SE	p	95% CI of Area	SAMP_GRP = 1
M51349_5	0.645	0.0987	0.0704	0.452 to 0.839	have higher values



M51349_5 (abnormals above cut-off)	Sensitivity	Specificity	TP	TN	FP	FN
0.200166025	95.5%	0.0%	21	0	15	1

FIGURE 47A

Test Receiver Operator Characteristic (ROC) curves

M51349_5 by SAMP_GRP

Performed by	Benjamin Silverman				Date	14 August 2002
0.24300717	95.5%	6.7%	21	1	14	1
0.276544758	95.5%	13.3%	21	2	13	1
0.407583283	95.5%	20.0%	21	3	12	1
0.468872073	90.9%	20.0%	20	3	12	2
0.50797997	90.9%	26.7%	20	4	11	2
0.524022195	90.9%	33.3%	20	5	10	2
0.553829455	88.4%	33.3%	19	5	10	3
0.632492332	86.4%	40.0%	19	6	9	3
0.668511881	86.4%	46.7%	19	7	8	3
0.72469887	86.4%	53.3%	19	8	7	3
0.898878277	81.8%	53.3%	18	8	7	4
1.029316771	77.3%	53.3%	17	8	7	5
1.075690084	72.7%	53.3%	16	8	7	6
1.089240673	72.7%	60.0%	16	9	6	6
1.114174748	68.2%	60.0%	15	9	6	7
1.121500907	63.6%	60.0%	14	9	6	8
1.249953453	63.6%	66.7%	14	10	5	8
1.288068701	59.1%	66.7%	13	10	5	9
1.602950201	54.5%	66.7%	12	10	5	10
1.607855826	50.0%	66.7%	11	10	5	11
1.647088646	45.5%	66.7%	10	10	5	12
1.746212668	40.9%	66.7%	9	10	5	13
1.951038891	40.9%	73.3%	9	11	4	13
2.009460734	36.4%	73.3%	8	11	4	14
2.05487892	31.8%	73.3%	7	11	4	15
2.427358406	27.3%	73.3%	6	11	4	16
2.511947452	27.3%	80.0%	6	12	3	16
2.798550882	22.7%	80.0%	5	12	3	17
2.924870548	18.2%	80.0%	4	12	3	18
3.300701226	13.6%	80.0%	3	12	3	19
3.830189124	13.6%	86.7%	3	13	2	19
4.333103582	13.6%	93.3%	3	14	1	19
5.408541047	9.1%	93.3%	2	14	1	20
6.411934306	9.1%	100.0%	2	15	0	20
12.05457475	4.5%	100.0%	1	15	0	21
34.56426486	0.0%	100.0%	0	15	0	22

Figure 47B

Test Receiver Operator Characteristic (ROC) curves

M66959_0 by SAMP_GRP


Performed by Benjamin Silverman

Date 14 August 2002

n | 37

SAMP_GRP	n
0	15
1	22

Curve	Area	SE	p	95% CI of Area	SAMP_GRP = 1
M66959_0	0.658	0.0928	0.0445	0.476 to 0.839	have higher values



M66959_0 (abnormals above cut-off)	Sensitivity	Specificity-	TP	TN	FP	FN
0.053847504	100.0%	6.7%	22	1	14	0

FIGURE 48A

Test Receiver Operator Characteristic (ROC) curves

M66959_0 by SAMP_GRP

Performed by	Benjamin Silverman				Date	14 August 2002
0.109620497	100.0%	13.3%	22	2	13	0
0.145348123	100.0%	20.0%	22	3	12	0
0.154709652	100.0%	26.7%	22	4	11	0
0.163431718	95.5%	26.7%	21	4	11	1
0.166354524	90.9%	26.7%	20	4	11	2
0.186467289	90.9%	33.3%	20	5	10	2
0.219563493	86.4%	33.3%	19	5	10	3
0.231184488	81.8%	33.3%	18	5	10	4
0.253045556	81.8%	40.0%	18	6	9	4
0.26206	77.3%	40.0%	17	6	9	5
0.268399456	77.3%	46.7%	17	7	8	5
0.286072607	72.7%	46.7%	16	7	8	6
0.290123221	72.7%	53.3%	16	8	7	6
0.305445727	68.2%	53.3%	15	8	7	7
0.307085278	63.6%	53.3%	14	8	7	8
0.339115437	59.1%	53.3%	13	8	7	9
0.34631703	54.5%	53.3%	12	8	7	10
0.382061205	54.5%	60.0%	12	9	6	10
0.409515884	50.0%	60.0%	11	9	6	11
0.423831733	45.5%	60.0%	10	9	6	12
0.448975118	45.5%	66.7%	10	10	5	12
0.467458457	45.5%	73.3%	10	11	4	12
0.515844068	40.9%	73.3%	9	11	4	13
0.518867449	40.9%	80.0%	9	12	3	13
0.525211053	36.4%	80.0%	8	12	3	14
0.562143936	36.4%	86.7%	8	13	2	14
0.565406222	31.8%	86.7%	7	13	2	15
0.773873943	27.3%	86.7%	6	13	2	16
0.868229793	22.7%	86.7%	5	13	2	17
1.024396807	22.7%	93.3%	5	14	1	17
1.086151053	18.2%	93.3%	4	14	1	18
1.2985479	18.2%	100.0%	4	15	0	18
1.628046623	13.6%	100.0%	3	15	0	19
1.853453489	9.1%	100.0%	2	15	0	20
2.12018388	4.5%	100.0%	1	15	0	21
3.039643834	0.0%	100.0%	0	15	0	22

Figure 48

Sample Spectra




FIGURE 49

662 Clarke and Others




Figure 1. Sample mass spectra from a nonrejection patient and a rejection patient.

FIGURE 50




Figure 2. ROC analysis of candidate biomarkers.

FIGURE 51